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CHAPTER 1. GENERAL INTRODUCTION 
 
 
General Introduction and Dissertation Organization 
Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are 
chronic, relapsing intestinal inflammatory enteropathies and as many as 1.4 and 2.2 million 
individuals in the United States and Europe, respectively, are suffering from these diseases.
1,7 
However, the etiology of IBD remains poorly understood and likely involves complex 
interactions among gut bacteria, epithelial barrier, host immune responses, and genetic 
susceptibility.
1
 The characterization of mucosal gene expression profiles in different IBD 
animal models will potentially provide molecular insights into the mechanisms that initiate or 
perpetuate IBD development. This dissertation will study how differentially regulated 
mucosal genes, induced by different agents (e.g., mild bacterial pathogen, Helicobacter bilis 
or anti-inflammatory drug, hypoxoside), modulate the development of murine colitis.  
The dissertation is composed of five chapters. Chapter 1 is a general introduction which 
includes the organization of dissertation and literature review. Chapter 2, Chapter 3 and 
Chapter 4 each consists of a research paper. The first paper, “Mucosal gene expression 
profiles following the colonization of immunocompetent gnotobiotic C3H mice with 
Helicobacter bilis: a prelude to colitis” is to be submitted for publication in Inflammatory 
Bowel Diseases. The second paper, “Effects of Helicobacter bilis colonization on murine 
colitis induced by dextran sodium sulfate” is to be submitted for publication in Clinical and 
Experimental Immunology. The third paper, “Oral treatment with hypoxoside ameliorates 
Brachyspira hyodysenteriae-induced murine colitis” is to be submitted for publication in 
American Journal of Physiology - Gastrointestinal and Liver Physiology. Chapter 5 is a 
general conclusion including summary of results and discussion of significant findings and 
recommendations for further research. References of each research paper follow the 
requirements of the specific journal to which it will be submitted. References of literature 
review and general conclusion follow the format of the journal Inflammatory Bowel Diseases.    
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Literature Review 
 
Introduction for Inflammation Bowel Diseases 
The major forms of idiopathic inflammatory bowel diseases (IBD), Crohn’s disease (CD) 
and ulcerative colitis (UC) are chronic inflammatory disorders of the gastrointestinal tract.
1
 
 
Crohn’s diseases vs. ulcerative colitis 
Both CD and UC cause inflammation of the bowel (intestine) characterized by 
symptoms such as bloody diarrhea with mucus, abdominal pain, rectal bleeding. However, 
there are some important differences in clinical and pathological features between these two 
forms of IBD.  
Crohn’s disease, named after American physician Burrill B. Crohn,2 affect the whole-
thickness of the intestinal wall (“transmural”) and most frequently cause severe lesions in 
the ileum, although they can occur at any site along alimentary tract. The inflamed sections 
can be interrupted by healthy sections. In contrast, ulcerative colitis usually affects the 
mucosa of intestine (“superficial”) and causes severe lesion only in colon. The inflamed 
sections tend to be continuous.
3
   
One of the major histological features of CD is the development of mucosal granuloma, 
which are composed of compact macrophages, giant cells, and epithelioid cells surrounded 
by marked infiltration of lymphoid cells, plasma cells, and other inflammatory cells.
4
 In 
contrast, ulcerative colitis is characterized by the formation of crypt abscesses, which are 
composed of neutrophilic exudate and sloughing and dying cells from the surrounding 
epithelium.
4
  
 It is important to differentiate between the two forms of IBD because of the differences 
in the course of disease and available treatment options.  In some cases, however, it may not 
be possible to tell the difference, in which case the disease is classified as indeterminate 
colitis.
3
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Epidemiology of IBD 
 Epidemiological information such as the incidence and prevalence across age, gender, 
race, geographic regions, or time is likely to provide some clues about the etiology of a given 
disease or syndrome.  With regards to age, the onset of IBD tends to occur in most 
individuals during the second or third decades of life indicating that some susceptibility 
factors may accumulate over time. There is no obvious gender difference for IBD patients, 
although some studies show that females slightly predominate in Crohn’s disease while 
males in ulcerative colitis.
5 
 
IBD is more likely to occur in blacks or Caucasians people, especially Jewish people, in 
comparison to individuals of Asian or Hispanic dissent.  For example, a North American 
study evaluating Crohn’s disease between 1982 and 1988 reported that the prevalence rates 
among Hispanic (4.1 per 100, 000) and Asians (5.6 per 100, 000) were much lower than that 
for Caucasians (43.6 per 100, 000) or African-Americans (29.8 per 100, 000).
6
 In addition, 
familial aggregation of IBD patients has long been recognized. First-degree relatives of 
affected individuals have a relative risk of 5-fold or greater than those in the general 
population.
4
 These results suggest genetic factors are involved in the development of IBD.  
Geographically, the greatest incidence and prevalence of IBD is in highly industrialised 
Western societies such as those in North America, northern Europe, and the United Kindom. 
It is estimated that more than 1.4 million and 2.2 million people in United States and Europe, 
respectively, suffer from this disease annually.
7
 Even though there was a rapid increase in 
incidence and prevalence of IBD during the latter half of the 20th century, the number of 
IBD patients in the United States and Europe has begun to stabilize. However, in other 
regions such as Eastern Europe, Asia, and other developing countries, the incidence and 
prevalence of IBD has begun to increase rapidly, possibly due to environmental or cultural 
changes associated with diet, lifestyle, and hygienic conditions.
8-10
 In addition, other risk 
factors such as smoking and appendectomy have been associated with incidence of IBD.
11
 
Collectively, epidemiological studies have suggested that both genetic and environmental 
factors contribute to the development of IBD.  
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Diagnosis of IBD   
Because the symptoms of IBD such as abdominal pain and rectal bleeding can occur in 
patients with parasitic infections, celiac disease, or colon cancer, the first diagnostic 
evaluation of a patient should rule out other causes. This should then be followed by 
serological and stool tests (e.g., complete blood cell count, electrolyte panel, and fecal occult 
blood test, stool culture) that can be used to measure the level or severity of inflammation, 
bleeding, and/or specific bacterial infection. However, the most convincing diagnosis for 
IBD comes from colonoscopy.
12
 In addition, radiologic (X-rays), and pathologic (analysis of 
tissues) examinations are often required to confirm the IBD diagnosis. Notably, recent 
advances in serologic markers, endoscopy, and radiology have led to rapid expansion of 
diagnosis and disease activity assessment of IBD.
13 
 
 
Treatment of IBD 
The goal of IBD treatment is to control ongoing inflammation including achieving 
remission (i.e., absence of symptoms) and, once that is accomplished, maintaining remission 
(i.e., prevention of flare-ups). Surgery is required in many patients with inflammatory bowel 
disease at some point in their disease. While surgery usually results in an improvement in 
quality of life, recurrence of disease occurs frequently with reported rates of 5-90% at 1 year, 
depending on the criteria used.
14
 At present, except surgery, there are 5 basic subcategories 
of medication for the treatment of IBD. (1) Aminosalicylates are compounds that contain 5-
aminosalicylic acids (5-ASA). They are the mainstay and first-line drugs for both inducing 
and maintaining remission in mild to moderate IBD patients, although not all patients 
respond to these drugs and some severe side-effects occur. It has been shown that 5-ASA is 
effective for the treatment of ulcerative colitis, whereas its effectiveness for treating Crohn’s 
disease is somewhat controversial.
15
 (2) Corticosteroids, which are powerful and fast-acting 
anti-inflammatory drugs, have been mainly used to achieve short-term remission. Long-term 
use of corticosteroids is not advised because of undesirable side effects such as 
immunosuppression. (3) Immunomodulators such asazathioprine and 6-mercaptopurine are 
immunosuppressive drugs used to maintain remission in Crohn's disease and ulcerative 
colitis. One of the disadvantages of immunomodulators is that, by suppressing the immune 
5 
  
system, they decrease the body’s ability to combat infection. (4) Broad-spectrum antibiotics, 
such as metroniazole, are also used to treat IBD patients. Aberrant host responses to antigens 
derived from the intestinal microflora, including commensal bacteria, has been implicated in 
the etiology of IBD and provides a rationale for the use of antibiotics in the treatment of the 
disease.
16
 However, available studies show that antibiotics are only effective in treating some 
septic complications in Crohn’s disease but are not useful for the treatment of ulcerative 
colitis.
17
  (5) More recently, several biological therapies have been developed to treat cases of 
IBD that do not respond to the other treatment modalities. Patients with IBD frequently 
experience relapse and traditional medical treatments are not potent enough to maintain 
remission over the long-term.
18
 Novel therapies such as biological therapies (e.g., 
monoclonal antibodies) have been developed in recent years with the potential to provide 
more effective and safe treatments for IBD. In contrast to conventional therapies, most of 
biological therapies not only reduce the IBD symptoms, but also target the specific disease 
mechanisms. In this way, these therapeutic approaches have the potential to alter the long-
term course of the disease or the underlying immunopathology. Many of the biological 
therapies include the use of monoclonal antibodies specific for lymphocyte adhension 
molecules (e.g., alpha4beta7),
19
 cytokines (e.g., TNFα, IL-12 and IL-23),20-22 or growth 
factors (e.g., granulocyte colony-stimulating factor).
23
 Another novel therapy employs the 
use of helminthes (Trichuris suis) to stimulate anti-inflammatory immune responses (i.e., IL-
10, Th2).
24
 However, the high cost and long-term safety associated with many of the 
biological therapies still needs to be addressed.
25
 
In efforts to develop complementary and alternative medicine (CAM) approaches, plant 
extracts with anti-inflammatory activities have been used to treat IBD patients and have been 
shown to prevent or ameliorate colitis in laboratory animals treated with DSS or TNBS.
26-30
 
These represent a different class of medicinal options for IBD patients. Though the exact 
components are not completely known, many of these plant extracts, usually as traditional 
medicine from countries such as China, India or Africa, have been used for centuries for 
multiple diseases, indicating that they may be safe for human.
26, 31, 32
 The anti-inflammatory 
effects of those plant extracts might be involved in the inhibition of inflammatory mediators, 
adhesive molecules or oxidative stress.
28-31
 For example, boswellic acid, an active component 
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of oleogum resins from Boswellia species could inhibit the production of 5-lipoxygenase and 
has shown efficacy in some autoimmune diseases including rheumatoid arthritis, bronchial 
asthma and inflammatory bowel disease with little side effects.
28
 Quercitrin, a common 
antioxidant flavonoid found in vegetables, can be converted into quercetin by gut bacteria 
and has been shown to inhibit DSS-induced colitis in rats  through down-regulation of the 
NF-κB pathway.27 
 
 Hypoxoside 
 Hypoxoside is an example of a botanical extract that has been shown to have anti-
inflammatory activities. The ability of this compound to ameliorate colitis caused by 
Brachyspira hyodysenteriae is discussed later in this dissertation (Chapter 4)  
Hypoxoside is a diglucosidic compound present in corm of the African medicinal plant 
Hypoxis hemerocallidea (also known as Hypoxis rooperi, African Potato),  a member of the 
family Hypoxidaceae.
33
 This extract has been widely used in southern African as traditional 
medicine for centuries and it use has been claimed to be an effective remedy/complementary 
medicine for an array of human aliments such as HIV/AIDS-related diseases, arthritis, 
diabetes mellitus, cancers, gastric and duodenal ulcers, and urinary tract infections.
34-38
 It 
gained more attention as an alternative medicine for HIV/AID patients following receipt of a 
strong recommendation from the Ministry of Health of South Africa and 14 other member 
states of the South African Development Community (SADC).
39
 The ingredients of African 
Potato have been included in some “over-the-counter” medicines.40   
 Rooperol is considered as the major bioactive compound in Hypoxis hemerocallidea 
corm extracts of the African Potato.
42
 The primary structure of the pro-drug, hypoxoside, 
consists of an E-pent-1-en-4-5-carbon unit containing two catechol groups to which the 
glucose moieties are attached.
41
 In the colon, hypoxoside can be converted into rooperol by 
β-glucosidase produced by members of the gut microflora.41  
It has been shown that rooperol has anti-inflammatory effects and has potential 
usefulness in the treatment of inflammatory diseases.
43-46
 Rooperol was shown to inhibit the 
production of TNF-α, IL-1, IL-6, and nitric oxide by endotoxin-stimulated human alveolar 
macrophages, human blood monocytes, histiocytic cells, and rat alveolar macrophages in 
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vitro.
43
 Rooperol decreased the mRNA and protein expression levels of vascular cell 
adhesion molecule-1(VCAM-1) and nitric oxide synthease (iNOS) in microvascular 
endothelial cells stimulated by TNF-α or IFN-γ.44 In addition, rooperol was shown to 
decrease the mRNA levels of pro-inflammatory cytokines in a human promonocytic cell line 
and inhibit the transient binding activity of transcriptional factors including NF- κB and AP-
1(c-jun/c-fos dimer).
45
 Similarly, H. hemerocallidea corm extracts were shown to have anti-
inflammatory effects on fresh egg albumin-induced acute inflammation in rats.
46
 In addition 
to inhibition of pro-inflammatory cytokines, the anti-inflammatory effects were also 
proposed to be associated with the inhibition of the 5-lipoxygenase pathway, but not 
cyclooxygenase.
47
 However, one recent in vitro study of rooperol showed a significant 
degree of inhibition of cyclooxygenase-1 and 2.
48 
Rooperol was also shown to inhibit the 
growth of gram-negative bacteria (e.g., Escherichia coli)
 48,49
 and gram-positive bacteria (e.g., 
Staphylococcus aureus)
48
. In addition, rooperol was shown to have significant anti-oxidative 
activity.
50
 Meantime, hypoxoside has not exhibited toxicity during in vitro or during clinical 
trials.
51, 52
 
. 
Animal models of IBD 
Animal models of IBD have played a key role in understanding the mechanisms of 
intestinal inflammation and in designing new therapeutic strategies for the treatment of IBD 
patients. Based upon the underlying method of disease induction, there are several broad 
categories of IBD animal models that have been used to study the mechanisms of disease: 
gene knockout (KO) (e.g., IL-2
-/-
, IL-10
-/-, TCRα-/- and Mdr1a-/-), transgenic (e.g., HLA-B27, 
Stat-4 transgenic), chemical (e.g., DSS, TNBS), adoptive transfer (e.g., CD4
+
 CD45RB
high
 
transfer), and spontaneous (e.g., C3H/HejBir, SAMP1/Yit).
53
 Based on the cellular and 
molecular mechanisms associated with the development of IBD, animal models can be 
placed into one of three types of basic defects: altered innate immunity (e.g., Mdr1a
-/-
, DSS), 
excessive T cell responses (e.g., IL-2
-/-
, Stat-4 transgenic), or altered regulatory mechanism 
(e.g., IL2
-/-
, IL-10
-/-
, TGFβ1-/- and TCRα-/-) (Table 1). Other models (e.g., C3H/HejBir, 
SAMP1/Yit) demonstrate milder defects in more than one component (Table 1). 
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Table 1. Representative murine colitis models
54 
 
Model 
Altered innate 
immune 
response   
Excessive 
effector T-
cell response 
Altered 
regulatory 
mechanisms 
Bacterial  
flora driven  Known defects 
Mdr1a
-/-
 √   Probable   Altered epithelial barrier 
DSS √   Possible  Direct damage to epithelial barrier 
Stat-4 trangenic  √  Probable Excessive T-cell responses  
     to enteric bacteria 
C3H/HeJBir √ √  Yes Impaired responses to TLR ligands 
     increased bacterial reactive T cells 
SAMP1/Yit √ √  Yes 
Epithelial cell defects; expanded B-cell 
population; increased activated T cell 
IL-2 deficient   √ Yes Decreased regulatory T cell 
IL-10 deficient √  √ Yes Lack Tr1 activity; lack TGFβ signaling 
TGFβ1 deficient √  √ No Decreased regulatory T cells 
TCRα deficient   √ Yes Loss of a regulatory B cell 
CD4
+
CD45RB
hi
   √ Yes Decreased regulatory T cells 
transfer      
Mdr: Multi-drug resistance; DSS: Dextran sodium sulfate; Stat-4: Signal transducer and activator of transcription 4   
IL: Interleukin; TGF: Transforming growth factor; TCR:T- cell receptor 
Modified from Elson CO, et al, 2005.  
 
IBD animal models with altered innate immunity  
1. Mdr1a-/- mice. These mice lack the multiple drug resistance genes for P-glycoprotein 
170 (pg170), a xenobiotic transporter normally expressed in multiple tissues including 
intestinal epithelial cells. Pg170 is involved in detoxification processes and maintenance of 
the intestinal barrier.
55
 These mice spontaneously develop colitis  around 12 weeks of age.
56
 
Polymorphisms in Mdr1 have been shown to be strongly associated with ulcerative 
colitis.
57,58
 Although pg170 is also expressed in lymphocytes, hematopoietic cells, and in 
epithelial cells of other tissues, it has been shown that the intestinal epithelial cell defect is 
the principle cause of colitis.
59,60
  
 Helicobacter bilis, a mild pathogen, has been shown to accelerate colitis development in 
Mdr1a 
-/-
 mice.
61,62
 In comparison to wild-type mice colonized with H. bilis, Mdr1a
-/-
 mice 
colonized with H. bilis were characterized by the upregulation of mucosal IFN-γ, IL-10 gene 
expression and increased lamina proprial cellularity with expansion of CD4 and CD8 T cells 
and B cells.  In addition, there was also increased antigen-specific recall responses by T cells 
recovered from the mesenteric lymph node (MLN) when stimulated with soluble H. bilis 
antigens. These proliferative responses were accompanied by the elaboration of IFN-γ, TNF-
9 
  
α, and IL-10.61 These results indicated that, upon H. bilis colonization, the defective mucosal 
barrier could lead to the disruption of gut homeostasis and activation of adaptive immune 
responses. 
2. Dextran sodium sulfate (DSS)-induced colitis. The addition of DSS into the drinking 
water can induce colitis in mice, rats, and hamsters accompanied by clinical signs such as 
bloody diarrhea, and weight loss. Macroscopic and microscopic changes include shortening 
of the colon, neutrophilic infiltration, and epithelial changes including fibrosis, crypt loss, 
goblet cell hyperplasia, and focal ulceration.
63-65
 Exposure to DSS can induce either acute 
colitis that occurs during the administration of DSS, or chronic colitis that occurs a short time 
after the cessation of DSS treatment. Colitis was shown to be present in SCID mice treated 
for short periods with DSS, suggesting T cells, B cells, and NK cells are not essential in the 
acute phase of DSS colitis.
66,67
 However, chronic colitis is considered to be caused by 
activation of lymphocytes mediated by cytokines secreted from activated macrophages.
63
 The 
pathogenesis of DSS-induced colitis is widely considered to be caused by the direct damage 
to the intestinal epithelial cells.
63 
The initiating events induced by DSS seems to decrease 
epithelial proliferation
68
 and/or increase epithelial permeability (e.g., defective tight-junction 
proteins)
69, 70
. The change in epithelial barrier function then allows lumen antigens to activate 
the resident immune cells such as macrophages facilitating the development of colonic 
inflammation
71
.   
The association of enteric bacteria with DSS-induced colitis is well described. Some 
bacterial species (e.g., Bacteroides, Enterobacter and Clostridium) have been shown to 
significantly increase after acute DSS-induced colitis.
 63
 The administration of antibiotics 
(e.g., metronidazole or the combination of metronidazole and ciprofloxacin) protected 
rodents from  acute DSS-induced colitis,
 72
 suggesting that bacteria or the host responses to 
bacteria can contribute to the development of colitis. Another study demonstrated that 
antibiotics with narrow specificities (e.g., metronidazole) could prevent the DSS-induced 
colitis but had no therapeutic benefit once colitis was established.
73 
On the other hand, broad-
spectrum antibiotics (e.g., vancomycin-imipenem) were able to more effectively prevent 
DSS-induced colitis, as well as treat colitis.
73
 This indicates that different subsets of bacteria 
have different propensities to initiate or perpetuate the development of DSS-induced colitis. 
10 
  
In addition, Staphylococcus aureus enterotoxin B has been shown to aggravate enteric 
inflammation in mice recovering from DSS-induced colitis, indicating some bacterial 
products can perpetuate colitis
74
. In this dissertation, the effects of Helicobacter bilis on the 
DSS-induced colitis will be discussed in Chapter 3. However, the exact roles of bacteria in 
DSS-induced colitis is still controversial and it has been reported that DSS-induced colitis 
could occur in germ-free environments.
75, 76 
   
 
IBD animal models with excessive T cell responses 
1.  STAT-4 transgenic mice. STAT-4 (Signal transducer and activating transcription 4) 
is essential in the signal transduction of the prototypical Th1 cytokine, IL-12.
77
 Stat-4 
transgenic mice develop chronic transmural colitis characterized by infiltrates of CD4
+
 T 
lymphocytes which produce predominantly TNFα and IFN-γ.78 
2.  C3H/HejBir mice. In these mice, colitis occurs spontaneously at 3 to 4 weeks of age 
and resolves by 10 to 12 weeks of age.
79
 The colitic lesions of these mice are characterized 
by ulcers, crypt abscesses, and regeneration of epithelium, but not thickening of the intestinal 
wall or formation of granulomas.
79
 Bacterial antigen-specific CD4
+
 T cells have been shown 
to play a key role in the mucosal inflammatory response of C3H/HejBir mice
 
indicating a 
pivotal
 
role of bacteria or bacterial products in the induction of colitis.
 80
 In addition to the 
excessive T cell responses, C3H/HejBir mice display impaired innate immune responses 
which also contributes to the increased susceptibility to colitis.
81
 
3. SAMP1/Yit mice. These mice spontaneously develop Crohn’s disease-like intestinal 
inflammation characterized by a discontinuous lesion localized to the terminal ileum that is 
heavily infiltrated with T cells, neutrophils, and macrophages.
82 
The localized transmural 
ileitis is a unique feature not shared with other mouse models of IBD.
83
 The inflammatory 
lesions of SAMP1/Yit mice develop by 10 weeks of age and the host immune response is 
characterized by a Th1-type profile.
84, 85
 The induction of SAMP ileitis has been shown to be 
mediate by aberrantly activated CD4
+
 T cells and B cells.
86
 However, increased intestinal 
epithelial permeability has been shown to be the primary factor influencing the increased 
susceptibility of SAMP1/Yit mice to the development of ileitis.
87
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 IBD animal models with altered regulatory mechanisms 
1. IL-2
-/-
 mice. Approximately 50% of IL2
-/-
 mice develop severe autoimmune diseases 
characterized by splenomegaly, lymphadenopathy, and autoimmune hemolytic anemia and 
die between 4 and 9 weeks of age. The remaining mice uniformly develop pancolitis between 
6 and 15 weeks of age.
88
 IL-2 is a critical T cell growth factor in vitro, but predominantly 
mediates immune regulation in vivo.
89
 Although IL-2 is dispensable for the development of 
regulatory T cells in thymus, it plays an essential role in maintaining peripheral tolerance by 
promoting the growth and survival of regulatory T (Treg) cells.
90
 IL-2
-/-
 mice failed to 
develop CD4
+
CD25
+
 Treg subset in the peripheray.
91
  
2. IL-10
-/-
 mice. IL-10 is an important immunoregulatory cytokine produced by various 
types of cells including Treg cells, B cells, dendritic cells, and macrophages. It down-
regulates the function of Th1 cells, NK cells, and macrophages. Mice deficient in IL-10
 
develop intestinal inflammation with age.
92
 IL-10
-/- 
mice lack Tr1 cell activity, as well as 
TGFß/Smad signaling, and fail to inhibit pro-inflammatory gene expression in intraepithelial 
lymphocytes (IELs).
93
  Similar to IL-2
-/-
 mice, IL-10
-/-
 mice display a Th1 cytokine pattern 
(e.g., elevated IFN- γ and IL-12).94 Recently, IL-10-/- mice have also been shown to produce 
high levels of IL-17 derived from IL-17–producing effector T cells, termed Th17.95 However, 
one recent study showed that colitis in IL-10
-/- 
mice was dependent on toll-like receptor (TLR) 
signaling while disease in IL-2
-/- 
mice is not TLR-dependent, indicating a fundamental 
difference in the underlying mechanisms causing colitis in these two models.
96 
 
3. TCRα-/- mice. TCR α-/- mice spontaneously develop inflammation and hypertrophy 
over the entire length of the colon by 16 weeks after birth.
97
 Hyperplasia of the colonic 
epithelium, occasional crypt abscesses and goblet cells and infiltration of lymphocytes, 
plasma cells, and neutrophils were also observed.
98
 In contrast to the Crohn’s disease-like 
colitis observed in IL-2
-/-
 and IL-10
-/- 
mice, the colitis in TCRα-/- mice resembles ulcerative 
colitis and is characterized by a Th2 cytokine profile.
99
 However, regulatory B cells have 
been shown to play a critical role in regulating pathogenic T cells (CD4
+
 TCRβ+ T cells).99  
4. CD45RB transfer model.  Murine CD4
+
CD45RB
high
 T cells have been characterized 
as naive T cells. Transfer of CD4
+
CD45RB
high
 T cells, but not total CD4
+
 T cells or 
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CD4
+
CD45RB
low
 T cells, into SCID or Rag
-/-
 recipient mice results in the induction of colitis 
four to eight weeks later.
100
 The disease in this model is progressively unremitting and 
eventually results death. The histological features of disease caused by the transfer of naïve T 
cells are similar to that observed in other colitis models and are limited to the intestine, 
especially the colon.
101
 Conclusions drawn from this model suggests that normal, naïve CD4
+
 
T cells contain pathogenic cells that can initiate intestinal inflammation and that 
inflammation is prevented by the presence of Treg cells. 
Notably, the presence of commensal bacteria is indispensible for the development of 
colitis in most of these models (Table 1). This is one of the most convincing pieces of 
evidence that support the etiological role of immune responses to commensal bacteria in IBD 
development.   
There are other colitis models that are less frequently used by to study IBD. Colitis 
model induced by Citrobacter rodentium is one example. Citrobacter rodentium is an 
attaching and effacing pathogen and able to adhere to intestinal epithelium.
102
 Infection of 
mice with C. rodentium results in a breach of the colonic epithelial barrier that result in the 
induction of a vigorous Th1 inflammatory response and colitis.
103 
 
Conclusions from IBD animal models 
There are many animal models for IBD now, including what was described above and 
were not yet discussed. These IBD animal models have revealed that a variety of alteration of 
immune responses, including innate or adaptive immunity or immune regulatory mechanisms, 
can result in intestinal inflammation similar to human IBD.  The recurring themes derived 
from these animal models include: (1) host genetic background modulates the disease activity; 
(2) presence of gut flora including commensal bacteria provides the constant antigenic 
stimuli driving chronic colitis; (3) chronic inflammation is T cell mediated;  and (4) defective 
epithelial barrier function and alteration of immune regulation can induce the development of 
colitis. Notably, not all the gut bacteria have the same effect on the development of colitis
73
. 
In Chapter 3 of this dissertation, the ability or propensity for Helicobacter bilis to exacerbate 
the development of DSS-induced colitis will be discussed.   
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Within the intestinal mucosa, the aspects of the immune system that are relevant to the 
development of IBD are comprised of three functional categories including innate immunity 
(e.g., epithelial barrier function), adaptive immunity (e.g., effector CD4 T cells) and immune 
regulatory mechanisms (e.g., regulatory T cells). Severe impairment of a single category can 
lead to disease as has been shown in many animal models of IBD (e.g., Mdr1a
-/-
 
mice).
56
However, mild defects in several categories  can also lead to disease (e.g., 
C3H/HejBir mice and SAMP1/Yit mice).
79, 82
 These observations  fit the “multiple-hit 
hypothesis”, which postulates that defects in two or more components of intestinal mucosal 
immune systems are required for the development of IBD in immunocompetent hosts.
54
  
Although alteration of one or several categories of mucosal immunity may contribute to IBD 
development, the specific mechanisms by which interaction of those categories maintains gut 
homeostasis or results in intestinal inflammation are complex and not yet completely 
understood.  
       
Development of Inflammatory Bowel Diseases 
Currently, the precise etiology of IBD remains unknown. However, several factors have 
been considered to contribute to the development of IBD. They include genetic susceptibility, 
immune responses, luminal antigen/adjuvant and environmental factors.
1
 The most widely 
held hypothesis is that IBD is induced by the dysregulation of immune responses, innate 
and/or adaptive, to gut commensal bacteria in genetically susceptible hosts.   
 
Gut mucosal tolerance/homeostasis 
It is estimated that human gut harbors about 10
14
 total bacteria that include about 300 to 
500 species or strains.
104 
The mammalian intestinal mucosa comprises the largest lymphoid 
tissue in the body and is often referred to as gut-associated lymphoid tissue. However, 
intestinal cells associated with healthy mucosal surfaces are hyporesponsive to the huge 
antigenic load created by the resident bacterial flora and dietary constituents. This 
unresponsiveness is commonly referred to as “mucosal tolerance”.105 
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The underlying mechanisms, by which mucosal tolerance is maintained, are 
incompletely understood and may involve regulation of the complex interactions between 
luminal bacteria, epithelial cells, and lamina proprial cells.
106
 
Luminal commensal bacteria play important roles in the development of the mucosal 
immune system and immune responses. This can be demonstrated in germ-free mice that do 
not have a resident bacterial flora. In comparison to conventional mice, germ-free mice have 
smaller Peyer’s patches, have fewer intraepithelial lymphocytes, have reduced cytokine 
production, have reduced serum immunoglobulin levels, and are more susceptible to 
infection.
107
 In addition, the presence of a commensal flora facilitates the induction of 
protective, structural, and metabolic benefits for the host epithelium. Following the 
colonization of germ-free mice with a commensal bacterium (e.g., Bacteroides 
thetaiotaomicron), the expression levels of multiple host genes involved in nutrient uptake, 
metabolism, angiogenesis, mucosal barrier function, and the development of enteric nervous 
system were increased.
108 
 
Gut commensal bacteria seem to be important in maintaining mucosal homeostasis. It 
has been shown that recognition of commensal bacteria through Toll-like receptors and 
activation of Myd88 signaling is critical for protection against mucosal injury.
109
 Commensal 
bacteria have been demonstrated to limit mucosal NF-κ B signaling by inhibition of epithelial 
proteasome function,
110
 degradation of I-κB111 and nuclear export of NF-κ B subunit p65 
through a peroxisome proliferator-activated receptor (PPAR) γ-dependent pathway.112 
As a single layer of cells between luminal bacteria and mucosal lymphoid tissues, the 
intestinal epithelial cells play a vital role in maintaining mucosal homeostasis. Interdigitated 
epithelial cells fortified by tight junction proteins such as occludin and claudin serve to 
maintain the physical barriers in healthy individuals.
113
 Mucus covering the surface of 
epithelial cells also contributes to mucosal homeostasis. For example, Muc2
-/-
 mice 
spontaneously develop colitis
114
 and mice deficient in the gene encoding core 3-derived O-
glycans, an important component of mucin core protein, were more susceptible to 
experimental colitis in comparison to wild-type mice.
115
 A defective mucus layer, both in 
thickness (e.g., absence of mucus in severely inflamed mucosa) or composition (e.g., 
abnormal glycosylation of mucin) has been reported in IBD patients.
116  
In addition,  
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paneth cells, a special epithelial cell type in small intestine, can secret defensins to combat 
against the luminal bacteria.
117
  
Within the intestinal lamina propria, there are various types of immune cells including T 
cells, B cells, macrophages, dendritic cells (DCs), granulocytes, mast cells, NK cells, and 
NK-T cells. Among them, DCs are key cells in maintaining mucosal homeostasis. Dendritic 
cells can directly sample bacteria via opening the tight junctions between epithelial cells and 
extending dendrites into the intestinal lumen.
118
 In addition, DCs express the whole set of 
pattern-recognition receptors and can differentiate between the pathogenic and commensal 
bacteria.
119
 The function of DCs is regulated by their location, number, and maturation state. 
In healthy mucosa, DCs display immature or non-inflammatory phenotypes that are 
maintained by the paracrine activity of thymic stromal lymphopoeitin (TSLP) factors 
released from intestinal epithelial cells.
120
 More importantly, with the aid of retinoic acid and 
TGF-β, a subpopulation of gut DC (CD103+) appear to convert peripheral CD4+ T cells into 
Foxp3
+
 Treg cells, which also contribute to the maintenance of mucosal homeostasis.
121
 In 
addition, a more recent study reported that a population of CD11b
+
F4/80
+
CD11c
–
 
macrophages also involved in the induction of Foxp3
+
 Treg cells in lamina propria.
122
   
Collectively, the complex interaction between commensal bacteria, intestinal epithelial 
cells and lamina proprial immune cells (e.g., DCs, Treg cells) controls the balance between 
effector and regulatory immune subpopulations through tightly regulated cytokine networks 
in order to effectively maintain mucosal homeostasis in healthy individuals. Other immune 
effector cells, such as granulocytes, mast cells, natural killer cells, natural killer T cells, and 
macrophages reside in their individual tissue compartments and intracellular inhibitory 
mechanisms prevent the production and/or release of inflammatory mediators that prevent 
the generation of tissue damage. 
 
Development of IBD 
Disruption of gut homeostasis and development of IBD are commonly hypothesized to 
be the consequence of dysregulation of immune responses to commensal bacteria in 
genetically susceptible hosts.
1
How and why individuals generate inappropriate host immune 
responses to commensal bacteria, thus, initiating and perpetuating the development of IBD, is  
16 
  
not fully understood. In other words, what are the host susceptibility factors which contribute 
to pathogenesis of IBD? In this regard, recent studies of IBD pathogenesis have provided 
some clues that address how IBD is initiated or perpetuated.   
 
Alteration of mucosa barrier functions. 
Intestinal epithelial cells form a physiological barrier between luminal bacteria and the 
lamina proprial immune cells. Firstly, decreased mucosal resistance and increased 
permeability has been reported for intestinal tissue recovered from IBD patients and can be 
used to predict relapse during clinical remission.
123,124
 Changes in mucosal permeability are 
also demonstrable in some first-degree relatives of Crohn’s disease patients.125 The increased 
permeability might be caused by the changes in expression and distribution of tight junction 
proteins such as claudin 2, 5, or 8 in patients with active Crohn's disease.
126
 Recently, it has 
been shown that the primary defect of SAMP1/Yit mice, a spontaneous colitis model, is the 
presence of a leaky intestinal epithelial barrier that was correlated with the altered gene 
expression of the tight junction proteins claudin-2 and occludin.
87
 
Secondly, intestinal epithelial cells also participate in the process of detoxification and 
biotransformation of drugs and xenobiotics.
127
 Loss or dysregulation of detoxification and 
biotransformation of intestinal epithelial cells has been shown to contribute to the initiation 
and progression of IBD.
127
 A set of genes involved in phase 1, phase 2, and cellular efflux 
transporters of detoxification processes were coordinately downregulated in the colon of 
patients with ulcerative colitis.
128
 Those downregulated genes are the target genes of nuclear 
receptor PXR(pregnane x receptor).
 128
 Recently a PXR polymorphism was identified to be 
strongly associated with IBD susceptibility.
129
 Downregulation of detoxification genes were 
also found in IBD animal models such as DSS-induced colitis and TCRα-/- mice.130 Mdr1a-/- 
mice spontaneously develop colitis, further supporting the importance of mucosal 
detoxification in the initiation and perpetuation of IBD.
56 
 
With regards to intestinal epithelial cells, the aberrant expression and distribution of 
pattern recognition receptors including TLRs and Nod2 were also found in IBD 
patients.
131,132
 In healthy individuals, TLR2 and TLR4 were rarely expressed on the apical 
surface of epithelial cells while TLR3 and TLR5 were constitutively expressed on the 
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basolateral membranes of epithelial cells.
133,134
 However, TLR2 and TLR4 were significantly 
upregulated but TLR3 is downregulated on epithelial cells of IBD patients.
135
 
 
Aberrant immunoregulation 
In intestinal mucosa, DCs play key roles in inducing mucosal tolerance and active 
immune responses by interacting with T cells in either the mesenteric lymph nodes or the 
lamina propria.
136
 The decision relative to the choice between the induction of active 
immunity and tolerance will depend on the subpopulation of DCs involved and their 
activation phenotype, which is influenced by mucosal microenvironment.
 136
 Therefore, one 
of the factors contributing to the initiation of IBD is the inappropriate induction of a DC 
phenotype that facilitates the induction of aberrant immune responses to commensal 
bacteria.
137 
Associated with a loss of mucosal barrier function, activation of DCs could be 
caused by dysfunctional or exaggerated TLR signaling related to the increase of phlogistic 
components from the lumen. Expression of TLR2/4 and the activation/maturation marker 
CD40 on DCs has been shown to be significantly upregulated in IBD patients.
137
  
Due to the presence of over-activated DCs and other factors, the progression of IBD 
development likely involves either an over-production of effector T cells or the lack of 
appropriate regulation of effector T cells. The loss of central or peripheral tolerance leads to 
the long term survival of T cells often mediated by defective apoptosis.
138 
Evidence of 
defective T cell apoptosis and prolonged T cell survival has been found in the mucosa of 
patients with Crohn’s disease.138 As a measure of the role activated T cells play in the 
pathogenesis of IBD, induction of T cell apoptosis has been used to treat IBD patients.
139
  
In addition, an imbalance between mucosal effector T cells and Treg cells might also 
increase the potential for the development of IBD. In Crohn’s disease, naïve T cells have 
been shown to differentiate into Th1 or Th17 effector T cells, while in ulcerative colitis, Th2 
T cells are associated with disease progression/severity.
140
 Under a separate set of conditions, 
T cells can differentiate into Treg cells including naturally occurring Foxp3
+
 Treg, Tr1, or 
Th3 cells.
141
 The importance of Treg cells in controlling IBD has been convincingly shown 
in IBD animal models. Mice deficient in IL-2, IL-10, or TGF-β which are all involved in 
Treg cell development have been shown to spontaneously develop colitis.
88, 92, 142
 For 
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example, TGF-β is a critical factor that serves to determine the balance between pro-
inflammatory Th17 T cells and anti-inflammatory Treg cells.
143
 Endogenous and exogenous 
factors that alter the production of TGF-β and other anti-inflammatory cytokines are likely to 
affect the development of IBD. Induction of SMAD7, an inhibitor of TGF-β signaling, was 
implicated as a potential underlying mechanisms contributing to colitis in IBD patients.
144
 In 
addition, other Treg cells such as CD8
+
 Treg cells were described in IBD and found to be 
reduced or absent in cells recovered from the lamina propria of IBD patients.
145
 However, in 
contrast to murine studies,  most human IBD studies indicate that immune activation is 
driven by aggressive innate or T-cell responses, rather than defective immunoregulatory 
functions.
1
 
It is clear that multiple factors and complicated interactions associated with epithelial 
cell barrier function or aberrant immunoregulation play central roles in initiating and 
perpetuating the development of IBD.  Consistently, several genes involved in epithelial 
barrier functions including Mdr1a, Slc22a4, and Slc22a5 have been identified to be IBD 
susceptible genes.
146
 In addition, a variant of IL-23R, a receptor expressed on the surface of 
Th17 T cells, has been strongly associated with the reduced risk of IBD
147
 suggesting that IL-
23R-mediated adaptive immunity is also critical in IBD development. So the identification of 
IBD susceptible genes reiterates the importance of epithelial barrier functions and immune 
responses in the development and maintenance of IBD.  
Following the initiation of IBD, there are some common or secondary events that 
precede the development of intestinal inflammation. First, activation of immune responses 
correlates with the upregulation of chemokines, chemokine receptors, and adhesive 
molecules leading to infiltration of different immune and inflammatory cell types. Up-
regulation of chemokines and chemokine receptors has been described in a series of studies 
examining clinical and experimental colitis.
148 
The major chemokine and chemokine 
receptors associated with the onset of IBD included CXCL8/IL-8, CCL5/RANTES, 
CCL2/MCP-1, CCL6/MCP-3, CCR5, CCR2, CCR1 and were involved in the infiltration of 
inflammatory cells such as neutrophils, macrophages, and T cells.
149
 Notably, α4β7+CCR9+ T 
cells, which can be effector T cells, are specifically recruited into the intestinal lamina 
propria, especially to the small intestine.
150
 The CCL5-CCR5 chemokine axis was identified 
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to be involved in preferential recruitment of FoxP3
+
 Tregs into inflamed small intestine in 
SAMP1/YP mice, which prevents further exacerbation of chronic inflammation in the 
intestine.
151
 
Chemokines and chemokine receptors are crucial inflammatory mediators of IBD and 
contribute to the pathogenesis of IBD.
152
 It has been reported that the use of chemokine or 
chemokine receptor antagonists as well as monoclonal antibodies specific for adhesion 
molecules can be used to treat IBD patients.
153,154
 For example, antibodies against the α4 
chain
155
 or the α4β7 integrin attenuated the severity of IBD.156 In addition, the influx of 
inflammatory cells into the mucosa results in the release of many metabolic and 
inflammatory mediators including cytokines, chemokines, nitric oxide, oxygen radicals, 
prostaglandins, leukotrienes, histamine, proteases, and matrix metalloproteinases, which 
eventually induces tissue damage.    
 
Mucosal gene expression profiles in IBD  
Inflammatory bowel diseases are idiopathic, multigenic disorders involving a complex 
interaction among genetic, environmental, and immunological factors.
157
Analysis of a single 
or select few genes is not likely to provide an accurate picture on how and why IBD develops. 
Microarray technology provides a novel and powerful tool that can be used to define the 
changes in the large-scale transcriptional profile and help to understand the complex 
molecular interactions associated with acute and/or chronic IBD.  
To date, multiple studies have utilized microarray technology to define mucosal genes 
expression profiles in IBD patients and/or animal models.
158-163, 128,130 
The methods and 
conclusions drawn by these studies vary due to that different microarray types, statistical 
methods, tissues/cell population, and stages of disease were employed. However, they do 
provide a broad picture regarding the changes in mucosal genes expression during the 
development of IBD. More importantly, several previously known and unknown groups of 
differentially expressed genes were identified by microarray analysis of intestinal samples 
collected during the development of IBD.
164 
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(1) Genes that mediate inflammation.  
This group of genes includes cytokines, chemokine/chemokine receptors, complement 
components, transcription factors or adaptor molecules in signal transduction. Predictably, 
this was the most strongly and consistently upregulated group of genes in both IBD patients 
and animal models. For example, upregulation of genes encoding IL-1ß, IL-6, IL-8, 
lymphotoxin-β, IL-1 receptor antagonist (IL-1RA), and cyclooxygenase-2 (Cox2) were 
reported in tissue samples recovered from inflamed colon in comparison to samples from 
sections of non-inflamed mucosa collected from patients with ulcerative colitis.
158
 Another 
study summarized a series of genes that are known to change transcriptional activity in IBD, 
including TNFα, IFN-γ, Ltβ, IL-6, IL-16, IL-18R1, IL-22, CCR2, CCR7, CCL2, CCL3, CCL4, 
CCL5, CCL7, CCL11, CCL17, CCL20, CXCR3, CXCL1, CXCL5, CXCL10.
163
 The up-
regulation of these genes reflected the induction of a non-specific inflammatory reaction 
characteristic of both Crohn’s disease and ulcerative colitis. Interestingly, most differentially 
expressed genes encoding cytokine or chemokine/chemokine receptors are detected in the 
CD45RB
high
 transfer model of colitis, in comparison to TNBS and DSS-induced colitis, 
suggesting that the CD45RB
high
 transfer model better resembles human IBD.
163
  
 
(2) Genes that inhibit inflammation.  
Genes encoding anti-inflammatory molecules are commonly upregulated in inflamed 
tissue, possibly providing a mechanism of negative feedback that facilitates tissue repair or 
restitution. For example, indoleamine 2, 3-dioxygenase (IDO) is a tryptophan-catabolizing 
enzyme that has been shown to be potent inhibitor of T cell responses.
165
  Over expression of 
IDO was reported in tissues samples recovered from patients with either form of IBD and in 
epithelial cells recovered from colitic mice using either the DSS-induced or TCRα-/- colitis 
models.
158, 166, 130
 Suppressor of cytokine signaling 3(SOC3) plays an important role in 
negative regulation of cytokine signaling and suppression of colitis.
167
 Expression levels of 
Socs3 were significantly upregulated in colonic epithelial cells of IL10
-/-
 and TCRα -/- mice, 
in SCID mice used in theCD45RB
high
 transfer model, and in mice with DSS-induced 
colitis.
130
 Another study identified five upregulated inflammatory signature genes (MRP14, 
GROγ and SAA1, TIMP1 and Elafin) in colonic tissue recovered from patients with ulcerative 
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colitis; it should be noted that two of these genes (TIMP1 and Elafin) have anti-inflammatory 
effects.
160 
 
 
(3) Genes that promote cell growth/apoptosis. 
The Reg gene family includes regenerating islet-derived 1A (Reg1a), Reg1b, Reg3b, and 
Reg3g and has been shown to stimulate the proliferation of pancreatic cells and gut epithelial 
cells.
168, 169
 The strong upregulation of Reg gene family has been shown in ulcerative 
colitis,
158
 Crohn’s disease,159 and various IBD animal models.130 Interestingly, in DSS-
induced colitis, Reg3g was only detectable in the acute stages of inflammation (e.g., at 4 days) 
as opposed to the restitution period indicating its role during acute inflammation.
130
 The S100 
gene family, including S100a8, S100a9, and S100b, encode inflammatory proteins produced 
by phagocytes and are involved in apoptosis.
170
 Upregulation of  the S100 gene family has 
been also shown in inflamed colon of patients with ulcerative colitis,
158,159, Crohn’s 
disease,
159 
and animal models.
163
 
 
(4) Genes that participate in detoxification process.  
One study showed that a set of detoxification-associated genes involving phase I (e.g., 
Cyp3A4) and phase II (e.g., Ugt1a3) enzymes along with cellular efflux transporters (e.g., 
Mdr1a) were coordinately downergulated in colonic (not ileum) tissues of patients with 
ulcerative colitis (not Crohn’s disease).128 These changes were correlated with the 
downregulation of pregnane X receptor (PXR), which was suggested to regulate many of 
these detoxification-associated genes.
128
 The fact that PXR gene locus is strongly associated 
with IBD predisposition
171
 and PXR agonist can ameliorate DSS-induced colitis
172
 
emphasized the importance of the dysregualtion of detoxification processes in the 
pathogenesis of IBD. Following the analysis of intestinal epithelial cells, the down regulation 
of several detoxification genes including cytochrome P450 genes (e.g., Cyp2c40), selenium 
binding protein 1(Sbp1), multidrug resistance gene 1a (Mdr1a), phenol sulfotransferase-1 
(Pst-1), carbonic anhydrase IV (Car4) has been reported in several animal models of chronic 
IBD.
130, 173
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(5) Genes that mediate fatty acid metabolism.   
Fatty acids play an important role in inflammatory processes as well as in ensuring 
nutrition and cellular integrity by providing a molecular source for phospholipid synthesis.
174
 
In comparison to control tissues, a series of genes associated with fatty acid metabolism were 
downregualted in colonic mucosal tissue recovered from patients with ulcerative colitis.
159
 
These findings are consistent with an earlier hypothesis that energy deficiency is a significant 
factor in the pathogenesis of colitis.
175
 Another study identified changes in the expression of 
the liver fatty acid-binding protein (L-fabp), which was significantly downregulated in 
inflamed mucosa of patients with ulcerative colitis, as one of inflammatory signature 
genes.
160
 In addition, the genes associated with fatty acid synthesis such as fatty acid 
synthase (Fasn) and sterol regulatory element binding transcription factor 1(Srebp1) were 
significantly downregulated in the colons of patients with ulcerative colitis, which could be 
partially associated with the loss of liver X receptor (LXR).
161
 Changes in the expression 
pattern of genes involved in fatty acid uptake, metabolism and synthesis may be partially a 
consequence of inflammation, but also seem to contribute substantially to IBD 
pathophysiology.
161
 Downregulation of fatty acid metabolism was also shown in other 
inflammatory disorders and was linked to a relative state of malnutrition.
176 
 
 
(6) Other genes.  
Not surprisingly, many other genes which have not been discussed here were 
upregulated or downregulated in the mucosa of IBD patients or animal models, in 
comparison to controls.
 158-163, 128,130
 Some of these genes might be involved in antigen 
presentation (e.g., genes encoding MHC I and MHC II), synthesis of immunoglobulin, cell 
adhesion, and tissue extravasation (e.g., genes encoding matrix metalloproteases, MMPs). 
For example, the MHC II genes associated with antigen-presentation  were upregulated in 
colitis of TCRα-/- mice, indicating the elevated antigen presentation activities in colitis.130 
Matrix metalloproteinases (MMPs) are responsible for the turnover and degradation of 
extracellular matrix and multiple MMPs (e.g., MMP-1, MMP-3, MMP-7, MMP-9, MMP-13) 
were significantly upregulated in colon of IBD patients, in comparison to control.
177-179
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Collectively, the general trend for IBD mucosal gene expression appears to be 
upregulation of genes associated with pro-inflammation, anti-inflammation, and cell 
growth/apoptosis along with the downregulation of genes associated with detoxification and 
fatty acid metabolism. These changes likely reflect the activation and regulation of immune 
responses, alteration of mucosal barrier functions, and metabolic activity, all of which are 
consistent with the major parameters believed to be associated with the development of IBD: 
aberrant immune responses, mucosal permeability, and genetic predisposition. Further more, 
this is consistent with the “multi-hit hypothesis”   that the onset of IBD in immunocompetent 
hosts requires at least two triggers such as the alteration of mucosal barrier function and 
dysregulation of immune function.   
 
Two animal models of intestinal inflammation used in this dissertation 
In this dissertation, two animal models were used to study changes in gene expression 
associated with a predisposition to develop colitis (i.e., H. bilis –induced intestinal 
inflammation and Brachyspira hyodysenteriae –induced colitis). Those two models are novel 
and different from previous classical IBD animal models.  
. 
Helicobacter bilis colonization in gnotobiotic C3H mice 
Helicobacter bilis is a microaerophilic, gram-negative spiral-shaped bacterium originally 
isolated from the livers and intestines of aged, inbred mice.
180
 It is a member of an expanding 
and genetically diverse group of enterohepatic Helicobacter spp including H. hepaticus, H. 
rodentium, H. muridarum.
181
 In addition to mice, H. bilis has been isolated from dogs, gerbils, 
rats, cats, and humans.
182,183
 Helicobacter bilis and other enterohepatic Helicobacter spp are 
widely spread among research and commercial rodent colonies and might significantly 
confound interpretations of some research.
184,185
Additionally, experimental infection of a 
variety of immune competent and genetically-engineered (i.e., transgenic) mouse strains with 
Helicobacter spp have been used to develop animal models of gastrointestinal diseases as 
well as idiopathic human disease syndromes such as inflammatory bowel disease.
185
 
Helicobacter bilis can either induce or accelerate the development of inflammatory 
bowel disease in immunodeficient rodents though H. bilis infection in immune competent 
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mice often results in subclinical disease. 
61,62, 186-189
 SCID mice inoculated either 
intraperitoneally or orally with H. bilis develop proliferative typhlocolitis.
186,187
 Co-infection 
of mice with H. bilis and H. rodentium has been associated with a outbreak of colitis in a 
SCID mouse colony.
190
 Helicobacter bilis alone or with H. hepaticus has been shown to 
accelerate the development of colitis in Mdr1a
-/-
 mice.
61,62
 In addition, H. bilis colonization 
induced moderate to severe colitis in IL-10
-/-
 mice, TCR α -/- mice, and athymic rats.188,189 
The increased severity of colitis in IL-10
-/-
 mice colonized with H. bilis correlates with the 
elevated expression of MHC class II and pro-inflammatory cytokines including IL-1α, IL-1β, 
and IL-1 receptor α in colon.188 Collectively, these studies strongly support a hypothesis that 
H. bilis renders the immunodeficient host more susceptible to the development of colitis, 
though T cells might not be strictly essential in this process.  
Emerging evidence suggests that subclinical Helicobacter infection may alter host 
responses to other experimental stimuli such as gut flora in unanticipated ways.
185 
Consistently, the recent studies in our laboratory showed that, H. bilis colonization  of  
immunocompetent C3H/HeN gnotobiotic mice triggered persistent antibody and cytokine 
responses to commensal bacteria in the absence of overt inflammation, indicating a 
dysregulation of gut homeostasis.
191-193
 Since immune responses to commensal bacteria play 
a key role in IBD etiology,
1
 it is hypothesized that immune responses to commensal bacteria 
induced by H. bilis colonization might initiate or perpetuate the development of IBD. Indeed, 
the data presented in Chapter 3 will show that H. bilis colonization increased host 
susceptibility to a subsequent colitic insult (e.g., low dose DSS), thus, H. bilis colonization in 
C3H/HeN gnotobiotic mice providing a novel IBD susceptibility model.  
C3H/HeN:Tac gnotobiotic mice are colonized by only eight commensal bacteria in the 
gut known as Altered Schaedler’s Flora (ASF) which includes ASF356, Clostridium cluster 
XIV; ASF360, Lactobacillus acidophilus; ASF361, Lactobacillus murinus;. ASF457, 
Mucispirillum schaedleri; ASF492, Eubacterium plexicaudatum; ASF500, low-G+C 
content-positive bacteria; ASF502, Clostridium cluster XIV; and ASF519, Bacteroides 
distasonis.
191
 One of the major advantages of this model is that immune response to each 
commensal bacterium can be studied individually due to the nature of defined-flora.   
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In contrast to germ-free mice, these gnotobiotic C3H mice have normal anatomical and 
physiological functions. Also in contras to many immunodeficient IBD models, these mice 
are immunocompetent. In conclusion, Helicobacter bilis colonization of C3H/HeN:Tac 
gnotobiotic mice is a unique and practical animal model to chronologically study the 
induction of host susceptible factors associated with mucosal inflammation.  
The studies related to the pathogenesis or virulence factors of H. bilis might greatly 
contribute to a better understanding of this IBD models. The biochemical characterization of 
H.bilis showed that H. bilis is urease, catalase and oxidase positive and can reduce nitrate to 
nitrite.
180
 Several enterohepatic Helicobacter species including H. bilis and H. hepaticus 
contain cytolethal distending toxin (CDT), which that has the potential to induce distention in 
cells and to arrest cell division in the G2/M phase of cell cycle.
194
 Cytolethal distending toxin 
has also been shown to play a key immunomodulatory role that facilitates persistent 
colonization of H. hepaticus and that, in IL-10
-/-
mice, this alteration of the host immune 
response results in the development of colitis .
195 
 It is possible that CDT of H. bilis has 
similar functions to that of H. hepaticus. 
 
 Brachyspira hyodysenteriae –induced colitis 
Brachyspira hyodysenteriae, previously referred to as Treponema hyodysenteriae or 
Serpulina hyodysenteriae, is a gram-negative, anaerobic spirochete and is the causative agent 
of swine dysentery, a mucohemorrhagic diarrheal disease characterized by severe 
inflammation of cecum and colon.
196
 Histological lesions in pigs include crypt elongation, 
superficial epithelial erosion, submucosal edema, inflammatory cell infiltration and mucosal 
hyperplasia etc.
197
 These characteristics are similar to that of human ulcerative colitis. 
Brachyspira hyodysenteriae infection has been used as a model to study infectious or 
bacterial-induced colitis.
197-199
 
  In addition to pigs, several other species of animals including guinea pigs and  chicks  
develop intestinal lesions after B. hyodysenteriae infection and  have been utilized as 
alternative models.
200, 201
 However, mice have been the most commonly used and well-
documented laboratory animal model used to study the pathogenesis of swine dysentery.
202
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In contrast to pigs, the lesions induced by B. hyodysenteriae in mice model are less severe 
and limited to the ceca.  
Intestinal inflammation induced by B. hyodysenteriae is characterized by the massive 
infiltration of inflammatory cells, particularly neutrophils. It has been shown that neutrophil 
depletion by anti-Ly6G treatment significantly reduced the intestinal lesions induced by B. 
hyodysenteriae infection.
202
 In addition, anti-CD18 treatment also inhibited neutrophil 
infiltration and reduced intestinal lesions.
202
 This study demonstrated the importance of 
neutrophil infiltration in the development of acute colitis induced by B. hyodysenteriae 
infection. Brachyspira hyodysenteriae infection also induced the temporal upregulation of 
pro-inflammatory cytokines (e.g., IL-1, IL-6, TNFα and MIP2) in murine cecal mucosa 
(unpublished data).   
The exact pathogenesis of B. hyodysenteriae-induced colitis is not completely 
understood. However, several virulence factors including hemolysin and lipopolysaccharide 
(LPS) have been suggested. 
203, 204
 It has been shown that the hemolysin of B. hyodysenteriae 
induces similar early morphologic changes in mice ceca as observed  following infection 
with B. hyodysenteriae.
203
 On the other hand, endotoxin-like preparations such as 
butanol/water extract of B. hyodysenteriae can induce IL-1 and TNF production by murine 
peritoneal exudate cells (PECs), indicating that spirochetal components have pathological 
characteristics and potentially contribute to intestinal inflammation.
204 
 
Convincing evidence shows that the presence of gut flora is indispensible for the lesion 
development induced by B. hyodysenteriae in both pigs and mice.
205-208
 Germ-free pigs or 
germ-free mice infected with B. hyodysenteriae alone did not develop intestinal lesions or 
clinical disease even though B. hyodysenteriae colonized the colon and invaded  the cecal 
mucosa.
205-208
  These results demonstrated that the presence of other commensal bacteria 
such as Bacteroides vulgatus is required for the development of colitis following infection 
with B. hyodysenteriae. Antibiotics have been widely used to treat swine dysentery induced 
by B. hyodysenteriae infection, generating concern for the development of antibiotic 
resistance bacteria.
209,210
 The use of drugs that would regulate host inflammatory responses 
as opposed to antibiotic therapy including plant extracts such as hypoxoside may represent a 
novel treatment option for diseases such as those caused by B. hyodysenteriae. 
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In this dissertation, we first studied the mucosal gene expression profiles at 15, 30 and 
45 days following the colonization of Helicobacter bilis in gnotobiotic immunocompetent 
mice. This study showed that H. bilis colonization could significantly and persistently 
downregulate the genes associated with detoxification processes, which is consistent with 
other microarray studies
128, 130,   178 
and might predispose the host to the development of 
colitis. Secondly, we demonstrated that H. bilis colonization can exacerbate colitis induced 
by dextran sodium sulfate treatment. The effects of H. bilis might be associated with both 
downregulation of detoxification-associated genes and upregulation of genes involved in the 
activtation /recruitment of macrophage and T cells.  Lastly, we switched to another other IBD 
model using Brachyspira hyodysenteriae - induced colitis. We were able to determine that  
hypoxoside, an anti-inflammatory drug extracted from an African traditional medicine 
Hypoxis hemerocallidea could ameliorate the colitis induced by B. hyodysenteriae infection. 
More importantly, the anti-inflammatory effects of hypoxoside appeared to be associated 
with the reduction of neutrophil infiltration, downregulation of genes involved in the NF-κB 
signaling pathways and the detoxification process resulting in decreased epithelial cell 
proliferation, but not anti-microbial activity.  In conclusion, the studies in this dissertation 
suggest differential mucosal gene expression induced by different agents such as with a mild 
bacterial pathogen, Helicobacter bilis or use of an anti-inflammatory drug, hypoxoside could 
alter the mucosal epithelial barrier functions and/or immune regulation of lamina propria, and 
then modulate the process of murine colitis development.    
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ABSTRACT 
Mechanisms associated with the development of inflammatory bowel diseases include 
aberrant immune responses to the resident flora, changes in mucosal barrier function, and 
genetic predisposition of the host. It has been shown that colonization of gnotobiotic mice 
with Helicobacter bilis triggers host immune responses to the commensal flora. The 
mechanisms by which H. bilis colonization affects mucosal homeostasis and the development 
of immune responses to the flora have not been determined. Using microarray analysis, 
changes in mucosal gene expression contributing to an increased susceptibility to colitis were 
evaluated following H. bilis colonization. Differential gene expression (q ≤ 0.05, fold 
change > 2) within the cecal mucosa was assessed at 15, 30, or 45 days following H. bilis 
colonization using Affymetrix Genechips. The expression of selective genes was confirmed 
by quantitative RT-PCR.  H. bilis colonization induced marked upregulation of genes 
associated with protein metabolism, immune responses, and downregulation of genes 
associated with fatty acid metabolism and detoxification which peaked at 15 days 
postinfection. A set of genes associated with glycoprotein synthesis and detoxification 
including Fut2, B3galt5, Ceacam12, Cyp4b1, and Ugt8a were uniquely identified and found 
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to be similarly expressed following the induction of colitis by dextran sodium sulfate or  
Brachyspira hyodysenteriae.In addition to the immune response-associated genes (e.g., 
interferon-inducible genes), genes associated with mucosal homeostasis, such as glycoprotein 
synthesis and detoxification, were shown to be differentially expressed and these changes 
correlated with the observed increased susceptibility to colitis induced by H.bilis colonization 
of gnotobiotic mice. 
Key Words: Helicobacter bilis, gene expression, mucosa, susceptibility, colitis 
 
INTRODUCTION 
Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative 
colitis (UC), are characterized by chronic, relapsing inflammation of the gastrointestinal tract.  
Although the exact etiology of the inflammatory disorders remains unknown, it is widely 
hypothesized that dysregulated innate and/or adaptive immune responses to antigens derived 
from the intestinal microflora contribute to the onset and/or severity of IBD.
1-3
   
Helicobacter bilis is a microaerophilic, gram-negative spiral-shaped bacterium and 
causes mild, subclinical inflammation in immunocompetent hosts.
4
 Several studies have 
linked H. bilis to the development of or acceleration of proliferative typhlocolitis in 
immunocompromised rodents such as SCID, Mdr1a
-/-
, IL-10
-/-
 and TCRα -/-mice, as well as 
athymic nude rats.
5-9
 Using immunocompetent C3H/HeN gnotobiotic mice, which harbor the 
eight members of the altered Schaedler’s flora (ASF), previous studies have shown that H. 
bilis colonization did not induce demonstrable inflammation yet triggered persistent antibody 
and cytokine responses to antigens derived from the resident flora, which were not observed 
in control mice.
10-12
 These results indicate that introduction of a novel bacterial species such 
as H. bilis into the gastrointestinal microbiota alters mucosal homeostasis which may 
increase the host’s susceptibility to the development of colitis. In contrast to many other IBD 
models using mice with various degrees of immunodeficiency and/or undefined microflora, 
immunocompetent gnotobiotic mice colonized with H. bilis provides a unique and practical 
model to study the roles of host immune responses to specific commensal bacteria in the 
development of IBD. However, the molecular mechanisms affecting the alteration of immune 
responses induced by H. bilis colonization remain unknown.  
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The advance of microarray technology has greatly expanded our ability to systematically 
monitor the effect of pathogens on the host gene expressions.
13
 In this study, Affymetrix 
Genechips were employed to study global and temporal gene expression profiles of cecal 
mucosa following the colonization of gnotobiotic mice with H. bilis. The differentially 
expressed genes were functionally classified and linked to host susceptibility to colitis. In 
addition to the immune response-associated genes, some genes associated with gut 
physiological homeostasis such as glycoprotein synthesis and detoxification were found to be 
differentially expressed and likely contributed to the increased susceptibility to colitis 
induced following H. bilis colonization. To assess whether or not the observed changes in 
mucosal gene expression were common to other colitic insults, two other models of colitis 
(dextran sodium sulfate and Brachyspira hyodysenteriae) were used to evaluate changes in 
gene expression.  The results of these studies identified a set of genes with similar changes in 
their pattern of gene expression as previously reported for other IBD animal models. Using 
an immunocompetent gnotobiotic mouse model, this study provides preliminary evidence 
and insights as to the types of factors or changes induced within the intestinal mucosa that 
might predispose the host to the development of colitis.  
 
MATERIAL AND METHODS 
Animals and Treatments. Eight to nine week old, gnotobiotic C3H/HeN: TAC mice 
colonized with the ASF were obtained from Taconic Farms (Germantown, NY) and 
gnotobiotically maintained at Iowa State University. Members of the ASF include ASF356, 
Clostridium cluster XIV; ASF360, Lactobacillus acidophilus; ASF361, Lactobacillus 
murinus; ASF457, Mucispirillum schaedleri; ASF492, Eubacterium plexicaudatum; ASF500, 
low-G+C content-positive bacteria; ASF502, Clostridium cluster XIV; and ASF519, 
Bacteroides distasonis. All animal-related procedures were approved by the Animal
 
Care and 
Use Committee at Iowa State University. 
Helicobacter bilis was cultivated and harvested as described.
10
 Mice were orally 
colonized once daily over three consecutive days with approximately 10
8 
CFU of H. bilis.   
Experimental colitis was induced by dextran sodium sulfate (DSS) (MP Biomedicals, 
Solon, OH), which was dissolved in drinking water to a concentration of
  
2% (weight/volume) 
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or oral infection with 10
8
 CFU Brachyspira hyodysenteriae 
10
. The spirochetal infection was 
confirmed by demonstration of β-hemolytic spirochetes recovered from colonic contents. 
Five days after DSS treatment or seven days after B. hyodysenteriae infection, cecal tissues 
were collected and total RNA were isolated using the RNeasy Mini Kit and RNase-Free 
DNase according to the manufacture’s protocol (Qiagen, Valencia, CA). 
Experimental design. Mice were randomly assigned into three pairs for each of four 
separate treatment groups (Control, H. bilis 15 DPI, H. bilis 30 DPI, and H. bilis 45 DPI). 
Two mice from each treatment group were assigned to a separate Genechip. Mice were 
inoculated with H. bilis at 15, 30, or 45 days prior to necropsy. H. bilis colonization was 
confirmed by both PCR 
10 
and bacteriological culture. At necropsy, samples of cecal tissues 
obtained from two mice within the same treatment were pooled in order to reduce the 
potential variability associated with evaluating individual tissue samples. Total RNA was 
isolated from cecal tissue samples as described above.    
Histology. Microscopic lesion scores were evaluated as previously described.
10
  Briefly, 
tissues were formalin-fixed, embedded in paraffin, sectioned at 5 μm, and stained with 
hematoxylin and eosin (H&E). Stained cecal sections were scored by a pathologist (Dr. J. M. 
Hostetter, Department of Veterinary Pathology, Iowa State University) in a blinded fashion. 
Histological scores were based on the severity of mucosal epithelial damage, degree of 
lamina propria cellular infiltrate, and architectural distortion.
10 
 
Affymetrix oligonucleotide array analysis. Total RNA samples extracted from cecal 
tissues were submitted to the Iowa State University Genechip Facility (Ames, IA). Labeling 
of samples, generation of cRNA, hybridization, staining, and scanning were performed 
according to protocols in the Affymetrix Expression Analysis Technical Manual (Affymetrix, 
Santa Clara, CA). Affymetrix Mouse genome 430 2.0 arrays were used in this experiment. 
Fluorescence intensity values (.CEL files) generated from hybridized and labeled 
genechips were analyzed using R software (http://www.r-project.org)  and a Bioconductor 
analysis package (0Hhttp://www.bioconductor.org). Data were normalized using Robust Multi-
array Average (RMA).
14
 False discovery rate (q value) of normalized data was computed 
using Storey and Tibshirani's default method.
15
 Differentially expressed genes were 
statistically filtered using a q value ≤0.05 and a estimated fold change relative to control 
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values ≥ 2 or ≤-2. The differentially expressed genes were clustered using both hierarchical 
cluster via Pearson correlation and K-means methods. Assignments of filtered genes to 
functional categories were performed by using Database for Annotation, Visualization and 
Integrated Discovery (DAVID) bioinformatics resource 2007 (National Institutes of Health, 
Bethesda)
16
 and/or literature-based classification schemes.  Fisher exact tests were performed 
to calculate P values and determine which particular annotation categories were over-
represented.    
 Quantitative reverse transcription polymerase chain reaction (qRT-PCR). Total 
RNA samples from mouse ceca were treated with Turbo DNA-free DNase (Ambion, Austin, 
TX) to remove genomic DNA contamination and were then reverse transcribed into cDNA 
by SuperScript™ III First-Strand Synthesis System (Invitrogen, Carlsbad, CA). The cDNA 
converted from 20 ng RNA was amplified using Platinum® SYBR® Green qPCR SuperMix-
UDG (Invitrogen). The PCR conditions used for these studies were established as follows: 
95°C for 10 minutes, and then followed by 40
 
cycles of amplification (95°C for 15 seconds, 
60°C for 60 seconds). The relative mRNA quantities were normalized against 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and control samples. The quantitative 
PCR was performed using a Rotor-Gene 3000 (Corbett Research, Mortlake, Australia). 
Standard curves for the selected genes and GAPDH were made using serial dilutions of 
cDNA. The correct sizes of the amplified PCR products were confirmed by gel 
electrophoresis.  The primer sequences used in these studies are available on request. 
Statistics. The data are expressed as mean ± SEM. The group comparisons were made 
using the robust Kruskal–Wallis non-parametric analysis of variance (ANOVA). If 
comparisons were statistically significant (P<0.05), then an analysis of the pairwise means 
were compared using a two-sided Wilcoxon rank-sum test. 
 
RESULTS 
Histological lesions. It has been shown that colonization of immunocompetent C3H 
gnotobiotic mice with Helicobacter bilis triggers persistent host immune responses to the 
resident commensal bacteria without the induction of overt macroscopic or microscopic 
inflammation 
10, 11
. In these studies, H. bilis colonization of gnotobiotic mice resulted in 
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subtle histological changes in cecal and colonic mucosa characterized by small increases in 
the density of lymphocytes and plasma cells within the lamina propria, and small increases in 
mucosal height. While the histological lesion scores at 15 DPI were higher than those at 30 
and 45 DPI, there was no statistically significant difference observed by light microscopy 
(Fig. 1). As previously demonstrated,
10,  11
 H. bilis colonization of gnotobiotic mice induced 
antigen-specific antibody responses to resident ASF that was observed at 15, 30, and 45 DPI 
(data not shown). Collectively, these data indicated that there were slight morphological 
changes within the colonic mucosa following H. bilis colonization that did not directly 
correlate with the development of host immune responses to the resident flora or the 
increased sensitivity of these mice to a subsequent colitic insult such as of DSS (Chapter 3). 
To extend these observations, changes in the transcriptional profile of the cecal mucosa was 
evaluated to elucidate the effect of H. bilis colonization on mucosal homeostasis.  
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Figure 1. Evaluation of cecal histological lesions of gnotobiotic mice following the 
colonization of Helicobacter bilis. Cecal tissues (0, 15, 30, 45 DPI) were stained with 
hematoxylin and eosin (H&E) and evaluated by a pathologist in a blinded fashion. 
Histological scores were determined as outlined in “Materials and Methods”. Bars represent 
the mean ± SEM; n=4-6 mice/group. There was no statistical difference between any of the 
groups.   
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Mucosal gene expression after H. bilis colonization.  
Overall gene expression patterns and functional annotation analysis 
In the absence of overt mucosal inflammation, it was hypothesized that H. bilis 
colonization would induce changes in the pattern of gene expression that would alter mucosal 
homeostasis. To evaluate the effect of H. bilis colonization on mucosal homeostasis, 
microarray analysis was performed at three separate time points following colonization.  
Scatterplots of overall gene expression profiles across experimental groups showed 
variable degrees of correlation between samples obtained from control mice versus those 
colonized with H. bilis. As indicated by the number of dots above or below the diagonal line, 
there was a marked discorrelation between the pattern of gene expression at 15 DPI and the 
controls (Fig. 2A). Similar levels of moderate discorrelation of gene expression levels existed 
between samples from mice infected for 30 or 45 DPI versus control mice (Fig. 2B and data 
not shown). However, there was high correlation between samples collected at 30 and 45 DPI 
(Fig. 2C). These data indicate that the overall gene expression profiles at 15 DPI differ from 
those of 30/45 DPI which may represent acute versus chronic changes in mucosal gene 
expression.  
Using q value ≤0.05 and an estimated fold change relative to control values ≥ 2 or ≤-2, 
115 differentially expressed genes were identified following H. bilis colonization, which 
could be separated into three patterns of gene expression by K-means cluster analysis (Fig. 3). 
Pattern 1 revealed a set of genes whose expression levels were upregulated at 15 DPI and 
returned to near background levels by 30 DPI (Fig. 3A). Pattern 2 defined a group of genes 
whose expression levels were upregulated at 15 DPI and remained elevated through 45 DPI 
(Fig. 3B). Pattern 3 included genes that were maximally down-regulated by 15 DPI and 
remained down-regulated through 45 DPI (Fig. 3C).  
Hierarchical clusters showed that, in comparison to samples from control mice, the 
greatest numbers of genes were differentially expressed at 15 DPI. In addition, there were few 
differentially expressed genes when samples from mice colonized for 30 and 45 days were 
compared (Fig. 4). This data was consistent with the correlation of overall gene expression 
profiles after H. bilis colonization as depicted by the scatterplot analysis in Figure 2 (i.e., 
tighter clustering along the diagonal line). 
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Figure 2.  Scatterplot analysis depicting comparative changes in mRNA expression over 
time following the colonization of gnotobiotic mice with Helicobacter bilis. Changes in gene 
expression over time were expressed as the overall signal intensity of all genes in the cecal 
mucosa of gnotobiotic mice at 0, 15, 30 or 45 days after H.bilis colonization. Dots above the 
diagonal line represent upregulated genes while dots below the diagonal line represent down-
regulated genes. (A) Comparison between samples collected at 15 DPI vs. control; (B) 30 
DPI vs. control; (C) 45 DPI vs. 30 DPI. n=6 mice/group. 
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Figure 3. Patterns of differentially expressed genes as determined by K-means cluster 
analysis following the colonization of gnotobiotic mice with Helicobacter bilis. Differential 
mucosal gene expression was defined using a q value ≤ 0.05 and fold change relative to 
control ≥ 2 or ≤-2. Three separate temporal patterns (1, 2, and 3) of gene expression were 
detected. The average expression levels of each gene across all time points were standardized 
to zero. (A) Pattern 1 contained 39 genes (B) Pattern 2 contained 41 genes (C) Pattern 3 
contained 35 genes. n=6 mice/group. 0: Control, 15: 15 DPI, 30: 30 DPI, 45: 45 DPI. 
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Figure 4.  Hierarchical cluster analysis and functional annotation of differentially 
expressed genes.  Genes were clustered using Pearson correlation. Functional annotation of 
the differentially expressed genes  (q value ≤ 0.05 and fold change relative to control samples 
of  ≥ 2 or ≤-2) for samples obtained from gnotobiotic mice at 15, 30 or 45 days following 
colonization with Helicobacter bilis are depicted. Orange to red colors represent upregulated 
genes over control, and gray to blue colors represent downregulated genes over control. The 
color bar and relative fold change it represents is denoted on the right. The gene lists were 
ontologically grouped using the DAVID bioinformatics resource 2007. P values were 
calculated using Fisher exact probability test and were used to determine the over-
represented functional annotations.   C: Control; 15: 15 DPI; 30: 30 DPI; 45: 45 DPI.  
A 
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The lists of differentially expressed gene were analyzed using the DAVID 
bioinformatics resource 2007 and several over-represented gene categories were identified. 
According to the P values and literature-based classification schemes, the most over-
represented ontological categories of upregulated genes were associated with protein 
metabolism (e.g., proteolysis and glycoprotein synthesis) and immune responses, while the 
most over-represented downregulated genes were associated with fatty acid metabolism and 
detoxification processes (Fig.4 , Table 2).  
Functional annotation analysis of K-means clusters showed that the expression profiles 
of genes associated with proteolysis and immune responses (e.g., Cd14) were in pattern 1 
(Table 1). Genes associated with glycoprotein synthesis and immune responses (e.g., IFN-
inducible genes) were in pattern 2 (Table 1) while downregulated genes were associated with 
pattern 3 (Table 2). These results showed that expression levels of genes associated with 
glycoprotein synthesis and fatty acid metabolism or detoxification processes tended to stay 
upregulated or downregulated through 45 DPI, respectively. While elevated at 15 DPI, 
expression levels of some genes associated with proteolysis and innate immune responses 
returned to control levels by 30 DPI.  
  Analysis of upregulated genes   
In addition to initiating immune responses to counter the impact of bacterial colonization, 
the host will often adjust metabolically and physiologically in an effort to maintain tissue 
homeostasis. An influx of inflammatory cells and elevated levels of serine proteases have 
been found in the intestine during inflammation, infection, and stress.
17
 In this study, we 
detected upregulation of genes associated with protein metabolism along with changes in 
immune response genes following colonization with H. bilis (Table 1). Following 
colonization by H. bilis, we observed marked upregulation of granzyme genes including an 
approximately 30-fold increase in Gzma, Gzmb at 15 DPI (Table 1). In addition, genes 
encoding mast cell proteases Mcpt1, Mcpt2, Mcpt9, and Cpa3 and mast cell surface receptors 
Fcer1a were upregulated 8-55 fold at 15 DPI (Table 1). The expression profile of these genes 
fell into pattern 1 (Table 1) as their level of expression returned to control levels by 30 DPI. 
The change patterns of proteolysis-associated genes may correlate with the level of 
inflammation.  
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 Table 1.  Selected upregulated genes in cecal mucosa of gnotobiotic mice following the 
colonization with Helicobacter bilis.  
 
      
Fold  
change       
Genebank 
ID Gene description
a 
15DPI 30DPI 45DPI 
Functional 
annotations
b 
Pattern 
NM_010370 Gzma: granzyme A 29.9 1.6 1.5 
Proteolysis 
/Immune response 1 
NM_013542 Gzmb: granzyme B 34.3 1.8 2.2 Proteolysis  1 
NM_008570 Mcpt1: mast cell protease 1 54.8 2.9 3.3 Proteolysis  1 
NM_008571 Mcpt2: mast cell protease 2 35.6 2.6 2.8 Proteolysis  1 
AY007568 Mcpt9: mast cell protease 9  12.4 1.5 1.3 Proteolysis  1 
NM_007753 
Cpa3: carboxypeptidase 
 A3, mast cell 8.1 1.6 1.9 Proteolysis  1 
AF114266 
Tgm2: transglutaminase 2, 
 C polypeptide 2.3 1.0 1.2 Proteolysis  1 
NM_009425 
Tnfsf10: tumor necrosis 
factor (ligand) superfamily 2.5 1.3 1.2 Immune response 1 
 , member 10      
NM_009841 Cd14: CD14 antigen 2.3 1.2 1.1 Immune response 1 
NM_011558 
Tcrg: T-cell receptor  
gamma chain   4.6 1.3 1.1 Immune response 1 
NM_010184 Fcer1a: Fc receptor, IgE, 11.3 1.3 1.6 Immune response  1 
  
high affinity I, alpha   
polypeptide           
NM_018876 Fut2: fucosyltransferase 2 9.3 2.0 2.0 
Protein amino 
acid glycosylation 2 
AI481328 Mgat2: mannoside acetyl- 2.6 1.4 1.5 
Protein amino 
acid glycosylation 2 
 glucosaminyltransferase 2      
BB430637 
 B3galt5: UDP-Gal: 
betaGlcNAc beta 1,3- 
galactosyltransferase, 92.2 6.1 6.0 
Protein amino 
acid glycosylation 2 
 polypeptide 5      
BF578266 
B3gnt7: UDP-
GlcNAc:betaGal  41.6 3.1 4.3 
Protein amino 
acid glycosylation 2 
 
beta -1,3-N-acetyl-
glucosaminyltransferase 7      
NM_026087 Ceacam12: CEA-related   101.9 14.1 17.2 Unknown 2 
 cell adhesion molecule 12      
NM_010259 
Gbp1: guanylate nucleotide 
 binding protein 1 4.4 1.5 1.7 Immune response 2 
BE197524 
Gbp2: guanylate nucleotide 
 binding protein 2 3.7 1.5 1.7 Immune response 2 
BM245961 
LOC667373: similar to 
 interferon-induced  protein 16.6 5.1 7.3 Immune response 2 
 
with tetratricopeptide 
repeats 1      
 
a
 Genes were selected by using q value ≤0.05, fold change relative to control ≥2. 
     b
 Functional annotations were identified by DAVID bioinformatics resource 2007. 
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The upregulation of genes associated with the immune response included Cd14 and 
multiple IFN-inducible genes (Tables 1 and 2). IFN-inducible genes included P47 GTPase 
(e.g., Ifi47), P65 GBP (e.g., Gbp1, Gbp2, and Loc667373), and Mx gene families and have 
been implicated in the immune response against bacteria.
18
 Interestingly, the expression 
change of Cd14 (returned to control levels, pattern 1) and IFN-inducible genes (remained 
elevated, pattern 2) belong to different gene expression patterns.  
Changes in the fucosylation or glucosylation of epithelial cell surface molecules have 
been noted following bacterial colonization.
19, 20
 Remodeling of cellular surface structures 
likely reflects an attempt by epithelial cells to adjust to changes in the bacterial flora. In this 
regard, four genes associated with glycoprotein synthesis (Fut2, Mgat2, B3galt5, B3gnt7) 
were significantly upregulated at all three time points. Two of those genes (Fut2 and B3galt5) 
are involved in the synthesis of type 1 Lewis antigens.
21
 In addition, Ceacam12 gene was 
strongly upregulated 15 days after H. bilis colonization and stayed upregulated at 30 and 45 
DPI. The fold changes over control for Ceacam12 were >40 fold at 15 DPI, and >10 fold at 
30 and 45 DPI (Table 1 and Fig. 5).  
Analysis of downregulated genes   
In addition to being precursors of inflammatory mediators, fatty acids exert nutritional 
and protective effects on enterocytes. Altered fatty acid metabolism has been previously 
reported in humans with inflammatory bowel diseases.
22-24
 Of the differentially expressed 
genes with known or predicted functions, the category with the most downregulated genes 
included those associated with fatty acid metabolism (Table 2). Downregulation of some 
genes such as Acsl1 that are involved with fatty acid biosynthesis might revive an earlier 
hypothesis that energy deficiency is a significant factor in pathogenesis of colitis.
25, 26
  
Using literature-based classification schemes, some of the downregulated genes were 
associated with detoxification and/or biotransformation processes (Table 2), which included 
drug transporters, phase I and phase II metabolic enzymes.
27-29
 Downregulated genes 
associated with phase I metabolism enzymes included carboxylesterase ( Ces1, Ces3), 
cytochrome P450 gene family (Cyp4b1, Cyp4f1), and epoxide hydrolase (Ephx2).  
Downregulated phase II metabolism enzymes included glucuronyl transferase (Ugt8) and 
glutathione transferase (Gstt1). Notably, Cyp4b1 and Ugt8a genes were strongly 
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downregulated at 15 DPI with a high magnitude of fold changes over controls and remained 
downregulated at 30 and/or 45 DPI, in comparison to control ( Table 2, Fig. 5).  
 
 
Table 2. Selected downregulated genes in cecal mucosa of gnotobiotic mice following the 
colonization with Helicobacter bilis. 
 
      
Fold 
change      
Genebank ID Gene description
a 
15DPI 30DPI 45DPI 
Functional 
annotations
b 
Pattern 
NM_008149 Gpam: glycerol-3-phosphate  -3.8 -1.8 -1.7 
Fatty acid 
metabolism 3 
 acyltransferase,mitochondrial     3 
BI413218 Acsl1: acyl-CoA synthetase -3.0 -1.3 -1.6 
Fatty acid 
metabolism 3 
  long-chain family member 1     3 
NM_013703 
Vldlr: very low density 
lipoprotein receptor -4.2 -1.7 -2.2 
Fatty acid 
metabolism 3 
AB078618 
Acot12:acyl-CoA 
thioesterase 12 -4.1 -1.4 -1.9 
Fatty acid 
metabolism 3 
NM_021456 Ces1: carboxylesterase 1 -3.0 -1.6 -1.5 Detoxification 3 
AI315015 Ces3: carboxylesterase 3 -3.2 -1.5 -1.5 
Detoxification 
/ Fatty acid 
metabolism 3 
NM_007823 Cyp4b1: cytochrome P450 -65.6 -2.1 -4.2 Detoxification 3 
 
, family 4, subfamily b, 
polypeptide 1     3 
NM_130882 Cyp4f13: cytochrome P450,  -2.0 -1.3 -1.5 Detoxification 3 
 
family 4, subfamily f, 
polypeptide 13     3 
NM_007940 
Ephx2: epoxide  
hydrolase 2, cytoplasmic -4.1 -1.9 -1.9 Detoxification 3 
BC012254 
Gstt1: glutathione S-
transferase, theta 1 -2.5 -1.8 -1.6 Detoxification 3 
NM_011674 
Ugt8a: UDP 
galactosyltransferase 8A -79.5 -2.3 -2.3 Detoxification 3 
 
 
a
 The genes were selected by using q value ≤ 0.05, fold change relative to control ≤ -2. 
b Functional annotations were identified by either DAVID bioinformatics resource 2007 or 
literature-based classification schemes 
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Detoxification genes have been shown to be regulated by three separate nuclear 
receptors including pregnane X receptor (Pxr), constitutive androstane receptor (Car , also 
referred as Nrli3), and peroxisome proliferator-activated receptor alpha (Ppara).
30
 The 
suppression of Pxr was linked to the downregulation of detoxification genes in IBD 
patients.
29
 In this study, qRT-PCR results showed that H. bilis colonization induced the 
significant downregulation of Car gene, rather than Pxr and Ppara gene (Fig. 5 and data not 
shown).   
 
Confirmation of Genechip data by qRT-PCR.  To confirm  the Genechip results, 
genes from different functional annotation groups were chosen for qRT-PCR analysis and 
included Gzmb, Mcpt2, Fut2, B3galt5, Ceacam12, Cyp4b1, Ugt8a and interferon-inducbile 
gene Ifi47 (Supplemental data). Expression of all selected genes demonstrated similar trends 
of change by both qRT-PCR and microarray analysis at each of the specific time points 
tested (Fig. 5). 
 
Analysis of gene expression patterns in other colitis models. In order to assess 
whether the changes in gene expression were unique to H. bilis colonization, changes in gene 
expression associated with two other models of colitis were evaluated. Dextran sodium 
sulfate (DSS) is a commonly used chemical to induce acute colitis in mice.
31
 Brachyspira 
hyodysenteriae is the causative bacterium of swine dysentery and induces typhlocolitis in 
mice and pigs 
32
. The expressions of a selected number of genes associated with mucosal 
inflammation (Fut2, B3galt5, Ceacam12, Cyp4b1 and Ugt8a) were evaluated following the 
onset of colitis induced by either DSS treatment or B. hyodysenteriae infection. Similar to the 
gene expression changes observed following the colonization with H. bilis, comparable 
changes in the gene expression of Fut2, B3galt5, Ceacam12, Cyp4b1 and Ugt8a were noted 
within the cecal mucosa following DSS treatment or B. hyodysenteriae infection (Fig. 6A 
and B). 
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 Figure 5. Analysis of mRNA expression via qRT-PCR in the ceca of gnotobiotic mice 
following the colonization of Helicobacter bilis. Cecal tissues were collected at 0, 15, 30, or 
45 days from separate groups of mice after H. bilis colonization. Total RNA was isolated, 
converted into cDNA, and. amplified using gene-specific primers as described in “Material 
and Methods”.  Expression of each individual gene was initially normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and the fold changes calculated as the 
relative difference to control samples. Each value represents mean ± SEM, n=6 mice. * 
P<0.05 vs. control. Gzmb: Granzyme B. Ifi47: Interferon gamma inducible protein 47. Fut2: 
Fucosyltransferase 2. B3galt5: UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 5. Ceacam12: CEA-related cell adhesion molecule 12.Cyp4b1: Cytochrome 
P450, family 4, subfamily b, polypeptide 1. Ugt8a: UDP galactosyltransferase 8A. Nrli3: 
Nuclear receptor subfamily 1, group I, member 3.   
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Figure 6.  Comparative analysis of mRNA expression of novel colitis-associated genes 
in the cecal mucosa of gnotobiotic mice after dextran sodium sulfate (DSS) treatment or 
Brachyspira hyodysenteriae infection. Mice were treated with 2% DSS in drinking water or 
infected with B. hyodysenteriae as described in Material and Methods. Total RNA was 
isolated from cecal tissues and the relative mRNA expression of specific genes was assessed 
by qRT-PCR. (A) Fold change over control after DSS treatment (B) Fold change over control 
after B. hyodysenteriae infection.  Individual gene expression values were normalized to 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and fold changes calculated as the 
relative difference to control samples. Each value represents mean ± SEM, n= 4-7 mice. * 
P<0.05 vs. Control, ** P<0.01 vs. Control. Filled bars represent the upregulated genes and 
open bars represent the downregulated genes.  Fut2: Fucosyltransferase 2. B3galt5: UDP-
Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5. Ceacam12: CEA-related cell 
adhesion molecule 12.Cyp4b1: Cytochrome P450, family 4, subfamily b, polypeptide 1. 
Ugt8a: UDP galactosyltransferase 8A. 
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DISCUSSION 
The current paradigm for the etiology of IBD includes the onset of inflammation induced 
by aberrant immune responses to commensal bacteria in genetically susceptible hosts
 1-3
. Yet, 
the extreme complexity of resident microflora in conventional or specific pathogen free mice 
makes it difficult to dissect the roles of specific commensal bacteria  to modulate intestinal 
inflammation.
11
 However, the use of gnotobiotic mice would permit a more refined analysis 
of the impact individual bacterial species may exert on mucosal homeostasis and 
susceptibility to colitis. Several studies have linked H. bilis to the development or 
acceleration of proliferative typhlocolitis in immunocompromised rodents.
5-9
 In this regard, 
recent studies from this laboratory have evaluated the impact of H. bilis colonization on the 
development of cellular and humoral immune response of C3H gnotobiotic mice to the 
individual members of the resident flora.
 10, 11
 These results indicated that introduction of 
novel bacterial provocateurs such as H. bilis into the gastrointestinal microbiota alters 
mucosal homeostasis and increases the host’s susceptibility to the development of colitis. 
However, the molecular mechanism by which H. bilis colonization evokes the host response 
to commensal bacterial in mice remains unknown. In addition to the changes in the host’s 
immune responsiveness to the resident flora, analysis of mucosal gene expression following 
colonization with H. bilis should provide insights with respect to changes in mucosal 
homeostasis that are predisposing towards rather than the direct underpinnings of acute or 
chronic inflammation. 
Using microarray analysis, H. bilis colonization of gnotobiotic mice induced notable 
upregulation of genes involved in protein metabolism (e.g., proteolysis, glycoprotein 
synthesis) and immune responses while downregulating genes involved in fatty acid 
metabolism and detoxification. Many genes associated with mucosal physiology and 
homeostasis were identified. Similar changes in gene expression associated with intestinal 
physiology have been observed in germ-free mice following colonization with Bacteroides 
thetaiotaomicron.
20
   
The magnitude of changes in gene expressions was greatest at 15 DPI suggesting that the 
mucosal tissue temporally regulated gene expression in an attempt to reestablish homeostasis 
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by 45 DPI.  However, from qRT-PCR and K-means cluster analysis, the expression levels of 
some genes at 30 and 45 DPI, especially genes associated with glycoprotein synthesis and 
detoxification remained differentially expressed in comparison to control mice. In response 
to a subsequent colitic insult, the small but significant alterations of mucosal gene expression 
observed at 45 DPI would likely predispose the host to the development of or increase the 
susceptibility to chronic colitis. These observations would be consistent with a “multiple hit 
hypothesis” leading to the development of chronic colitis.33 In this regard, preliminary data 
has shown that exposure to an otherwise innocuous dose of DSS induced severe colitis in H. 
bilis-colonized gnotobiotic mice (Chapter 3, manuscript in preparation).  
B3glat5 encodes an essential enzyme for the biosynthesis of type 1 Lewis antigen, 
including Le
b
, Le
a  
and sLe
a
 antigen, within cells of  the gastrointestinal epithelium and 
pancreatic tissue.
21
 Fut2 is also involved in the biosynthesis of Le
b
 antigen.
34
 Le
b
 antigen on 
gastric epithelial surface has been identified as a primary receptor for the attachment of 
Helicobacter pylori to gastric epithelial cells by binding to the BabA adhesin on the surface 
of the bacteria.
35
 This receptor-ligand interaction is considered to be critical in facilitating the 
initial colonization and long-term persistence in the stomach. Ceacam12 encodes a 
glycoprotein which belongs to the carcinoembryonic antigen (CEA) family, a subfamily of 
the immunoglobulin (Ig) superfamily.
36
 Upregulation of genes within the Ceacam family 
may provide a mechanism that facilitates bacterial colonization effectively counteracting 
epithelial exofoliation.
37, 38
 Alteration of mucosal epithelial cell glycosylation has been 
shown to affect bacterial adherence and invasion contributing to the development of IBD.
39-41
  
Collectively, the upregulation of genes involved in glycoprotein synthesis or surface 
remodeling of epithelial cells might affect bacterial adherence to the mucosa and, therefore, 
bacterial-host cross-talk which potentially increases host susceptibility to colitis. Interestingly, 
in comparison to 30 and 45 DPI, the highest expression levels of genes involved in 
glycoprotein synthesis at 15 DPI correlate with the greatest gut H. bilis numbers at the same 
time point (Supplemental figure 2A).    
Of the downregulated genes identified, Ces1 and Ces3 encode carboxylesterases 
involved in the hydrolysis of ester- and amide-bond-containing drugs such as opiods.
42
 
Cyp4b1, one member of cytochrome P45 gene family, participates in the metabolism of 
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certain xenobiotic that are protoxic, including valproic acid, 3-methylindole, 4-ipomeanol, 3-
methoxy-4-aminoazobenzene, and numerous aromatic amines.
43
 Gstt1, a subunit of 
glutathione S-transferases, is involved in mucosal protection against toxins and its 
polymorphism had been associated with inflammatory bowel disease patients.
44
 While the 
functions of Ugt8a is intestine is unknown, UDP-galactosyltransferases have been shown to 
be involved in detoxification of exogenous compounds such as phenols, flavones.
45
 In 
addition, the detoxification-associated transcription factor Car(Nr1i3) was downregulated 
after H. bilis colonization. Agonists of detoxification-associated transcription factors have 
been shown to ameliorate the DSS-induced colitis,
46
 indicating that regulation of mucosal 
detoxification processes by targeting transcriptional factors may be therapeutically useful for 
IBD patients.
46
  In addition, cytolethal distending toxin (CDT) was considered as an 
important virulence factor of H. bilis.
47
 It will be of interest to examine if the defective 
mucosal detoxification can affect the host ability to effectively detoxify or eliminate this 
toxin.   
In addition to forming a physiological barrier between luminal bacteria and immune 
cells within the lamina propria, intestinal epithelial cells participate in the process of 
detoxification and biotransformation of drugs and xenobiotics.
27
 Loss or dysregulation of 
detoxification and biotransformation processes by the intestinal epithelium may contribute to 
the initiation and progression of IBD.
27-29
 Downregulation of detoxification genes has been 
described for several animal models of IBD including DSS-induced colitis, TCRα-/-, and 
transfer of CD45RB
hi
 T cells and in human patients.
48, 49, 29
 It is still unknown whether 
dysregulated detoxification functions are the causal factor of IBD or arise secondary to 
inflammation. However, Mdr1a
-/-
 mice, which exhibit defective drug transporter gene and 
detoxification functions, spontaneously develop colitis,
50
 supporting the former hypothesis. 
Furthermore,  H.  bilis colonization has been shown to accelerate the development of colitis 
in Mdr1a
-/-
 mice
 6-7
  indicating H. bilis might exacerbate the defective detoxification 
functions of intestinal epithelial cells. Likewise, mice were shown to be more susceptible to 
DSS-induced colitis following suppression of another colonic detoxification 
enzyme,glutathione S-transferase.
51, 52
 Thus, the persistent downregulation of several genes 
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involved in the different stages of epithelial cell detoxification following colonization with H. 
bilis might predispose the host to the onset of colitis.  
Defective or altered mucosal barrier function has been widely considered to be one of 
the factors contributing to the development of IBD.
1
 Additionally, genes associated with 
mucosal barrier function such as Mdr1a, Slc22a4, Slc22a5 (solute carrier family 22 member 
4 and 5), and Dlg5 (discs, large homolog 5) have been identified and investigated as potential 
IBD susceptibility genes.
53, 54
 In the present studies, several genes associated with 
glycoprotein synthesis and detoxification such as Fut2, B3galt5, Ceacam12, Cyp4b1 and 
Ugt8a were shown to be similarly affected in mice following onset of DSS-induced colitis or 
B. hyodysenteriae-induced colitis,  indicating the importance of these genes in maintaining 
mucosal homeostasis and barrier function independent of the colitis model studied. In 
contrast, inoculation of the gnotobiotic mice with killed H.  bilis did not induce changes in 
mucosal gene expression (data not shown). In conclusion, this study provides insights 
respective to changes in mucosal gene expression following colonization of the host with H. 
bilis. Furthermore, these results indicate that H. bilis colonization perturbed mucosal 
homeostasis increasing the susceptibility of the host to the development of colitis (Chapter 3, 
manuscript in preparation). Although H. bilis colonization did not result in significant 
histopathological lesions, the cumulative effects of H. bilis colonization on mucosal gene 
expression (e.g., increased protein glycosylation and dysregulation of detoxification) would 
likely predispose the host to a more severe inflammatory response to a subsequent colitic 
insult, which is consistent with a “multiple hit hypothesis” for the development of IBD.33   
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Supplemental Figure 1. Measurement of antibody responses to Helicobacter bilis and 
altered Schadler’s flora (ASF) of gnotobiotic mice at 15, 30 and 45 days after the 
colonization of Helicobacter bilis.  Sera samples collected at necropsy were diluted and 
added into the 96-well microtiter plates coated with the whole cell lysates of H. bilis or ASF. 
Isotype specific antibody responses were measured by enzyme-linked immunosorbent assay 
(ELISA). n = 6 mice. ** P<0.01. (A) Antibody responses to H. bilis.  (B) IgG2a –specific 
antibody responses selected members of ASF. H. bilis colonization induced antibody 
responses to both H. bilis and ASF.  
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Supplemental Figure 2. Quantitation of cecal Helicobacter bilis and altered Schadler’s 
flora (ASF) of gnotobiotic mice at 15, 30 and 45 days after the colonization of Helicobacter 
bilis. DNA was extracted from cecal contents. Quantitative PCR protocols were developed 
and optimized to detect the 16S rRNA sequence of H. bilis and each ASF bacterium (Riley 
LK, et al, 1996. Sarma-Rupavtarm RB et al, 2004). Helicobacter bilis numbers were 
normalized to per gram cecal contents. Previously published rRNA operon numbers for each 
ASF strain were used to correlate qPCR results to bacterial cell numbers. n=6 mice. * P<0.05, 
** P<0.01. (A) The number of H. bilis (B) The number of ASF. The number of H. bilis 
peaked at 15 DPI and went down / stabilized at 30 and 45 DPI. H. bilis colonization did not 
alter the number of ASF in the gut.  
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Supplemental Figure 3. The effects of hypoxoside treatment on the expression levels of 
genes Cyp4b1 and Ceacam12 in ceca of C3H mice infected with Brachyspira hyodysenteriae. 
Mice were orally treated with hypoxoside for seven days prior to B. hyodysenteriae infection 
and the treatments continued daily for seven days postinfection (DPI). Seven days after B. 
hyodysenteriae infection, mice were necropsy and ceca tissues were collected. RNA were 
extracted from ceca tissues and converted into cDNA. cDNA were amplified via quantitative 
PCR using the gene specific primers. The quantitation of specific genes was normalized into 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Control: mice didn’t receive B. 
hyodysenteriae challenge or hypoxoside treatment;   Hypox only: mice received hypoxoside 
treatment but not B. hyodysenteriae challenge; Hypox + B. hyo: mice received both 
hypoxoside treatment and B. hyodysenteriae challenge; B. hyo only: mice received B. 
hyodysenteriae challenge but not hypoxoside treatment. n=6 mice. * P <0.05 vs. all other 
groups. Cyp4b1: Cytochrome P450, family 4, subfamily b, polypeptide 1. Ceacam12: CEA-
related cell adhesion molecule 12.  
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The list of all differentially expressed genes in cecal mucosa of gnotobiotic mice 
following the colonization of Helicobacter bilis. 
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ABSTRACT 
Colonization with Helicobacter bilis has been shown to induce or accelerate the 
development of colitis in immune-deficient mice and to trigger host immune responses to 
commensal bacteria in immunocompetent mice. These results indicate that H. bilis 
colonization affects mucosal homeostasis and likely increases host susceptibility to IBD. 
However, the molecular and cellular mechanisms governing the effects of H. bilis 
colonization on the development of colitis remain unknown. In this study, mice were 
colonized with H. bilis for 6 weeks and then treated with a low dose of dextran sodium 
sulfate (DSS, 1.5 %) for five days followed by a four day restitution period. Severity of DSS-
induced lesions was assessed.  Gene expression profiles and mucosal cellular infiltration 
were characterized. Helicobacter bilis colonization increased severity of intestinal 
inflammatory lesions induced by DSS. Particularly, H. bilis colonization activated genes 
associated with immune cell activation (e.g., Cd28 and Tnfsf13b) and chemotaxis (e.g., Itgb2, 
Ccl8, and Ccr5). Consistent with these observations, increased infiltration/proliferation of 
mucosal and/or MLN T cells, B cells, macrophages, but not neutrophils, were observed in 
colonic tissue from mice colonized with H. bilis and treated with DSS, in comparison to mice 
treated with DSS alone. In addition, H. bilis colonization downregulated the expression 
levels of the detoxification-associated genes, Cyp4b1 and Ugt8a. Activation/recruitment of 
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immune cells and downregulation of detoxification-associated genes induced by 
Helicobacter bilis colonization might be associated with the increased host susceptibility to 
DSS colitis. 
Keywords: Helicobacter bilis, colitis, dextran sodium sulfate, cell infiltration, 
detoxification 
INTRODUCTION 
Accumulating evidence from animal models and patients with inflammatory bowel 
disease (IBD) (i.e., Crohn’s disease and ulcerative colitis) demonstrate a pivotal role for 
bacteria in the induction or exacerbation of enteric inflammation [1]. For example, colitis is 
often more severe in regions heavily colonized with bacteria and antibiotic therapy has been 
used to treat Crohn’s disease [2, 3]. More convincingly, IL-2-/-, IL-10-/-, TCRα -/- mice, and 
HLA-B27 transgenic rats only develop colitis when colonized with an intestinal microflora [4, 
5]. The current etiological hypothesis supports the contention that aberrant immune responses 
to the microflora, along with genetic susceptibility of the host, are major contributors to the 
development of IBD [6].   
However, not all bacteria have the same effect on or potential to induce the development 
of IBD. For instance, Bacteriodes vulgatus is preferentially able to induce colitis in HLA-
B27 transgenic rats, whereas other bacteria such as Escherichia coli stimulate no 
inflammatory response in this model of colitis [7]. Enterohepatic Helicobacter spp (EHS), a 
bacterial genus naturally infecting many laboratory rodents, has been linked to the induction 
of colitis and has significantly contributed to the morbidity of immunodeficient mice [8]. In 
addition, EHS have been isolated from a subset of IBD patients and has also been shown to 
cause bacterial-induced colitis [9-11]. More importantly, emerging evidence suggests that 
inflammatory responses to EHS infections alter host responses to other experimental stimuli, 
although Helicobacter-associated disease is not clinically observable in most 
immunocompetent rodents [12].  
Helicobacter bilis, one of the most prevalent EHS in laboratory animals, has been shown 
to induce or accelerate colitis in immunodeficient rodents including SCID, multiple drug 
resistance-deficient (Mdr1a
-/-
), IL-10
-/-, or TCRα -/- mice and athymic nude rats [13-17]. 
Furthermore, H. bilis colonization has been shown to induce differential host immune 
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responses including antibody and cytokine responses against antigens derived from the 
resident flora in immunocompetent mice [18-20]. These results suggest that introduction of H. 
bilis might disrupt mucosal homeostasis, thus, increasing host susceptibility to IBD. However, 
the molecular and cellular mechanisms mediating the increased sensitivity to colitis 
following H. bilis colonization remain unknown.  
Common features of intestinal inflammation, such as IBD, include the massive 
infiltration of leukocytes (e.g., granulocytes, macrophage, and lymphocytes) into the 
intestinal mucosa and the production of cytokines (e.g., IL-1β, TNFα and IFNγ) and 
chemokines (e.g., CXCL8, CCL5, CCR5) [21]. However, there are important differences in 
immunopathological features between different forms of intestinal inflammation. For 
example, histological features of Crohn’s disease include the development of mucosal 
granulomas that are characterized by the presence of compact macrophages, giant cells, and 
epithelioid cells surrounded by a marked infiltration of lymphoid cells, plasma cells, and 
other inflammatory cells.  In contrast, ulcerative colitis is characterized by crypt abscesses 
that are composed of infiltrating neutrophils and sloughing epithelium [22]. In addition, 
Crohn’s disease is often associated with a TH1-type cytokine profile; on the other hand, 
ulcerative colitis appears to present with a TH2-type profile [22].  
 In the present study, we demonstrated that H. bilis colonization increased the severity of 
colitis induced by dextran sodium sulfate (DSS) and further characterized the changes in the 
mucosal gene expression profile and inflammatory cell infiltration following H. bilis 
colonization that might increase the host’s susceptibility/sensitivity to colitis. Our results 
suggest that Helicobacter bilis colonization evoked significant increases in genes associated 
with T cell and B cell activation (e.g., Cd28 and Tnfsf13b expression), macrophage 
infiltration, and negatively affected epithelial detoxification activities (e.g., Cyp4b1 and 
Ugt8a). Thus, H. bilis colonization affected mucosal homeostasis by aggravating 
mechanisms that enhanced the sensitivity or susceptibility to enteric inflammation. The 
identification of host factors that predispose to the onset of colitis following colonization 
with bacterial provocateurs such as H. bilis will advance the understanding of mechanisms of 
colitis and lead to new intervention strategies for the prevention and control of colitis.   
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MATERIAL AND METHODS 
Mice and bacteria. Eight to nine week old, gnotobiotic C3H/HeN:Tac mice colonized 
with the altered Schaedler’s flora (ASF) were obtained from Taconic Farms (Germantown, 
NY) and gnotobiotically maintained at Iowa State University. Members of the ASF include 
ASF356, Clostridium cluster XIV; ASF360, Lactobacillus acidophilus; ASF361, 
Lactobacillus murinus; ASF457, Mucispirillum schaedleri; ASF492, Eubacterium 
plexicaudatum; ASF500, low-G+C content-positive bacteria; ASF502, Clostridium cluster 
XIV; and ASF519, Bacteroides distasonis. All animal-related procedures were approved by 
the Animal
 
Care and Use Committee at Iowa State University. 
Helicobacter bilis was cultivated and harvested as previously described [18].  Mice were 
orally colonized once daily over three consecutive days with approximately 10
8 
CFU of H. 
bilis per day.   
Experimental design. At six weeks post-infection with H. bilis, mice were exposed to 
drinking water containing 1.5% DSS (M.W. 36, 000 - 50, 000, MP Biomedicals, Solon, OH) 
for five days, followed by four days with regular drinking water. Mice ( n = 10 to 14 per 
group) were divided into two groups: DSS group in which mice were treated with DSS alone 
and H. bilis + DSS group in which mice were colonized H. bilis and treated with DSS. At the 
termination of the experiments, mice were euthanized and the ceca/colon, MLN, and sera 
were collected for further analysis. Control normal mice and mice that colonized with H. bilis 
alone were also included in this study.   
Gross inflammatory lesion score and histology. Inflammatory lesion scores were 
evaluated as previously described [18].  Briefly, gross inflammatory lesions were scored 0 to 
3 as follows: cecal atrophy and excess intraluminal mucus = 3; atrophy and excess 
intraluminal mucus localized to the cecal apex = 2; increased cecal mucus with no evidence 
of atrophy = 1; and no gross lesions = 0. For microscopic lesions, cecal and colonic tissues 
were formalin-fixed, embedded in paraffin, routinely processed, sectioned at 5 μm, and 
stained with hematoxylin and eosin. Stained tissue sections were scored by a pathologist (Dr. 
J. M. Hostetter, Department of Veterinary Pathology, Iowa State University) that was blinded 
to the treatment groups. Histological scores were based on the severity of mucosal epithelial 
damage, degree of lamina proprial cellular infiltrate, and architectural distortion [18].   
84 
  
Affymetrix oligonucleotide array analysis. RNA samples extracted from colonic 
tissues were submitted to the Iowa State University Genechip Facility (Ames, IA). Labeling 
of samples, hybridization, staining, and scanning were performed according to protocols 
outlined in the Affymetrix Expression Analysis Technical Manual (Affymetrix, Santa Clara, 
CA). Affymetrix Mouse genome 430 2.0 arrays were used for these experiments. 
Fluorescence intensity values (.CEL files) generated from hybridized and labeled 
genechips were analyzed using R software (1Hhttp://www.r-project.org) and a Bioconductor 
analysis package (2Hhttp://www.bioconductor.org). Data were normalized using Robust Multi-
array Average (RMA) [23]. False discovery rate (q value) of normalized data was computed 
using Storey and Tibshirani's default method [24]. Differentially expressed genes were 
statistically filtered using a q value ≤0.05 and a estimated fold change ≥ 2 or ≤-2.  
Assignments of filtered genes to functional categories were performed by using Database for 
Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics resource 2007 
(National Institutes of Health, Bethesda) [25]. Fisher exact tests were performed to calculate 
P values and determine which particular annotation categories were over-represented.   
Quantitative reverse transcription polymerase chain reaction (qRT-PCR). Total 
RNA was isolated from colonic tissues using the RNeasy Mini Kit (Qiagen, Valencia, CA) 
and then reverse transcribed into cDNA by SuperScript™ III First-Strand Synthesis System 
(Invitrogen, Carlsbad, CA). The cDNA was amplified using Platinum® SYBR® Green 
qPCR SuperMix-UDG (Invitrogen). The PCR conditions used for these studies were as 
follows:  95°C for 10 minutes, followed by 40
 
cycles of amplification (95°C for 15 seconds, 
60°C for 60 seconds). The relative mRNA quantities were normalized against 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific mRNA. The quantitative 
PCR was performed using a Rotor-Gene 3000 (Corbett Research, Mortlake, Australia). 
Standard curves for the selected genes and GAPDH were made using serial dilutions of 
cDNA. The correct sizes of the amplified PCR products were confirmed by agarose gel 
electrophoresis. The primer sequences are available upon request.  
Myeloperoxidase (MPO) Assay. The assay measuring MPO was modified from a 
previously published method [26]. Briefly, colonic tissue samples were collected, 
homogenized, and sonicated in phosphate buffered saline (PBS) containing 0.1 mM 
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phenylmethanesulphonylfluoride (PMSF). The resulting lysate was centrifuged and the 
supernatant was aliquoted into a microtiter plate. MPO activity was determined 
colorimetrically using 3,3', 5,5'-tetramethylbenzidine(TMB) as a substrate at an optical 
density of 405 nm. Serial dilutions of freshly prepared neutrophils recovered from murine 
peripheral blood were used to generate standard curves. The MPO levels were normalized 
based on the total protein of each sample. 
F4/80
+
 macrophage immunohistochemistry. Macrophages were identified using the 
monoclonal antibody F4/80, a pan-surface marker on murine macrophages. Paraffin-
embedded colon tissue sections were deparaffinized, rehydrated, and digested with a 2% 
protease (Sigma, St Louis, MO) in 0.05 M Tris buffer(PH=7.6) for 20 minutes. After 
blocking with normal rat sera for 20 minutes, the sections were incubated with 0.5 µg/ml 
affinity purified anti-mouse F4/80 monoclonal antibody (clone BM8, eBioscience, San Diego, 
CA) overnight at 4°C. Endogenous peroxidase activity was blocked with 3% H2O2 for 20 
minutes. Subsequently, the sections were incubated with Biotin-SP-AffiniPure F(ab')2 
Fragment Goat Anti-Rat IgG (H+L) (Jackson Immunoresearch Laboratory, West Grove, PA) 
for 30 minutes and HRP-Streptavidin for 15 minutes. The sections were then incubated with 
a diaminobenzidine (DAB) substrate to reveal brown/black staining at the site of HRP 
localization. After staining, the sections were washed in distilled water, counterstained with 
hematoxylin, and mounted. Stained sections were photographed under a microscope.   
Semiquantitative approach as previously described [27] was used to score the frequency 
of positive cells. The immunoreactivity of the stains was scored by the following scale: 0=no 
immunoreactive cells, 1=rare immunoreactive cells, 2=scattered immunoreactive cells, 3= 
clusters of immunoreactive cells, 4=nearly diffuse staining. 
Lamina propria lymphocytes (LPL) Isolation. The technique used for LPL isolation 
was modified from a previously described method [28]. Cleansed whole colons were cut into 
1 cm pieces and incubated with 20 ml Hanks' Balanced Salt Solution (HBSS) containing 1.25 
µM ethylenediaminetetraacetic acids (EDTA) in a shaking water bath at 37°C for 18 minutes 
to release intraepithelial lymphocytes and epithelial cells. After washing, colonic tissues were 
incubated with cell culture medium containing 0.5 mg/ml DNAse I collagenase for 20 min 
with agitation. At the end of the agitation, the tissues were subjected to further mechanical 
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disruption by aspirating up and down using a 1 ml syringe. The resulting cell suspensions 
were filtered through sterile gauze to remove large debris. After washing, cells were layered 
onto a 30:70 % Percoll gradient. Cells were centrifuged at 2,200 × g at room temperature for 
20 min. The LPLs collected from the 30:70 interface were washed and maintained on ice 
until used.  
Flow cytometry. Lamina propria lymphocytes and MLN cell suspensions were 
incubated with mAbs 17A2 (anti-CD3 mAb; PharMingen Franklin Lakes, NJ), 6D5 (anti-
CD19 mAb, Southern Biotechnology, Birmingham, AL) and IgG isotype controls on ice for 
20 minutes and then washed. The final concentration of all antibodies used in these studies 
was 1 μg/ml. Two color flow cytometric analyses were performed using a BD FACScan flow 
cytometer and CellQuest analysis software. Total CD3 and CD19 positive cells were 
calculated using the following formula: Total specific cells= (total MLN or LPL cells per 
mouse × percentage of specific cells determined by flow cytometry).    
Cell proliferation. Antigen presenting cells (APC) were prepared as follows: single cell 
suspensions of spleen cells (2 × 10
7
/ml) from healthy C3H mice were incubated with whole 
cell sonicates of pooled ASF antigens (200 µg/ml), Helicobacter bilis (200 µg/ml), or cell 
medium alone overnight at 37°C. The cell suspension was then treated with mitomycin C (50 
µg/ml) for 30 minutes and then washed five times with medium.   
 Single cell suspensions (2×10
6
 /ml) of MLN cells were co-cultured with antigen-pulsed 
APC preparation (2×10
6
 /ml) at 37°C for five days. Cellular proliferation was assessed by the 
addition of 
3
H-thymidine during the last 8 hours of the culture period and proliferation (i.e., 
3
H-thymidine incorporation) was measured using a liquid scintillation counter.  
Detection of antigen-specific serum antibodies. Antigen-specific serum antibodies 
were measured by ELISA as previously described [19]. Briefly, wells of 96-well microtiter 
plates (Immulon II) were coated with 10 μg/ml sonicated whole cell lysates of H. bilis and 
each of the individual ASF.  After blocking the wells with 1 % gelatin, diluted serum (1:250) 
was added into each well and incubated at 4 
o 
C overnight.  Then, alkaline phosphatase 
conjugated goat anti-mouse IgG1, IgG2a, IgA, or IgE (for ASF analysis, only anti-IgG1 and 
anti-IgG2a were used) (Southern Biotech, Birmingham, AL) were added to one set of 
triplicate samples and incubated for 4 hours at room temperature. Colorimetric reactions 
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were developed using p-nitrophenyl phosphate at room temperature. Optical densities were 
measured at 405 nm using a microtiter plate reader.  
Statistical analysis. The results are expressed as mean ± standard error (SE). The gross 
and histological lesions were analyzed using the wilcoxon rank-sum test. Other data are 
analyzed by student t-test or analysis of variance (ANOVA).  
 
RESULTS 
 Helicobacter bilis colonization increased severity of intestinal inflammatory lesion 
induced by dextran sodium sulfate. Helicobacter bilis has been shown to induce/accelerate 
the development of colitis in immunodeficient mice [13-17] and triggered persistent immune 
responses to commensal bacteria by six weeks post-infection in immunocompetent mice [18, 
19], suggesting that colonization affected mucosal homeostasis and increased host 
susceptibility to colitis. To directly test this hypothesis, H. bilis colonized mice were treated 
with low dose DSS (1.5 %) and the subsequent histological changes were evaluated.  
Macroscopically, exposure of the gnotobiotic mice to low dose DSS did not induce 
observable gross lesions. However, co-treatment of gnotobiotic mice with H. bilis and DSS 
induced significantly higher gross lesion scores than DSS alone (P < 0.01).  Macroscopic 
lesions in the co-treatment group were characterized by the presence of increased cecal 
atrophy and intraluminal mucus (Fig. 1A).   
Individually, H. bilis colonization and DSS treatment induced subtle increases in the 
histological score, while the co-treatment of H. bilis and DSS induced significantly (P<0.01) 
more severe histological lesions that were characterized by increased mucosal height, 
inflammatory cell infiltration, mucosal edema, and epithelial erosion (data not shown, Fig. 1). 
In addition, the severity of histological lesions for each treatment was similarly represented 
in both ceca and colon (Fig. 1B, C). Notably, more epithelial ulceration was observed in mice 
colonized with H. bilis and treated with DSS, in comparison to mice treated with DSS alone 
(Fig. 1D). Collectively, H. bilis colonization significantly increased the sensitivity of the host 
to DSS-induced inflammation.   
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(B) Cecal histological lesions (C) Colon histological lesions 
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(D) Representative photomicrographs 
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Figure 1. Effect of Helicobacter bilis colonization on the severity of macroscopic and 
microscopic lesions following exposure to dextran sodium sulfate (DSS). Six weeks after H. 
bilis colonization, mice were treated with 1.5% DSS in their drinking water for five days 
followed by a four day restitution period. Upon termination of the experiment, lesion scores 
were determined as described in Materials and Methods.  (A) Macroscopic cecal lesion 
scores: the gross lesion scores for control and H. bilis colonized mice were 0 ± 0 and 0.92 ±  
0.15, respectively ; (B) Cecal histological scores: the cecal lesion scores for control and H. 
bilis colonized mice were 4.33 ± 0.25 and 0.92 ± 0.15, respectively ; (C) Colonic histological 
scores: the colonic lesion scores for control and H. bilis colonized mice were 4.69 ± 0.28 and 
6.42 ± 0.44, respectively ;; (D) Representative diagram of histological lesions induced by 
DSS (top) or H. bilis + DSS (bottom). Open bars represent DSS group, filled bars represent 
H. bilis + DSS group. n = 10 to 14 mice per group. ** P < 0.01 vs. DSS group. 
 
H. bilis colonization upregulated the expression levels of genes associated with 
immune cell activation and chemotaxis. To directly assess the molecular effects of H. bilis 
on the DSS-induced colitis, mucosal gene expression profile between DSS group and H. bilis 
+ DSS group were compared via Affymetrix genechip. Based upon accepted statistical 
criteria (q value ≤0.05 and a estimated fold change ≥ 2 or ≤-2), 106 probe sets were defined 
as upregualted in the H. bilis plus DSS treated group in comparison to the group treated with 
DSS alone. However, no genes were identified to be downregulated using these statistical 
criteria.  
The biological themes of 106 probe sets were analyzed using “biological process” of 
Gene Ontology (GO) terms in the DAVID bioinformatics resource 2007. The results showed 
that those genes were strongly associated with biological processes such as “defense 
response” and “immune response”. The immune response-associated genes include genes in 
the “immune activation”, “humoral immune responses” and “chemotaxis” subgroups (Table 
1).  
Some of the upregulated genes were involved in TCR signaling suggesting increased T 
cell activation (Table 2). For example, Cd28 which encodes a co-stimulatory molecule 
involved in T cell activation/proliferation [29] was found to be upregulated. Fyb, which 
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encodes an adaptor protein that interacts with the Src family tyrosine kinase Fyn [30], and 
Lcp2 (referred to as Lcp2 or SLP-76), another essential adaptor protein in the TCR signaling 
pathway [31], were also upregulated. In addition, integrin beta 2 chain (encoded by 
Itgb2/Cd18) which forms a heterodimer along with integrin alpha L chain (encoded by 
ItgaL/Cd11a) form the co-stimulatory integrin lymphocyte function-associated antigen-1 
(LFA-1) [32], was also upregulated. The upregulation of these genes indicates the H. bilis 
colonization may result in the activation of mucosal T cells.  
Activation of  B cells induced by H. bilis colonization was indicated by the upregulation 
of Tnf13b (also named B-cell activating factor, BAFF), which is central to the survival and 
activation of peripheral B cells [33]. A series of genes associated with immunoglobulin 
synthesis (e.g., Igm, Igh-vj558 and Igj) were also upregulated in H. bilis + DSS groups, in 
comparison to DSS group (see Supplemental data).  In addition, the upregulated genes also 
include interferon-regulatory factor 4 (Irf4) which has been shown to be essential for the 
development of Th-17 T cells [34].  
Helicobacter bilis colonization also induced the upregulation of a series of genes 
associated with chemotaxis (Table 2). The chemokine, Ccl8, plays a role in the recruitment 
of monocytes, lymphocytes, basophils, and eosinophils [35]. Ccr5 and Ccr10 can be 
expressed on the surface of T cells and/or macrophages and have been shown to be involved 
with the infiltration of regulatory T cells into sites of mucosal inflammation [36, 37]. Integrin 
beta 2 chain (encoded by Itgb2/Cd18) combines with the alpha M chain (encoded by 
Itgam/Cd11b) to form the integrin macrophage receptor 1(Mac-1), which may be involved in 
the recruitment of monocytes and neutrophils [38]. Upregulation of these genes suggests H. 
bilis colonization might induce the recruitment of various inflammatory cells or regulatory T 
cells into intestine mucosa. The gene expression changes of Cd28, Itgb2, and Ccr5 were 
confirmed by qRT-PCR (Fig. 2). 
Take together, the microarray results (H. bilis + DSS group vs. DSS group) showed that 
consistent with the increased severity of intestinal lesions, H. bilis colonization upregulated 
genes involved in activation/recruitment of various immune cells. These results indicate the 
mucosa of the H. bilis colonized mice might be primed and more readily recruit immune cells 
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into the mucosa. However, it is still unknown what types of immune cells may play critical 
roles on how H. bilis colonization effects the development of colitis.     
 
Table 1. The annotation analysis of mucosal differentially expressed genes derived from a 
comparison between DSS group and H. bilis + DSS group.  
 
Annotation
a, b
 Gene no. Percentage P Value
b
 
Defense response 31 33.3% 1.40E-21 
Response to biotic stimulus 31 33.3% 3.19E-21 
Immune response 27 29.0% 3.13E-19 
Immune cell activation 12 12.9% 8.22E-12 
Cell activation 12 12.9% 8.77E-12 
Response to pest, pathogen or parasite 17 18.3% 1.63E-10 
Response to other organism 17 18.3% 2.68E-10 
Humoral immune response 10 10.8% 5.66E-09 
Organismal physiological process 29 31.2% 8.07E-09 
Response to stimulus 31 33.3% 1.21E-08 
Response to external stimulus 14 15.1% 2.41E-08 
Lymphocyte activation 9 9.7% 3.54E-08 
Inflammatory response 9 9.7% 5.31E-08 
Lymphocyte proliferation 7 7.5% 5.35E-08 
Response to stress 17 18.3% 3.60E-07 
Chemotaxis 7 7.5% 1.17E-06 
Taxis 7 7.5% 1.17E-06 
 
a. Gene expression profiles of DSS treatment group was compared to that of H. bilis + 
DSS group and differentially expressed genes were filtered by false discovery rate q ≤ 
0.05 and estimated fold change ≥ 2 
b. The functional overrepresentation of differentially expressed genes was analyzed by 
DAVID bioinformatics resource 2007. Fisher exact tests were performed to calculate 
P values and determine which particular annotation categories were over-represented.   
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Table 2. The representative mucosal differentially expressed genes derived from a 
comparison between DSS group and H. bilis + DSS group.   
 
Gene Name
a
 
GeneBank  
ID 
Fold 
change
b
 
q 
values Annotation
c
 
Cd28: CD28 antigen NM_007642 5.4 0.016 Immune cell activation 
Fcgr2b: Fc receptor, IgG, low affinity IIb BM224327 2.4 0.028 Immune cell activation 
Fyb: FYN binding protein BB157866 2.3 0.050 Immune cell activation 
Itagl: integrin alpha L (Cd11a) BI554446 3.6 0.039 Immune cell activation 
Irf4: interferon regulatory factor 4 U34307 6.1 0.010 Immune cell activation 
Lilrb3:leukocyte immunoglobulin-like 
receptor, subfamily B (with TM and ITIM 
domains), member 3 U96693 3.0 0.035 Immune cell activation 
Lst1: leukocyte specific transcript 1 U72644 2.2 0.035 Immune cell activation 
Lat2: linker for activation of T cells 
family, member 2 AF257136 2.8 0.004 Immune cell activation 
Lcp2: lymphocyte cytosolic protein 2 BC006948 2.4 0.049 Immune cell activation 
Tnfsf13b: tumor necrosis factor receptor     
 superfamily, member 13b AK004668 6.5 0.035 Immune cell activation 
Itgam: integrin alpha M (Cd11b) NM_008401 2.7 0.044 
Immune cell activation 
/Chemotaxis 
Itgb2: integrin beta 2 (Cd18) NM_008404 3.1 0.032 
Immune cell activation 
/Chemotaxis 
Ccl8: chemokine (C-C motif) ligand 8 NM_021443 7.0 0.037 Chemotaxis 
Ccr10: chemokine (C-C motif) receptor 10 AF215982 3.4 0.004 Chemotaxis 
Ccr5: chemokine (C-C motif) receptor 5 X94151 3.5 0.047 Chemotaxis 
C3ar1: complement component 3a 
receptor 1 NM_009779 2.1 0.049 Chemotaxis 
Fcer1g: Fc receptor, IgE,      
high affinity I, gamma polypeptide NM_010185 2.3 0.032 Chemotaxis 
Vcam1: vascular cell adhesion molecule 1 BB250384 3.5 0.044 Chemotaxis 
 
a. Gene expression profiles of DSS treatment group was compared to that of H. bilis + 
DSS group and differentially expressed genes were filtered by false discovery rate q ≤ 
0.05 and estimated fold change ≥ 2. 
b. Fold change was defined as the comparative gene expression levels between H. bilis 
+ DSS group and DSS alone group. 
c. The functional overrepresentation of differentially expressed genes was analyzed by 
DAVID bioinformatics resource 2007. 
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Figure 2. Analysis of mRNA expression of selected genes in the colon of mice treated 
with DSS alone or treated with H. bilis plus DSS.  Gnotobiotic mice had been colonized with 
H. bilis for six weeks prior to exposure to 1.5 % DSS in their drinking water. The mice were 
exposed to DSS for five days followed by a four day restitution period. At this time, total 
RNA was isolated from colonic tissues and converted into cDNA. cDNA were then amplified 
via quantitative PCR using gene specific primers. The gene expression levels were 
normalized against the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Cd28: CD28 antigen; Itgb2: Integrin beta 2; Ccr5: chemokine receptor 5. Open bars represent 
DSS group, filled bars represent H. bilis + DSS group. n = 6-8 mice per group. ** P<0.01.  
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1B1BHelicobacter bilis colonization increased the infiltration/proliferation of mucosal and/or 
MLN macrophages, T cells and B cells and but not neutrophils. To dissect the cellular 
components of mucosa after H. bilis colonization and/or DSS treatment, we analyzed the 
mucosal neutrophils, macrophages, T cells, and B cells. Neutrophil infiltration is a prominent 
feature of acute inflammation. MPO is an enzyme located in neutrophil granules and is an 
indictor of neutrophil or granulocyte infiltration [39]. We measured the MPO levels after 
DSS treatment and/or H. bilis colonization by normalizing against total protein. The H. bilis 
plus DSS treated group had significantly lower MPO levels (P<0.05) compared to the DSS 
alone group (Fig. 3). In addition, increased neutrophil infiltration in histological sections in H. 
bilis plus DSS group was not observed (data not shown). This result suggested that 
neutrophil infiltration might not play a major role in the development of inflammation 
induced by exposure to low dose DSS in gnotobiotic mice previously colonized with H. bilis.  
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Figure 3. Analysis of colonic myeloperoxidase (MPO) levels in the colon of mice 
treated with DSS alone or treated with H. bilis plus DSS. Gnotobiotic mice had been 
colonized with H. bilis for six weeks prior to exposure to 1.5 % DSS in their drinking water. 
The mice were exposed to DSS for five days followed by a four day restitution period. At 
this time, colonic tissue samples were homogenized and sonicated. The resulting lysate were 
centrifuged and MPO levels in supernatants were measured as described in Materials and 
Methods. Open bars represent DSS group, filled bars represent H. bilis + DSS group. n = 10 
to 14 mice per group. * P < 0.05 vs. H. bilis + DSS group.  
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  Tissues were also prepared for immunohistochemical analysis to detect the presence of 
macrophages using the F4/80 monoclonal antibody. Microscopic analysis revealed a notable 
increase in the numbers of macrophages in the lamina propria and submucosa of mice in the 
H. bilis + DSS group, in comparison to mice treated with DSS alone (Fig. 4). Interestingly, 
macrophages were observed within ulcerative lesions of mice in the H. bilis + DSS group, 
indicating the macrophage infiltration may be involved in the development of inflammatory 
lesions (Fig. 4). 
In order to study the effects of H. bilis on mucosal and MLN T and B cells, LPL and 
MLN cells were isolated and single cell suspensions were prepared.  Based upon flow 
cytometric analysis, the results showed that LPL populations from mice in the H. bilis + DSS 
group had a significant (P < 0.05) increase of approximately 2-fold  in total CD3
+
 T cells and 
a moderate increase in total CD19
+
 B cells in the intestinal mucosa, in comparison to cells 
recovered from mice treated with DSS alone (Fig. 5A). With regards to MLN cells, H. bilis 
colonization induced a significant (P < 0.01) increase in the total numbers of both CD3
+
 T 
cells and CD19
+
 B cells (Fig. 5B). While total numbers of CD3
+ 
T cells and CD19
+ 
B cells in 
the mucosa were similiar, the number of CD3
+
 T cells were much higher than those of 
CD19
+
cells in MLNs of mice colonized with H. bilis. Consistent with the increased numbers 
of T cells and B cells in MLN, there was a significant increase in antigen-specific 
proliferative responses of MLN cells upon the stimulation with APC pulsed with ASF or H. 
bilis whole cell lysates (Fig. 6). These results demonstrate the presence of antigen-specific 
lymphocytes in the MLN of mice following H. bilis colonization.   
Consistent with the activation and proliferation of  B cells, a strong increase in antibody 
responses to both H. bilis and commensal bacteria ASF was observed in serum samples 
obtained from  mice colonized with H. bilis and treated with DSS, in comparison to mice 
treated with DSS alone (Fig. 7A, B, C). Notably, IgG2a antibody responses predominated 
over IgG1 antibody responses to both H. bilis and ASF (Fig. 7A, B, C). In addition, IgG2a 
antibody responses to some commensal bacteria such as ASF 356, 502, and 519 in mice from 
the H. bilis + DSS group were higher than responses to other ASF antigens (Fig. 7C).  
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Figure 4. Immunohistochemical analysis of F4/80
+ 
macrophages in colonic mucosa of 
mice treated with DSS alone or treated with H. bilis plus DSS. Gnotobiotic mice had been 
colonized with H. bilis for six weeks prior to exposure to 1.5 % DSS in their drinking water. 
The mice were exposed to DSS for five days followed by a four day restitution period. At 
this time, colonic tissues were fixed and routinely processed as described in Materials and 
Methods. Paraffin-embedded colon tissue sections were deparaffinized, rehydrated and 
treated with protease enzymatic digestion. The sections were then stained with rat anti-mouse 
F4/80 monoclonal antibody followed by biotin labeled goatanti-rat secondary antibody and 
HRP-Streptavidin. The sections were incubated with a diaminobenzidine substrate to reveal 
brown/black staining for F4/80
+ 
cells. Black bars represent 50 μm.  The arrows point to 
representative F4/80
+ 
cells.  (A) Semiquantitative analysis of  F4/80
+
 cells (B) Representative 
photomicrographs of F480
+
 cells. 40 x magnifications. n =5-6 mice. P<0.01.    
 
Helicobacter bilis colonization downregulated the expression levels of 
detoxification-associated genes.  Intestinal epithelial cells participate in the process of 
detoxification and biotransformation of drugs and xenobiotics [40]. Loss or dysregulation of 
detoxification and biotransformation processes by the intestinal epithelium may contribute to 
the initiation and progression of IBD [41]. In this regard, H. bilis colonization was shown to 
induce the downregulation of detoxification-associated genes such as Cyp4b1 (Cytochrome 
P450, family 4, subfamily b, polypeptide 1) and Ugt8a (UDP galactosyltransferase 8A). The 
downregulation of these genes might create a predisposition of the host to the development of 
colitis (Chapter 2).  
In order to further examine the effects of H. bilis on DSS-induced colitis, the expression 
levels of some detoxification-associated genes in intestine mucosa were analyzed. The results 
showed that mice in the H. bilis + DSS group had significantly (P < 0.05) lower expression 
levels of mRNA for genes associated with phase I (i.e., Cyp4b1) and phase II (i.e., Ugt8a) 
detoxification/biotransformation than mice treated with DSS alone (Fig. 8). These results 
indicate that H. bilis colonization affected the detoxification function of the intestinal 
epithelium and potentially contributed to the increased susceptibility of these mice to DSS-
induced colitis.   
98 
  
(A) 
CD3 CD19
0
50
100
150
DSS
H.bilis+DSS
**
Cell makers
T
o
ta
l 
c
e
ll
 n
u
m
b
e
r
p
e
r 
m
o
u
s
e
 L
P
L
 (
1
0
4
)
 
(B) 
CD3 CD19
0
200
400
600
800
1000
1200
1400
DSS
H.bilis+DSS
**
*
Cell makers
T
o
ta
l 
c
e
ll
 n
u
m
b
e
r
p
e
r 
m
o
u
s
e
 M
L
N
 (
1
0
4
)
 
 
Figure 5. Effects of Helicobacter bilis colonization on the total CD3
+
 T cell and CD19
+
 
B cells in lamina propria and mesenteric lymph node (MLN) following exposure to DSS. At 
necropsy, mouse lamina propria lymphocytes (LPL) and MLN cells were isolated and total 
cell numbers were counted. The percentage of CD3
+
 and CD19
+
 cells in total cells were 
measured by flow cytometry. The data presented represent the total CD3
+
 and CD19
+
 cells 
per mouse colon or MLN. (A) Total numbers of CD3
+
 and CD19
+
 LPL (B) Total numbers of 
CD3
+
 and CD19
+
 MLN cells. Open bars represent DSS group, filled bars represent H. bilis + 
DSS group. n = 6-8 mice. *P < 0.05, ** P < 0.01.   
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Figure 6.  Analysis of antigen-specific mesenteric lymph node (MLN) cell proliferation 
of cell recovered from mice treated with DSS alone or treated with H. bilis plus DSS. 
Gnotobiotic mice had been colonized with H. bilis for six weeks prior to exposure to 1.5 % 
DSS in their drinking water. The mice were exposed to DSS for five days followed by a four 
day restitution period. At this time, MLN cells and LPLs were recovered from individual 
mice.  2 ×10
6 
cells/ml unfractioned MLN cells were incubated for 5 days with antigen-
presenting cells (1:1) that had been incubated overnight with or without whole cell lysates of 
the altered Schaedler’s flora organisms, H. bilis. 3H-Thymidine was added into cell 
supernatant 8 hours before harvest and proliferation was measured by liquid scintillation. 
Open bars represent DSS alone group, filled bars represent H. bilis + DSS group. n = 6-8 
mice per group. *P < 0.05, ** P < 0.01.   
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(B) IgG1 antibody responses to ASF (C) IgG2a antibody responses to ASF 
 
Figure 7.  Measurement of antibody responses to Helicobacter bilis and altered 
Schadler’s flora (ASF) in the sera of mice treated with DSS alone or treated with H. bilis + 
DSS. Gnotobiotic mice had been colonized with H. bilis for six weeks prior to exposure to 
1.5 % DSS in their drinking water. The mice were exposed to DSS for five days followed by 
a four day restitution period. Sera samples collected at necropsy were diluted and added into 
the 96-well microtiter plates coated with the whole cell lysates of H. bilis or each ASF. 
Isotype specific antibody responses were measured as described in Materials and Methods. n 
= 6 to 10 mice. * P<0.05, ** P<0.01 vs. DSS group. (A) Antibody responses to H. bilis.  (B) 
IgG1 to ASF. (C) IgG2a to ASF.  
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Figure 8. Analysis of mRNA expression for detoxification-associated genes in the colon 
of mice treated with DSS alone or treated with H. bilis plus DSS. Gnotobiotic mice had been 
colonized with H. bilis for six weeks prior to exposure to 1.5 % DSS in their drinking water. 
The mice were exposed to DSS for five days followed by a four day restitution period. Total 
RNA was isolated from colonic tissues and converted into cDNA. cDNA samples were then 
amplified via quantitative PCR using gene specific primers. The mRNA expression levels 
were normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Cyp4b1: 
Cytochrome P450, family 4, subfamily b, polypeptide 1. Ugt8a: UDP galactosyltransferase 
8A. Open bars represent DSS group, filled bars represent H. bilis + DSS group. n = 6 to 8 
mice per group. * P<0.05.    
 
DISCUSSION 
In the present study, it was shown that Helicobacter bilis colonization exacerbated colitis 
in immunocompetent gnotobiotic mice. H. bilis colonized mice developed more severe colitis 
following exposure to a low dose of DSS compared to non-H. bilis colonized control mice. 
This increased sensitivity to a colitic insult was accompanied by an increase in the colonic 
expression mRNA specific for adhesion molecules and chemokines/chemokine receptors, 
such as Itgb2, Ccl8, Ccr5. Cellular analysis also indicated that H, bilis colonization increased 
the infiltration of leukocytes including macrophages, T cells, B cells into the lamina propria 
of mice treated with DSS. More importantly, the infiltrated leukocytes appeared to be 
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activated as suggested by the upregulation of mRNA specific for T cell and B cell activation 
markers (e.g., Cd28, Tnfsf13b) and increased antigen-specific antibody responses to both H. 
bilis and commensal ASF bacteria. These results suggested that colonization of mice with H. 
bilis has a potent immunomodulatory effect that provides a predisposing stimulus towards the 
development of colitis. While playing the role of provocateur, H. bilis colonization alone 
does not induce overt-inflammation in an immunocompetent host [18]. The results of the 
present study supports the contention that H. bilis, at least in part, through the recruitment 
and/or activation of mucosal immune cells, is capable of priming a mucosal immune 
response that contributes to initiation and/or exacerbation of IBD. Helicobacter bilis has been 
shown to be prevalent in many rodent colonies used for biomedical research and this has 
confounded the analysis of many studies [8, 12]. Because H. bilis has been also shown to be 
present in the human gut [9, 10], the elucidation of deleterious effects of H. bilis colonization 
has upon the development of colitis has the potential to improve biomedical research and 
enhance treatment of IBD patients.  
 In contrast to increased histological lesions and upregulation of some adhesion 
molecules potentially involved in neutrophil infiltration (e.g., Itgb2/Cd18), mice treated with 
H. bilis plus DSS had significantly lower colonic myeloperoxidase levels than mice treated 
with DSS alone. Histological examination also showed that the expected infiltration of 
neutrophils into the colonic tissues of mice treated with H. bilis plus DSS did not occur. The 
lack of a demonstrable neutrophil infiltration suggested that; 1) neutrophils might infiltrate 
into the colonic mucosa at an earlier time point (e.g., prior to the DSS restitution period), or 2) 
prior H. bilis colonization facilitated the induction of chemokine responses that favored 
recruitment of other immune cells, or 3) H. bilis itself might have some pathogenic factors 
that inhibit the infiltration or activation or neutrophils. Regardless, the recruitment/activation 
of macrophages and lymphocytes induced by H. bilis colonization indicates that any 
neutrophilic infiltration that did occur was not sufficiently effective to prevent immuno-
stimulatory effects of H. bilis. Defective neutrophil functions and the presence of lamina 
propria graulomas are frequently observed in patients with Crohn’s disease [42-44]. In this 
context, the present results indicate that intestinal inflammation induced by DSS treatment in 
H. bilis colonized mice appears to mimic the characteristic lesions of Crohn’s disease rather 
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than ulcerative colitis. Also, the antibody responses to both H. bilis and ASF suggest a Th1-
bias (IgG2a vs. IgG1) which is similar to that observed in patients with Crohn’s disease [6].   
Macrophages have been implicated to be a crucial cell type involved in the pathogenesis 
of DSS-induced colitis [45, 46]. The present study demonstrated that H. bilis colonization 
increased the infiltration of F4/80
+
 matures macrophages into lamina propria and submucosa 
of mice treated with DSS. In addition, the upregulation of mRNA expression for genes 
associated with macrophage cell surface molecules (i.e., Igtam/Cd11b) and chemokines (e.g., 
Ccl8) was observed in tissues from mice with DSS-induced colitis. As these results do not 
elucidate a cause or effect, further investigations are needed to clearly define the role of 
macrophages in the lamina propria of mice colonized by H. bilis.  
The activation and recruitment of lymphocytes into the lamina propria indicated that H. 
bilis colonization induced the activation of adaptive immunity. Notably, H. bilis colonization 
induced host antibody responses to commensal bacteria ASF356, 502, and 519, as well as 
antibody responses to H. bilis. Immune responses to commensal bacteria have been 
suggested to be one of the key mechanisms associated with the development of colitis [6]. 
Furthermore, ASF 356, 502, and 519 are members of the Clostridium or Bacteroides species 
that have been shown to exacerbate the disease activity in IBD patients [47, 48].  
Of particular importance, the downregulation of mRNA specific for two detoxification-
associated genes was observed in mucosa of mice colonized with H. bilis and treated with 
DSS. Dysregulation of detoxification genes of intestinal epithelial cells has been implicated 
in IBD patients and animal models [41].This result indicated that H. bilis colonization might 
affect the detoxification ability and barrier function of intestinal epithelial cells. Impaired 
epithelial functions, such as increased permeability, have been shown to be the primary 
defect and lead to activation of adaptive immunity and development of intestinal 
inflammation in SAMP1/Yit mice [49]. It would be of considerable interest to determine 
whether alteration of potential epithelial functions (e.g., detoxification activity) can initiate or 
perpetuate the development of adaptive immunity including recruitment/activation of 
mucosal immune cells that results in chronic mucosal inflammation.   
Despite the potential effects on detoxification activity and recruitment/activation of 
mucosal immune cells, H. bilis colonization alone did not induce overt mucosal inflammation. 
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The requirement of both H. bilis colonization and a second colitic insult (e.g., low-dose DSS) 
in order to induce the development of severe colitis is consistent with the “multiple-hit 
hypothesis” for the development of IBD [4]. It was suspected that each factor alone (e.g., H. 
bilis or DSS) plays distinct roles in altering the mucosal functions and the combination of 
these two factors leads to the development of colitis. The effects of H. bilis seem to alter the 
epithelial barrier function and recruit/activate the resident immune cells in lamina propria 
establishing a state of subclinical inflammation. The effects of DSS treatment appear to 
change the epithelial barrier function by reducing the colonic epithelial proliferation leading 
to loss of the progenitor cell compartment [50] and exposing the underlying lamina propria to 
a multitude of phlogistic components and antigens. Indeed, there was an observed 
downregulation of genes associated with the cellular proliferation following DSS treatment 
(data not shown).  Subsequently, the deterioration of barrier function [51] allows gut flora, 
including H. bilis, to further activate the mucosal innate immune cell population, resulting in 
chronic, mucosal inflammation [52].   
In summary, Helicobacter bilis increased the host sensitivity to DSS-induced colitis in 
immunocompetent mice, probably due to the increased recruitment and/or activation of 
intestinal inflammatory cells such as macrophage, T cells, and B cells in combination with 
the dysregulation of epithelial detoxification processes. The results of the present studies 
suggest that persistent colonization by bacterial provocateurs such as Helicobacter bilis may 
be a potential predisposing environmental factor in the initiation and/or exacerbation of 
colitis.  
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Supplemental Figure 1. Analaysis of mRNA of selected genes associated with lamina 
prorprial lymphocytes (LPL) recovered from mice treated with DSS alone or treated with H. 
bilis plus DSS. Gnotobiotic mice had been colonized with H. bilis for six weeks prior to 
exposure to 1.5 % DSS in their drinking water. The mice were exposed to DSS for five days 
followed by a four day restitution period. At this time, total RNA was isolated from colonic 
tissues and converted into cDNA. cDNA were then amplified via quantitative PCR using 
gene specific primers. The gene expression levels were normalized into glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). IL17: Interleukin 17, Foxp3: Forkhead box P3, TGFβ: 
Transforming growth factor, beta. Open bars represent DSS group, filled bars represent H. 
bilis + DSS group. n = 6-8 mice per group. * P<0.05.   
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Supplemental Table 1. The list of mucosal differentially expressed genes derived from a 
comparison between H. bilis + DSS group and DSS group.   
Gene
a
 Gene Title Gene Symbol Fold change
b
 
GeneBank  
ID 
q 
values 
1452565_x_at --- --- 5.0 M11024 0.036 
1435560_at --- --- 3.6 BI554446 0.039 
1421420_at --- --- 3.4 AF215982 0.004 
1448061_at --- --- 3.3 AA183642 0.029 
1425471_x_at --- --- 2.5 BC003855 0.033 
1418204_s_at allograft inflammatory factor 1 Aif1 2.6 NM_019467 0.039 
1452535_at 
Anti-CD4 immunoglobulin heavy chain (VH2-
DQ52-JH3 region) --- 4.8 Z95476 0.035 
1417597_at CD28 antigen Cd28 5.4 NM_007642 0.016 
1437025_at CD28 antigen Cd28 2.9 AV313615 0.028 
1427301_at CD48 antigen Cd48 3.2 BE634960 0.035 
1426112_a_at CD72 antigen Cd72 4.2 BC003824 0.044 
1436530_at CDNA clone MGC:107680 IMAGE:6766535 --- 2.2 AA666504 0.035 
1419684_at chemokine (C-C motif) ligand 8 Ccl8 7.0 NM_021443 0.037 
1422259_a_at chemokine (C-C motif) receptor 5 Ccr5 3.5 X94151 0.047 
1417381_at 
complement component 1, q subcomponent, alpha 
polypeptide C1qa 2.3 NM_007572 0.042 
1417063_at 
complement component 1, q subcomponent, beta 
polypeptide C1qb 2.7 NM_009777 0.039 
1434366_x_at 
complement component 1, q subcomponent, beta 
polypeptide C1qb 2.2 AW227993 0.039 
1449401_at 
complement component 1, q subcomponent, 
gamma polypeptide C1qg 2.4 NM_007574 0.044 
1442082_at complement component 3a receptor 1 C3ar1 2.9 BB333624 0.032 
1419483_at complement component 3a receptor 1 C3ar1 2.6 NM_009779 0.035 
1419482_at complement component 3a receptor 1 C3ar1 2.1 NM_009779 0.049 
1425407_s_at C-type lectin domain family 4, member a2  Clec4a2  2.1 BC006623 0.005 
1429954_at C-type lectin domain family 4, member a3 Clec4a3 4.8 AK014135 0.006 
1425951_a_at C-type lectin domain family 4, member n Clec4n 2.7 AF240358 0.049 
1419627_s_at C-type lectin domain family 4, member n Clec4n 2.5 NM_020001 0.032 
1422978_at cytochrome b-245, beta polypeptide Cybb 3.1 NM_007807 0.022 
1436778_at cytochrome b-245, beta polypeptide Cybb 3.0 AV373944 0.022 
1436779_at cytochrome b-245, beta polypeptide Cybb 2.9 AV373944 0.036 
1435343_at dedicator of cytokinesis 10 Dock10 2.2 BF715043 0.035 
1453677_a_at Der1-like domain family, member 3 Derl3 3.5 AK007348 0.006 
1450241_a_at ecotropic viral integration site 2a Evi2a 2.8 NM_010161 0.049 
1451161_a_at EGF-like module containing, Emr1 2.1 U66888 0.039 
  mucin-like, hormone receptor-like sequence 1     
1422120_at ELL associated factor 2 Eaf2 4.1 AY034479 0.049 
1445688_at Endothelin converting enzyme 1 (Ece1), mRNA Ece1 2.0 BG073119 0.036 
1434067_at expressed sequence AI662270 AI662270 5.7 BE688410 0.022 
1434068_s_at expressed sequence AI662270 AI662270 4.4 BE688410 0.038 
1418340_at 
Fc receptor, IgE, high affinity I, gamma 
polypeptide Fcer1g 2.3 NM_010185 0.032 
1417876_at Fc receptor, IgG, high affinity I Fcgr1 2.4 AF143181 0.032 
1435477_s_at Fc receptor, IgG, low affinity IIb Fcgr2b 2.4 BM224327 0.028 
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a
 Gene Title 
Gene 
Symbol 
Fold 
change
b
 
GeneBank  
ID q values 
1455332_x_at Fc receptor, IgG, low affinity IIb Fcgr2b 2.1 BM224327 0.014 
1451941_a_at Fc receptor, IgG, low affinity IIb Fcgr2b 2.0 M14216 0.032 
1422953_at formyl peptide receptor, related sequence 2 Fpr-rs2 2.8 NM_008039 0.049 
1452117_a_at FYN binding protein Fyb 2.3 BB157866 0.050 
1431296_at G protein-coupled receptor 15 Gpr15 2.1 AA555873 0.049 
1424927_at GLI pathogenesis-related 1 (glioma) Glipr1 2.5 BC025083 0.026 
1420394_s_at glycoprotein 49 A  Gp49a 2.5 U05264 0.028 
1449175_at G-protein coupled receptor 65 Gpr65 2.2 NM_008152 0.049 
1446745_at hypothetical LOC433637 LOC433637 2.2 BB490675 0.021 
1460423_x_at Ig kappa chain IgM 48.1 U29768 0.011 
1427851_x_at immunoglobulin heavy chain (J558 family) Igh-VJ558 29.8 AF065324 0.011 
1429381_x_at immunoglobulin heavy chain (J558 family)  Igh-VJ558  3.1 AK007826 0.006 
1425763_x_at immunoglobulin heavy chain (J558 family)  Igh-VJ558  2.4 BC019425 0.013 
1421653_a_at immunoglobulin heavy chain (J558 family)  Igh-VJ558 2.1 NM_134051 0.003 
1424305_at immunoglobulin joining chain Igj 4.4 BC006026 0.004 
1427757_at immunoglobulin kappa chain variable 21 (V21) Igk-V21 31.7 D29670 0.049 
1452417_x_at immunoglobulin kappa chain, constant region  Igk-C 2.3 AV057155 0.007 
1427455_x_at immunoglobulin kappa chain, constant region Igk-C  2.3 BI107286 0.011 
1427660_x_at immunoglobulin kappa chain, constant region Igk-C 2.1 BC013496 0.006 
1452536_s_at 
Immunoglobulin kappa light variable region (IgKV 
gene) Igk-V1 29.4 Z95478 0.011 
1427858_at 
Immunoglobulin kappa light variable region (IgKV 
gene) Igk-V1 3.5 U29768 0.022 
1452463_x_at Immunoglobulin lambda chain, mAb 667 Igk-V8 3.6 BG966217 0.042 
1426200_at Immunoglobulin lambda chain, mAb 667 Igk-V8 3.4 AY058910 0.044 
1451951_at Immunoglobulin light chain variable region Igk-V8 27.1 U62386 0.011 
  (IGLV gene), clone F22-4     
1421408_at immunoglobulin superfamily, member 6 Igsf6 2.1 NM_030691 0.044 
1427262_at inactive X specific transcripts Xist 1159.1 L04961 0.000 
1436936_s_at inactive X specific transcripts Xist 122.6 BG806300 0.006 
1422046_at integrin alpha M Itgam 2.7 NM_008401 0.044 
1450678_at integrin beta 2 Itgb2 3.1 NM_008404 0.032 
1421173_at interferon regulatory factor 4 Irf4 6.1 U34307 0.010 
1423555_a_at interferon-induced protein 44 Ifi44 8.2 BB329808 0.044 
1416296_at interleukin 2 receptor, gamma chain Il2rg 2.8 L20048 0.042 
1424302_at leukocyte immunoglobulin-like receptor, Lilrb3 3.0 U96693 0.035 
  subfamily B (with TM and ITIM domains), member 3    
1425548_a_at leukocyte specific transcript 1 Lst1 2.2 U72644 0.035 
1426169_a_at linker for activation of T cells family, member 2 Lat2 2.8 AF257136 0.004 
1421571_a_at lymphocyte antigen 6 complex, locus C Ly6c 3.6 NM_010741 0.044 
1418641_at lymphocyte cytosolic protein 2 Lcp2 2.4 BC006948 0.049 
1427076_at macrophage expressed gene 1 Mpeg1 2.1 L20315 0.028 
1422062_at macrophage scavenger receptor 1 Msr1 2.0 BC003814 0.035 
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1419599_s_at 
membrane-spanning 4-domains, subfamily A, 
member 11 Ms4a11 4.5 NM_026835 0.022 
1419598_at 
membrane-spanning 4-domains, subfamily A, 
member 6D Ms4a6d 4.2 NM_026835 0.022 
1424754_at 
membrane-spanning 4-domains, subfamily A, 
member 7 Ms4a7 2.0 BC024402 0.039 
1427577_x_at Monoclonal antiidiotypic antibody IgK --- 8.3 BF301241 0.010 
  (hypervariable region) mRNA     
1427576_at Monoclonal antiidiotypic antibody IgK --- 6.0 BF301241 0.022 
  (hypervariable region) mRNA     
1431320_a_at myosin Va Myo5a 2.3 AK002362 0.045 
1428786_at NCK associated protein 1 like Nckap1l 2.0 BM238906 0.028 
1418465_at neutrophil cytosolic factor 4 Ncf4 2.5 NM_008677 0.039 
1451821_a_at nuclear antigen Sp100 Sp100 2.8 U83636 0.044 
1417483_at nuclear factor of kappa light polypeptide  Nfkbiz 2.7 AB026551 0.044 
 gene enhancer in B-cells inhibitor, zeta     
1430700_a_at phospholipase A2, group VII  Pla2g7 2.2 AK005158 0.035 
 (platelet-activating factor acetylhydrolase, plasma)    
1417426_at proteoglycan 1, secretory granule Prg1 2.8 NM_011157 0.044 
1428947_at RIKEN cDNA 2010001M09 gene 2010001M09Rik 19.2 AK008016 0.011 
1424704_at runt related transcription factor 2 Runx2 2.5 D14636 0.049 
1450165_at schlafen 2 Slfn2 2.1 NM_011408 0.049 
1425738_at similar to anti-glycoprotein-B of human  LOC243469 40.2 M35669 0.006 
 Cytomegalovirus immunoglobulin Vl chain      
1453472_a_at SLAM family member 7 Slamf7 2.2 AK016183 0.042 
1420819_at src-like adaptor Sla 2.1 NM_009192 0.050 
1419186_a_at 
ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 4 St8sia4 2.4 NM_009183 0.044 
1456147_at 
ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 6 st8sia6 3.7 BB486599 0.018 
1457753_at toll-like receptor 13 Tlr13 2.4 BI655907 0.044 
1448021_at Transcribed locus --- 5.5 AA266723 0.039 
1435144_at Transcribed locus --- 2.8 BM243379 0.014 
1451860_a_at tripartite motif protein 30 Trim30 3.2 AF220015 0.049 
1423182_at 
tumor necrosis factor receptor superfamily, member 
13b Tnfrsf13b 6.5 AK004668 0.035 
1420782_at 
tumor necrosis factor receptor superfamily, member 
17 Tnfrsf17 6.4 NM_011608 0.029 
1446234_at 
Ubiquitously transcribed tetratricopeptide repeat 
gene Utx 2.5 BB125985 0.049 
 , X chromosome, mRNA (cDNA clone IMAGE:5356391)    
1448162_at vascular cell adhesion molecule 1 Vcam1 3.4 BB250384 0.044 
 
a. Gene expression profiles of DSS treatment group was compared to that of H. bilis + DSS group and 
differentially expressed genes were filtered by false discovery rate q ≤ 0.05 and estimated fold change 
≥ 2. 
b. Fold change was defined as the comparative gene expression levels between  H. bilis + DSS group and 
DSS alone group. 
114 
  
 
CHAPTER 4: ORAL TREATMENT WITH HYPOXOSIDE 
AMELIORATES Brachyspira hyodysenteriae-INDUCED  
MURINE COLITIS 
 
A paper to be submitted to the journal American Journal of Physiology 
- Gastrointestinal and Liver Physiology  
 
Zhiping Liu
1
, Jennifer Wilson-Welder
1
,  
Jesse M. Hostetter
2
, Albert E Jergens
3
 and Michael J Wannemuehler
1
 
 
1   
Department of Veterinary Microbiology and Preventive Medicine, and 
2 
Department of Veterinary Pathology, and 
3
Department of Veterinary Clinical Sciences, 
College of Veterinary Medicine,  Iowa State University, Ames, Iowa 
  
ABSTRACT 
Brachyspira hyodysenteriae is the causative agent of swine dysentery and induces a 
characteristic mucosal inflammatory response resulting in pronounced typhlocolitis in mice 
and swine. Hypoxoside has been reported to be an anti-inflammatory drug extracted from an 
African medicinal plant, Hypoxis hemerocallidea. In vitro studies have shown that 
hypoxoside inhibits the secretion of pro-inflammatory cytokines and the nuclear binding 
activity of NF- B. The aim of this study was to evaluate the ability of hypoxoside to prevent 
or ameliorate B. hyodysenteriae-induced colitis. Mice were orally treated with hypoxoside 
for seven days prior to B. hyodysenteriae infection and the treatments continued daily for 
seven days postinfection (DPI) . At the termination of the experiment (i.e., seven DPI), gross 
and histological lesions, weight loss, and mucosal myeloperoxidase activity were evaluated. 
In addition, expression of NF- B-associated genes, the protein level of active NF- B subunit 
p65, epithelial cell proliferation, and the number of gut B. hyodysenteriae were also 
measured. Hypoxoside treatment significantly (P <0.05) reduced the severity of B. 
hyodysenteriae -induced lesions, weight loss, and tissue levels of myeloperoxidase. NF- B-
associated genes were downregulated and the protein levels of active p65, and the degree of 
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epithelial proliferation were decreased after hypoxoside treatment. Mechanistically, there 
was no direct evidence that hypoxoside was anti-microbial based on qPCR assessment of B. 
hyodysenteriae within cecal contents. In conclusion, oral treatment with hypoxoside 
ameliorated B. hyodysenteriae-induced colitis and these results suggest that pro-drugs such as 
hypoxoside have therapeutic potential for ameliorating enteropathies mediated by overly 
active host inflammatory processes.   
Key Words: Hypoxoside; Brachyspira hyodysenteriae; colitis; NF- B  
 
INTRODUCTION 
Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are 
chronic and relapsing intestinal inflammatory disorders leading to diarrhea, abdominal pain, 
and weight loss. As many as 1.4 and 2.2 million individuals in the United States and Europe, 
respectively, are suffering from these diseases, and these diseases are reported to have a 
significant impact upon the cost of health care and loss of productivity (29, 46, 48). The 
exact etiology of IBD is still unknown though genetic defects, increased epithelial 
permeability, and dysregulation of host immune responses to gut flora are considered to be 
three major factors contributing to the pathogenesis of IBD (11, 30, 43). Mouse models of 
experimental colitis induced by gene knockout, chemicals, adoptive transfer, or spontaneous 
development are widely utilized to study the mechanisms underlying the development of IBD 
and to design new therapeutic strategies for the treatment of IBD (8, 10, 21). In addition, 
microbial infections, such as Citrobacter rodentium, Helicobacter hepticus, have also been 
used to evaluate the induction of inflammation leading to acute or chronic colitis (8, 24).  
 Brachyspira hyodysenteriae, a gram-negative anaerobic spirochete that is the causative 
agent of swine dysentery, induces colonic inflammation that is similar in both swine and 
mice (18, 19, 20, 36, 37, 41). In mice, the cecal histological lesions induced by B. 
hyodysenteriae include submucosal edema, inflammatory cell infiltration of the lamina 
propria, and erosions of mucosal epithelium (41).    
Like other local inflammatory responses, B. hyodysenteriae-induced inflammation was 
associated with leukocyte infiltration, production of pro-inflammatory cytokines, and 
activation of NF- B (13, 42). In comparison, excessive or inappropriate activation of NF- B 
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has been also observed in human IBD and other inflammatory diseases (2, 9). In addition, 
blockage of NF- B pathway serves as an important therapeutic intervention strategy for 
managing inflammatory diseases (2, 9).   
Currently, some anti-inflammatory drugs such as 5-aminosalicylates, corticosteroids 
sulfasalazine are commonly used to treat IBD patients (7). However, current therapies not 
only show limited benefits but also have unwanted side effects (7, 16). It is, therefore, 
desirable to explore new classes of agents that are equally or more effective anti-
inflammatory compounds and that may cause fewer deleterious side effects. 
Hypoxoside is a diglucoside present in the corm of an African medicinal plant, Hypoxis 
hemerocallidea (also known as Hypoxis rooperi, African Potato), a member of the family 
Hypoxidaceae (1). This African traditional medicine has been widely used in southern Africa 
and claimed to be an effective remedy for an array of human aliments such as HIV/AIDS-
related diseases, arthritis, diabetes mellitus, cancers, gastric and duodenal ulcers, and urinary 
tract infections (38). 
In the colon, hypoxoside can be converted by β-glucosidase produced by gut bacteria 
into its aglucone compound called rooperol (23). It has been shown that rooperol has anti-
inflammatory effects and possible usefulness in the treatment of inflammatory disease (3, 14, 
15, 25, 38). For example, rooperol was shown to inhibit the in vitro production of TNF-α, IL-
1, IL-6, and nitric oxide by endotoxin-stimulated human alveolar macrophage, human blood 
monocytes, histiocytic cells, and rat alveolar macrophage (14). Results of another study 
showed that rooperol decreased the mRNA and protein expression levels of vascular cell 
adhesion molecule-1(VCAM-1) and nitric oxide synthase (iNOS) in microvascular 
endothelial cells stimulated with TNF-α or IFN-γ (3). Rooperol was also shown to decrease 
the expression of mRNA specific for pro-inflammatory cytokines in human promonocytic 
cell line and inhibit the binding activity of transcriptional factors including NF- B and AP-
1(c-jun/c-fos dimer) (15). Recently, rooperol was shown to inhibit the enzymatic activities of 
cyclooxygenase-1 and 2 and might interfere with the synthesis of other inflammatory 
mediators such as prostaglandins (25).  In vivo, it has been shown that oral injection of 
hypoxoside inhibited fresh egg albumin-induced acute inflammation (edema) within the hind 
paws of rats (38).  
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Based on these observations, it was hypothesized that orally administered hypoxoside 
would ameliorate mucosal inflammation through the downregulation or inhibition of 
proinflammatory cytokines and/or NF- B pathways. In the present study, it was 
demonstrated that oral treatment with hypoxoside ameliorated the colitis induced by B. 
hyodysenteriae. The anti-inflammatory effect of hypoxoside correlated with the 
downregulation of genes regulated by the NF- B pathway in the colonic mucosa rather than 
displaying a direct anti-microbial effect.   
 
MAMTERIAL AND METHODS 
Animals. Eight to nine week old, C3H/HeOuJ mice were obtained from The Jackson 
Laboratory (Bar Harbor, ME). All animal-related procedures were approved by the Animal
 
Care and Use Committee at Iowa State University. 
Bacteria. Brachyspira hyodysenteriae strain B204 was grown anaerobically at 37
 o 
C in 
trypticase soy broth (BBL Microbiology Systems, Cockeysville, MD) supplemented with 
5 % horse serum (HyClone Laboratories, Logan, UT), 0.5 % yeast extract (BBL), 0.05 % L-
cysteine (Sigma, St. Louis, MO) and 1 % VPI salt solutions. Highly motile, log phase 
cultures were used for all challenge inoculation. The concentration of bacteria was 
determined using a Petroff-Hausser counting chamber (Hausser Scientific, Horsham, PA). 
Forty-eight hours prior to bacterial challenge, the diet was switched from conventional 
rodent chow (CRC) to Harlan Teklad 85420 (TD) diet (Harlan Sprague Dawley, Madison, 
WI) which had been previously shown to induce more consistent lesions following B. 
hyodysenteriae infection than CRC did (18). The TD diet alone had no deleterious effects on 
the mice or upon the intestinal mucosa (data not shown). Mice were maintained on the TD 
diet for the remainder of the experiment. Four hours prior to bacterial challenge, mice were 
fasted. Mice were orally inoculated with 1 x 10
8
 B. hyodysenteriae in 0.5 ml culture broth. 
The TD diet was returned to the cages immediately after inoculation. Control mice were 
inoculated with 0.5 ml culture broth without bacteria. B. hyodysenteriae colonization was 
confirmed bacteriologically at the termination of the experimental period.  
Hypoxoside. Hypoxoside was a gift from Dr. Anthony Allison (Dawa Corp., Belmont, 
California). Fresh hypoxoside solution was made by dissolving hypoxoside in sterile 
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deionized water to a concentration of 60 mg/ml. Using a 22 gauge feeding needle, each 
mouse was orally intubated with 0.25 ml of the hypoxoside solution (15 mg) or water each 
day beginning seven days prior to challenge.    
Experimental design. Mice were randomly assigned into four experimental groups. The 
first group was designated as “Control”, which did not receive either B. hyodysenteriae 
challenge or hypoxoside treatment; the second group was designated as “Hypox only”, which 
only received the hypoxoside treatment but not the  B. hyodysenteriae challenge; the third 
group was designated as “Hypox + B. hyo”, which received both the hypoxoside treatment 
and the B. hyodysenteriae challenge; the fourth group was designated as “B. hyo only”, 
which received the B. hyodysenteriae challenge but not the hypoxoside treatment.  
Mice in “Hypox only” and “Hypox + B. hyo” groups were treated with hypoxoside 
beginning seven days prior to B. hyodysenteriae challenge and the treatments continued daily 
for another seven days postinfection (DPI). Mice in “Hypox + B.hyo” and “B. hyo only” 
were challenged with B. hyodysenteriae on experimental day seven. The experiment was 
terminated seven DPI.  
Gross and histological inflammatory lesion score. Gross and histological 
inflammatory lesion scores of ceca were evaluated as previously described (20). Briefly, 
gross inflammatory lesions were scored 0 to 3 as follows: cecal atrophy and excess 
intraluminal mucus = 3; atrophy and excess intraluminal mucus localized to the cecal apex = 
2; increased cecal mucus with no evidence of atrophy = 1; and no gross lesions = 0. For 
histological lesions, cecal tissues were formalin-fixed, embedded in paraffin, sectioned at 5 
μm, and stained with hematoxylin and eosin (H&E). Stained tissue sections were scored by a 
pathologist (Dr. J. M. Hostetter, Department of Veterinary Pathology, Iowa State University) 
in a blinded fashion. Histological scores were based on the severity of mucosal epithelial 
damage, degree of lamina propria cellular infiltrate, and architectural distortion.  
Myeloperoxidase (MPO) activity assay. The assay measuring MPO was modified from 
a previously published method (39). Briefly, ceca were collected, homogenized, and 
sonicated in phosphate buffered saline (PBS) containing 0.1 mM 
phenylmethanesulphonylfluoride (PMSF). The resulting lysate was centrifuged and 
supernatant was aliquoted into a microtiter plate. MPO activity was determined 
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colorimetrically using 3,3', 5,5'-tetramethylbenzidine(TMB) as a substrate at an optical 
density of 405 nm. Serial dilutions of freshly prepared neutrophils recovered from murine 
peripheral blood were used to generate standard curves.  
Pathway-specific microarray analysis of NF- B -associated genes. At necropsy, 
murine cecal samples were collected and stored in RNAlater (Ambion, Austin, TX). Total 
RNA was isolated using the RNeasy Mini Kit and RNase-Free DNase according to the 
manufacture’s protocol (Qiagen, Valencia, CA).  
Oligo GEArray® Mouse NF- B Signaling Pathway Microarray (Superarray, Frederick, 
MD) were used to compare transcript levels of NF-кB-associated genes in different 
experimental groups. Three milligrams of total RNA was converted into cRNA, hybridized to 
each array and detected by chemiluminescence according to the manufacturer’s protocols. 
The array signals were captured by CCD camera and analyzed using “GEArray Expression 
Analysis Suite” (Superarray). Expression of each gene was normalized to housekeeping 
genes. The genes affected by hypoxoside treatment were selected by comparing the gene 
expression levels of “B. hyo only” group to “Hypox + B. hyo” group. The genes displaying a 
two or more fold change between these two groups were analyzed.  
Active NF- B p65 quantification. Activation of NF- B within the ceca mucosa was 
measured using the TransAM NF- B P65 Chemi Transcription Factor Assay Kit (Active 
Motif, Carlsbad, CA). Cecal tissues were homogenized in ice-cold Complete Lysis Buffer, 
incubated on ice for 30 minutes and then centrifuged at 10,000 x g for 10 minutes. The 
supernatants were collected and total protein concentrations were measured by Bradford 
colorimetric assay. To evaluate NF- B activity, each protein extract (50 μg) was incubated in 
separate wells of a 96-well plate that contained immobilized nucleotide sequences for the 
consensus NF- B binding site (5 -GGGACTTTCC-3 ). Detection of NF- B binding activity 
in each tissue extract was detected by chemiluminescence according to the manufacturer’s 
directions. 
Measurement of intestinal epithelial cell proliferation.  After administration in vivo, 
5-bromo-2-deoxyuridine (BrdU) can be incorporated into replicating cells (S phase of cell 
cycle) and this approach was used to assess mucosal epithelial cell proliferation in the cecal 
mucosa of mice in each of the four experimental groups. One hour before necropsy, each 
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mouse received an intraperitoneal injection of 0.5 ml PBS containing 2.5 mg BrdU 
(Boehringer Mannheim Corporation, Indianapolis, IN). At necropsy, ceca tissues were 
collected, fixed in formalin, and then embedded in paraffin. Paraffin-embedded tissue were 
routinely processed and sectioned for the purpose of immunohistochemical staining using the 
ZYMED
 ®
 BrdU Staining Kit (Invitrogen, Carlsbad, CA). Proliferation of mucosal epithelial 
cells in ceca was assessed microscopically by calculating the percentage of BrdU-stained 
epithelial cells in the cecal epithelium. Only those crypt units visible in their entire length 
(i.e., luminal shoulder to glandular base) were analyzed and a minimum of 5 crypts were 
counted.  
Quantification of the number of Brachyspira hyodysenteriae in the ceca of infected 
mice. DNA was extracted from 100 mg cecal contents using QIAamp DNA stool Mini Kit 
(Qiagen). Quantitative PCR protocols to measure the number of B. hyodysenteriae were 
developed and optimized to detect the gene nicotinamide adenine dinucleotide hydride 
(NADH) oxidase (nox) of B. hyodysenteriae (26). The respective primer pairs were: H1 
(forward primer) (5'-ACTAAAGATCCTGATGTATTTG-3') and H2 (reverse primer) (5'-
CTAATAAACGTCTGCTGC-3'). DNA was amplified using Platinum® SYBR® Green 
qPCR SuperMix-UDG (Invitrogen) under the following conditions: 95°C for 10 minutes, 
followed by 35 cycles at 95°C for 30 seconds, 58°C for 90 seconds, 68°C for 2 minutes, 
followed by a final cycle at 68°C for 10 minutes in Rotor-Gene 3000(Corbett Research, 
Mortlake, Australia). Standard curves of DNA encoding NADH oxidase were made by using 
DNA from a series of B. hyodysenteriae culture dilutions. The correct sizes of the amplified 
PCR products were confirmed by gel electrophoresis. The specificity of this primer pair was 
also confirmed by the absence of PCR products amplified from the DNA of ceca contents in 
mice without B. hyodysenteriae infection.  
4B4BStatistical analysis. The results are expressed as mean ± standard error. The gross and 
histological lesions were analyzed using the robust Kruskal–Wallis non-parametric test while 
other data were analyzed by analysis of variance (ANOVA).  
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RESULTS 
Hypoxoside ameliorated cecal inflammation lesions induced by Brachyspira 
hyodysenteriae. Macroscopically, B. hyodysenteriae infection of C3H mice induced cecal 
lesions characterized by cecal atrophy and increased intraluminal mucus. Compared to mice 
infected with B. hyodysenteriae, the challenged mice in the hypoxoside treated group (Hypox 
+ B. hyo) had significantly (P < 0.05) lower cecal lesion scores indicating that hypoxoside 
treatment ameliorated or prevented the development of cecal lesions (Fig. 1 A, B). In 
addition, hypoxoside treatment significantly (P <0.05) prevented the weight loss induced by 
B. hyodysenteriae infection (Fig. 1C). Microscopically, hypoxoside treatment attenuated the 
characteristic mucosal hyperplasia, submucosal edema, erosion of epithelial cells, and 
leukocyte infiltration induced by B. hyodysenteriae infection (Fig. 2A, 2B).  
Similarly, the inhibitory effects of hypoxoside treatment on inflammatory lesions were 
observed at several time points after B. hyodysenteriae infection (e.g., 3, 10, and 21 DPI) 
(data not shown). Collectively, these results showed that hypoxoside treatment can 
ameliorate the cecal inflammation induced by B. hyodysenteriae infection.  
Hypoxoside treatment reduced the myeloperoxidase activity. The infiltration of 
leukocytes, especially neutrophils, is a common characteristic of acute inflammation. 
Myeloperoxidase is an enzyme found in the granules of neutrophils and has been commonly 
used as an indirect marker of neutrophil infiltration (22). Our experimental results showed 
that hypoxoside significantly attenuated the overproduction of MPO in the cecal tissue 
following B. hyodysenteriae infection (Fig. 3), indicating that the anti-inflammatory effects 
of hypoxoside also inhibited neutrophil infiltration. There was no significant difference in 
MPO levels among Control, Hypox only and Hypox + B. hyo groups, although the tissue 
samples from mice in the Hypox + B. hyo group tended to have lower MPO levels than those 
from the control group (P=0.08, Fig. 3) 
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Figure 1. The effects of hypoxoside treatment on gross lesion and weight change 
induced by Brachyspira hyodysenteriae infection in mice. (A) Gross cecal lesion scores.  ** 
P < 0.01 vs. Control, Hypox only; # P < 0.05 vs. Hypox + B. hyo. (B) Photomicrographs of 
representative murine ceca from each of the four treatment groups. (C) Changes in body 
weight on day seven after B. hyodysenteriae infection.*P<0.05 vs. all other groups. a: 
Control, b: Hypox only, c: Hypox + B. hyo, d: B. hyo only. n=5-6 mice. Hypox: Hypoxoside; 
B. hyo: Brachyspira hyodysenteriae.  
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Figure 2. The effects of hypoxoside treatment on the cecal histological lesions induced 
by Brachyspira hyodysenteriae infection in mice. (A) Cecal histological lesion scores. ** P < 
0.01 vs. Hypox only, Hypox + B. hyo; # P < 0.05 vs. Control. (B) Representative 
hematoxylin and eosin stained sections of the proximal cecum from mice in each treatment 
group. n=5 to 6 mice per group. Hypox: Hypoxoside; B. hyo: Brachyspira hyodysenteriae. 
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Figure 3. The effects of hypoxoside treatment on cecal myeloperoxidase (MPO) activity 
in mice. Ceca were homogenized, sonicated and supernatants clarified by centrifugation. The 
supernatant was aliquoted into a microtiter plates and MPO levels were determined 
colorimetrically at an optical density of 405 nm. ** P < 0.01 vs. all other groups. P=0.08 
Control vs. Hypox + B. hyo. n=5-6 mice. Hypox: hypoxoside; B. hyo: Brachyspira 
hyodysenteriae.   
NF- B Pathway specific microarray identified the genes affected by hypoxoside 
treatment. The NF- B pathway is multi-component signaling pathway regulating many 
aspects of cellular activities such as stress, inflammation, cell proliferation, and survival. The 
classical pathway of NF-κB activation induced by proinflammatory signals proceeds through 
IκB kinase (IKK)-mediated phosphorylation of cytoplasmic NF-κB inhibitors, the IκBs, 
leading to the formation and translocation of p50/p65 heterodimer into the nucleus (6, 34, 40). 
Recently, an alternative activation pathway for NF-κB, activated by stimulation of CD40, 
lymphotoxin-β receptors (Ltbr) or B-cell-activating factor and based upon the NF-κB 
inducing kinase (Nik)/IKKα-dependent processing of p100 to p52 was described (5, 31, 44, 
49).This pathway preferentially leads to the formation and translocation of p52/RelB 
heterodimers into the nucleus.  
To investigate the effects of hypoxoside on inflammation induced by B. hyodysenteriae 
infection, NF- B pathway specific microarrays were employed to study the mucosal gene 
expression profiles after hypoxoside treatment. The results showed that B. hyodysenteriae 
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infection substantially increased the gene expression levels of a series of genes associated 
with the NF- B pathway (Fig. 4 and Table 1). However, hypoxoside treatment reduced the 
expression levels of many genes upregulated following B. hyodysenteriae infection. Thus, the 
gene expression profile of mice in the Hypox + B. hyo group was similar to that of control 
mice (Fig. 4). Notably, the Hypox only group had the lowest level of gene expression among 
all groups tested, indicating that the dose of hypoxoside used reduced the homeostatic level 
of NF- B signaling (Fig. 4). Additionally, the histological evaluation (Fig. 2) of the mice in 
the Hypox only group indicated that there were no deleterious effects of this treatment. By 
comparing the gene expression profile from B. hyo only and Hypox + B. hyo experimental 
groups, 20 genes were identified to be downregulated by at least 2 fold with the treatment of 
hypoxoside (Table 1). 
 
Figure 4. The effects of hypoxoside treatment on gene expression profiles regulated by 
the NF-қB pathway. Treatment with hypoxoside began seven days prior to challenge with 
Brachyspira hyodysenteriae. Cecal tissue was recovered from mice seven days after 
challenge with B. hyodysenteriae. Cecal RNA was converted into biotin-labeled cRNA and 
hybridized into NF-қB oligo nucleotide microarrays. Hybridization of gene-specific cRNA 
samples to their specific targets was detected by chemiluminescence as described in 
Materials and Methods. Hypox: Hypoxoside; B. hyo: Brachyspira hyodysenteriae.   
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Hypoxoside treatment downregulated a series of genes associated with the NF- B 
signaling pathway. These included genes encoding cell surface receptors (e.g., Ltbr), adaptor 
proteins (e.g., Myd88, Irak1), IKB kinases (e.g., Chuk (Ikka), Ikbke), and transcriptional 
factors (e.g., Nfkb1(p105) and Nfkb2(p100)).  In addition, the downregulated genes also 
included Bcl3, Map3k14 (Nik) and Map3k7ip1 (Tab1) all of which are upstream regulators of 
NF-kB activation. The precursor protein for p50, encoded by p105, forms a dimer with p65 
in classical NF- B pathway.The precursor protein for p52, encoded by p100,  forms a dimer 
with RelB in alternative NF- B pathway (40). Bcl3 is co-activator of both p50 and p52 (4, 
12). Notably, in addition to genes involved in classical NF- B pathways (e.g., Myd88, Ikka 
and p105), the list of downregulated genes included genes involved in the alternative 
pathway (e.g., Ltbr, Nik, Ikka and p100) (40). These results indicate that hypoxoside 
treatment could downregulate expression of genes associated with different stages of both 
classical and alternative NF- B signaling pathway. In addition, hypoxoside treatment also 
downregulated genes involved in MAPK signaling (e.g., Mapk14 (P38), Fos) and cell growth 
(e.g., Akt1, Egr1), indicating that the inhibition of MAPK signaling and inflammation-
associated cell proliferation by hypoxoside treatment.  
Quantification of the effect of hypoxoside on the levels of active NF- B p65. Upon 
activation, transcriptional factor p65 can be dissociated from I- B and translocated into 
nucleus. To directly address the inhibition of NF- B by hypoxoside treatment at the level of 
activated protein, the quantity of active NF- B p65 protein was measured in extracts of cecal 
tissue. The results showed that B. hyodysenteriae infection significantly increased (P < 0.05) 
the amount of active NF- B p65 protein in comparison to control mice (Fig. 5). Although the 
dual treated group (i.e., Hypox + B. hyo) had a higher level of p65 than that of the control 
group, they had significantly lower levels of active p65 than the tissue samples from the mice 
in the B. hyo only group (P<0.05), suggesting that hypoxoside treatment, at least partially, 
inhibited the activation of NF- B p65.  
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Table 1. Hypoxoside treatment downregulated gene expression levels in the NF-қB 
pathway induced by Brachyspira hyodysenteriae infection.  
 
 
Gene name
a
 
Gene Bank 
ID 
Fold change
b
 
NF-қB /MAPK signaling   
Ltbr: Lymphotoxin B receptor NM_010736 -3.65 
Myd88: Myeloid differentiation primary response gene 88 NM_010851 -5.11 
Irak1: Interleukin-1 receptor-associated kinase 1 NM_008363 -2.20 
Chuk: Conserved helix-loop-helix ubiquitous kinase NM_007700 -13.04 
Ikbke:Inhibitor of kappaB kinase epsilon NM_019777 -3.59 
Bcl3: B-cell leukemia/lymphoma 3 NM_033601 -3.43 
Nfkb1: Nuclear factor of kappa light chain gene  NM_008689 -4.91 
enhancer in B-cells 1, p105   
Nfkb2: Nuclear factor of kappa light polypeptide  NM_019408 -2.44 
gene enhancer in B-cells 2, p49/p100   
Map3k14: Mitogen-activated  NM_016896 -15.04 
protein kinase kinase kinase 14   
Map3k7ip1: Mitogen-activated protein   NM_025609 -2.85 
kinase kinase kinase 7 interacting protein 1   
Mapk14: Mitogen activated protein kinase 14 NM_011951 -2.33 
Fos: FBJ osteosarcoma oncogene NM_010234 -6.01 
Others   
Akt1: Thymoma viral proto-oncogene 1 NM_009652 -3.23 
Casp8: Caspase 8 NM_009812 -3.55 
Ecm1: Extracellular matrix protein 1 NM_007899 -2.21 
Egr1:Early growth response 1 NM_007913 -8.69 
Gja: Gap junction membrane channel protein alpha 1 NM_010288 -10.44 
Litaf: LPS-induced TNF factor NM_019980 -6.23 
Ppm1a: Protein phosphatase 1A, magnesium dependent, 
alpha isoform 
NM_008910 -4.25 
Tollip: Toll interacting protein NM_023764 -9.53 
 
 
a. Gene expression levels of “Hypox + B. hyo” group were compared to those of “B. 
hyo only” group.  
b. Fold change were defined as comparative gene expression levels between “B. hyo 
only” group and “Hypox + B. hyo” group. Negative fold changes represent the 
magnitude of gene expression hypoxoside treatment downregulated. 
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Figure 5. The effects of hypoxoside treatment on active cecal mucosal p65 protein 
levels   in mice. Seven days postinfection, cecal tissues were collected and lysates were 
prepared as described in Materials and Methods. The supernatant were collected and 
incubated in a 96-well plate that contained immobilized nucleotide sequences for the 
consensus NF- B binding site. Active p65 levels in cell extract of mouse ceca were measured 
by ELISA with chemiluminescent readout. * P < 0.05 vs. Control, # P < 0.05 vs. all other 
groups. n=5-8 mice. Hypox: Hypoxoside; B. hyo: Brachyspira hyodysenteriae.   
Hypoxoside treatment reduced the intestinal epithelial cell proliferation. One of the 
key histological features of cecal lesions induced by B. hyodysenteriae infection is mucosal 
hyperplasia (18, 41). To correlate the reduction of histological lesions and mucosal 
hyperplasia (Fig. 2) with regulation of cell growth/proliferation, epithelial cell proliferation 
was assessed by measuring BrdU incorporation (Fig. 6A, B). Immunohistochemical staining 
of tissue sections from control and hypoxoside treated mice revealed that there was about 
10% proliferating epithelial cells at the base of crypts (Fig. 6A). The cecal tissue recovered 
from B. hyodysenteriae infected mice displayed about approximately a three-fold increase in 
the number (Fig 6A) of proliferating cells that extended above the base of the crypts. More 
importantly, hypoxoside treatment significantly (P<0.01) reduced the number of proliferating 
cells within the cecal epithelium following infection with B. hyodysenteriae to a level similar 
to that observed for control mice and mice treated with hypoxoside alone (Fig. 6A).  
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Figure 6. The effect of hypoxoside treatment on cecal epithelial cell proliferation in 
mice shown by BrdU staining. Seven days postinfection with Brachyspira hyodysenteriae, 
mice received an intraperitoneal injection of BrdU one hour before necropsy. As described in 
Materials and Methods, cecal tissues were processed and sectioned for immunohistochemical 
staining to detect BrdU incorporation. Data is presented as the percentage of proliferating 
mucosal epithelial cells (A) The quantitative analysis of percentage of BrdU positive cells in 
crypts. For each group, five complete crypt units per mouse were included in the data anlysis 
** P<0.01 vs. all other groups. (B) Photomicrographs of representative murine cecal BrdU 
staining. Magnifications of pictures are 40X. n = 5 to 6 mice per group. Hypox: Hypoxoside; 
B. hyo: Brachyspira hyodysenteriae.  
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Evaluation of the antibacterial effects of hypoxoside on B. hyodysenteriae. To 
determine whether the anti-inflammatory effect of hypoxoside is associated with potential 
anti-microbial activity, the ability of hypoxoside to inhibit in vitro bacterial growth was 
evaluated for multiple bacterial species. Addition of hypoxoside (0 to 1 mg/ml) to in vitro 
culture medium did not inhibit the growth of Lactobacillus murinus, L. acidophilus, 
Bacteroides distasonis, Escherichia coli, Enterococcus faecalis, Staphylococcus epidermidis, 
or Helicobacter bilis (data not shown). With respect to in vitro inhibition of B. 
hyodysenteriae growth, there was an extension of the lag phase of growth in broth cultures, 
but the treated cultures eventually grew as well as the untreated cultures (data not shown).  In 
addition, the number of B. hyodysenteriae in the cecal contents of B. hyodysenteriae mice 
(with or without hypoxoside treatment) was quantified using quantitative PCR. The result 
showed that hypoxoside treatment did not significantly (P > 0.05) alter the number of B. 
hyodysenteriae in the ceca of infected mice (Fig.7). These data suggested that the effect of 
the hypoxoside treatment (i.e., reduction of mucosal inflammation) was not the result of anti-
microbial activity on the resident flora or on B. hyodysenteriae, but on the host inflammatory 
response.  
 DISCUSSION 
Hypoxoside, a traditional medicine of southern Africa, has been used as a drug for a 
series of human aliments for centuries (38). One of medicinal properties associated with the 
use of hypoxoside has been its anti-inflammatory activity. Although in vitro studies showed 
that rooperol, the active component of hypoxoside, blocks the production of inflammatory 
mediators (3, 14, 15, 25), no in vivo experiments have been performed to demonstrate the 
anti-inflammatory property of hypoxoside on colitis. In this paper, it was shown that oral 
treatment of mice with hypoxoside could significantly reduce the colitis induced by B. 
hyodysenteriae. In addition, the inhibitory effects of hypoxoside on the bacterial-induced 
colitis correlated with the downregulation of the NF- B pathway in the colonic mucosa 
rather than exerting a direct anti-microbial effect. 
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Figure 7. The effects of hypoxoside treatment on the number of cecal Brachyspira 
hyodysenteriae in mice. At the termination of the experiment, cecal contents were collected 
from each mouse and used to extract DNA for bacterial quantification as described in 
Materials and Methods.  DNA was extracted from separate cecal contents of mice in Hypox 
+ B. hyo group and B. hyo only group. The bacterial numbers were quantified using real-time 
PCR with specific B. hyodysenteriae primers. Standard curves were generated by using DNA 
from pure culture B. hyodysenteriae. Bacterial numbers were then normalized based on a per 
gram equivalence. n = 6 mice per group.  Hypox: Hypoxoside; B. hyo: Brachyspira 
hyodysenteriae.   
 
Neutrophil infiltration is a hallmark of inflammatory reactions including colitis. It is one 
of several host defense mechanisms employed to counteract the deleterious effects of 
bacterial infections. Inflammatory mediators released by neutrophil include nitric oxide, 
reactive oxygen species, and prostaglandins which can contribute to tissue damage (e.g., 
submucosal edema and epithelial erosion) (27). The amelioration of tissue lesions by 
treatment with hypoxoside correlated with the reduction of neutrophil infiltration as assessed 
microscopically and by reduction in myeloperoxidase activity (Fig. 3). The inhibition of 
neutrophil activity are consistent with previous studies that showed that blockage of CD18 or 
direct depletion of neutrophils attenuated/abrogated lesion severity in mice infected with B. 
hyodysenteriae (41).  
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Transcription factor NF- B is a key regulator of the inducible expression of many genes 
associated with intestinal inflammation, including pro-inflammatory cytokines/chemokines, 
growth factors, adhesion molecules, cell surface receptors, transcription factors and others 
(35).  Excess or inappropriate activation of NF- B has been observed in IBD patients and in 
various animal models of IBD; in addition, drugs inhibiting NF- B pathway have been used 
to treat IBD (2, 9). Consistent with the role of NF- B activation in IBD, the present studies 
suggest that hypoxoside treatment directly inhibited the expression of genes associated with 
NF- B signaling cascades. Meanwhile, the levels of activated p65 decreased as a 
consequence of hypoxoside treatment. These results indicate that inhibition of NF- B 
signaling might contribute to the anti-inflammatory effects of hypoxoside. In addition, NF-
B participates in the regulation of cell proliferation and death in many cell types and 
typically promotes the cell proliferation and suppresses apoptosis (28). Consistent with this, 
genes associated with cell proliferation were found to be downregulated (Table 1) and 
epithelial cell proliferation based on BrdU incorporation ( Fig. 6) was attenuated after 
hypoxoside treatment. 
NF- B signaling includes two distinct pathways (i.e., classical and alternative signaling 
pathways). In contrast to classical pathway, the alternative NF- B pathway is generally 
involved in biological processes including secondary lymphoid organ development, initiation 
of adaptive immunity, cell survival, and proliferation (40). Surprisingly, it was observed that, 
in addition to classical NF- B signaling, hypoxoside had the capability to attenuate the 
activation of alternative pathways following B. hyodysenteriae infection. Differential 
contribution of the two NF- B activation pathways to IBD pathogenesis is still unknown. 
However, activation of alternative NF- B signaling was shown in animal models of 
ulcerative colitis (17).  
Notably, the amount of active p65 detected in the mucosa of mice that had been treated 
with hypoxoside and challenged with B. hyodysenteriae was significantly (P<0.05) higher 
than that detected for the control group (Fig. 5). This indicated that; 1) inhibition of NF- B 
activity alone may not be solely responsible for the observed anti-inflammatory effects of 
hypoxoside, or 2) the dose of hypoxoside used was not sufficient to completely inhibit the 
activation of NF- B. In this regard, rooperol has been shown to reduce the binding activity of 
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transcriptional factors such as activating protein 1(AP-1) in vitro, indicating that AP-1 might 
also play a role in hypoxoside effects (15). Consistent with these observations, it was shown 
that hypoxoside downregulated the Fos gene which encodes an essential component of AP-1 
(Table 1).  
Unexpectantly, there was no significant downregulation of the proinflammatory 
cytokines such as IL-1β, TNF-α detected after hypoxoside treatment (data not shown). The 
inability to detect changes in the expression of mRNA specific of the pro-inflammatory 
cytokines may be related to the experimental end point chosen for these studies (i.e., 7 DPI). 
Preliminary data relative to these studies indicated that the expression of proinflammatory 
cytokine genes, such as TNF α, peaked between two and three DPI and rapidly returned to 
background levels (data not shown).  
 The in vitro evaluation of bacterial growth in the presence of hypoxoside and in vivo 
quantiation of B. hyodysenteriae in cecal contents supported the conclusion that the anti-
inflammatory effects of hypoxoside were not dependent upon a bactericidal activity. The lack 
of anti-microbial effects by hypoxoside is in contrast to other studies, which reported that 
hypoxoside inhibited the growth of Escherichia coli and Staphylococcus aureus, albeit at 
levels of 4 mg/mL (25, 47). The reasons for these differences in the assessment of the anti-
bacterial activity of hypoxoside are currently unknown and may be associated with different 
bacterial culture conditions and doses of hypoxoside used in the studies (e.g., 1 mg/mL v.s. 4 
mg/mL).  
Hypoxoside could be a new candidate for treatment of colitis. The toxicity of 
hypoxoside was shown to be low or absent (45) which is consistent with the long-time usage 
of this drug in southern Africa. In addition to anti-inflammatory effects, hypoxoside has also 
been perceived to provide nutritional and anti-oxidant benefits that might be helpful for 
maintaining overall health (32, 33). More importantly, hypoxoside appears to have exerted 
the anti-inflammatory effects locally (i.e., mucosa) and not systemically as demonstrated by 
the fact that no hypoxoside or rooperol was found in sera of individuals treated with oral 
hypoxoside (23). This would suggest that the therapeutic use of drugs such as hypoxoside 
would not have adverse systemic effects; this should be viewed as a promising outcome, 
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given the fact that long-term usage of many current anti-inflammatory drugs (e.g., 
corticosteroids) has systemic adverse effects (50).   
In summary, this paper demonstrated for the first time that a plant extract, hypoxoside, 
could ameliorate bacterial-induced  colitis and might provide  therapeutic benefits for other 
forms of colitis. The anti-inflammatory effect of hypoxoside correlated with the 
downregulation of genes regulated by the NF- B pathway within the colonic mucosa rather 
than displaying a direct anti-microbial effect.   
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Supplemental Figure 1. The chemical structures of hypoxoside and rooperol. 
Hypoxoside can be converted into its active form rooperol by beta-glucosidase. 
 
(Drewes SE, Hall AJ, Learmonth RA, Upfold UJ. Isolation of hypoxoside from Hypoxis 
rooperi and synthesis of [E]-1,5 Bis[3’,4’-dimethoxypheny1] pent-1-en-1-ync. 
Phytochemistry 23:1313-1316, 1984. )  
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Supplemental Figure 2. Gene table of NF- B signaling pathway-specific microarray.  
(http://www.superarray.com)  
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Supplemental Figure 3. Illustration of classical and alternative NF- B signaling 
pathway. In classical NF- B activation, signaling is typically triggered through TNFR, IL-1R 
or TLR. Signals mediated by MAP/ERK Kinase kinase 3 (MEKK3) and IKKβ finally result 
in the degradation of I- Bα and translocation of the RelA/p50 homodimer to the nucleus. In 
the alternative NF- B activation pathway, signals triggered via CD40, LTβR, or BAFF-R are 
mediated by NIK and IKKα, which leads to p100 processing and the translocation of p52 
dimers into the nucleus.  
 
( Nishikori M. Classical and alternative NF- B activation pathways and their roles in 
lymphoid maligancies. J. Clin. Exp. Hematopathol 45(1):16-24, 2005. ) 
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Supplemental Table 1. The effects of hypoxoside on bacterial growth in vitro. 
Members of the Altered Schaedler Flora, Brachyspira hyodysenteriae and selected 
bacterial species isolated from healthy C3H/HeOuJ mice were evaluated for in vitro growth 
after inoculation into broth media containing differing doses of hypoxoside. Broth tubes or 
plates contained concentrations of hypoxoside: 0, 15.6, 62.5, 250, or 1000 mg/ml. Growth 
was monitored for 12 to 24 hours (broth cultures) up to 72 hours (plate cultures). Optical 
Density (OD) or absorbance measurements were made using Spectronic 20 
Spectrophotomer, direct counts were made with the aid of a Petroff-Hausser counting 
chamber. The results were summarized using three independent experiments.     
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CHAPTER 5. GENERAL CONCLUSION 
 
Summary of results 
Inflammatory bowel disease (IBD), a chronic and relapsing intestinal inflammation, 
affects about 3.6 million individuals in the United States and Europe and is reported to have a 
significant impact upon the cost of health care.
1- 3
 However, the etiology of IBD is still 
unknown and likely involves complex interactions among genetic susceptability, gut bacteria 
flora and host immune system.
4-6
  
The characterization of mucosal gene expression profiles in different IBD animal models 
will potentially provide molecular insights into the mechanisms that initiate, perpetuate or 
ameliorate IBD development. In this dissertation, alteration of mucosal gene expression 
profiles induced by different agents including a mild bacterial pathogen, Helicobacter bilis or 
an anti-inflammatory drug, hypoxoside) were characterized. The association between 
differential mucosal gene expression and modulation of colitis development was studied.  
 As a mild pathogen, Helicobacter bilis has been shown to induce and/or accelerate the 
development of colitis in immune-deficient rodents.
7-11 
In an immunocompetent host, H. bilis 
colonization did not induce demonstrable inflammation yet triggered persistent antibody and 
cytokine responses to commensal bacteria.
12, 13
 These results indicate that colonization of a 
novel bacterium such as H. bilis into gut might alter mucosal homeostasis and increase host 
susceptibility to colitis. However, the molecular and cellular mechanisms governing the 
effects of Helicobacter bilis colonization on the host mucosal homeostasis and colitis 
development remain unknown.  
 Using microarray analysis, changes in mucosal gene expression potentially contributing 
to an increased susceptibility to colitis were evaluated in gnotobiotic C3H mice at 15, 30 and 
45 days following H. bilis colonization.  Our results showed that H. bilis colonization 
induced marked upregulation of genes associated with protein metabolism, immune 
responses, and downregulation of genes associated with fatty acid metabolism and 
detoxification which peaked at 15 days postinfection. Interestingly, genes with similar 
biological functions follow similar temporal expression change patterns.  For instance, 
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expression levels of genes associated with proteolysis (e.g., Gzma and Mcpt1) and innate 
immune responses (e.g., Cd14) went up at 15 DPI and returned back to control levels at 30 
and 45 DPI. In contrast, expression levels of genes associated with glycoprotein synthesis 
(e.g., Fut2 and B3galt5) and detoxification (e.g., Cyp4b1and Ugt8a) were upregulated or 
downregulated, respectively, at 15 DPI and stayed differentially expressed at 30 and 45 DPI, 
although the magnitude of gene expression over control mice decreased at these time points. 
Interestingly, some of these genes (e.g., Fut2, B3galt5, Ceacam12, Cyp4b1, and Ugt8a) were 
also differentially expressed in other colitis models including dextran sodium sulfate (DSS) 
and Brachyspira hyodysenteriae –induced colitis.  
To directly determine if H. bilis colonization increased the sensitivity to DSS-induced 
colitis, mice were colonized with H. bilis for 6 weeks and then treated with a low dose of 
dextran sodium sulfate (DSS, 1.5 %) for five days followed by a four day restitution period. 
Our results demonstrated that H. bilis colonization increased the severity of colitis induced 
by DSS. Mucosal gene expression profiles showed that mice colonized with H. bilis plus 
treated with DSS had significant increases in the expression levels of genes associated with 
activation of immune cells (e.g.,  Cd28, Tnfsf13b/Baff) and recruitment of immune cell 
including the adhesive molecules(e.g.,  Itgb2/Cd18, Itgam/Cd11b  and ItagL/Cd11a), 
chemokines/chemokine receptors(e.g.,  Ccl8, Ccr5and Ccr10).  Consistently, increased 
infiltration and/or proliferation of T cells, B cells and macrophages in the intestine mucosa 
and/or MLN were observed in mice treated with H. bilis + DSS in comparison to mice 
treated with DSS alone. The upregulation of the cell activation markers (e.g., Cd28, 
Tnfsf13b/BAFF), pro-inflammatory cytokines IL17, and significant increased antibody 
responses to H. bilis and ASF suggest the T cell and B cell were activated. Surprisingly, 
neutrophil infiltration was not observed. In addition, the detoxification-associated genes 
Cyp4b1 and Ugt8a were found to be downregulated in mice treated with H. bilis + DSS in 
comparison to mice treated with DSS alone.  
Lastly, we used another other IBD model, Brachyspira hyodysenteriae - induced colitis.  
Brachyspira hyodysenteriae is the causative agent of swine dysentery and induces a 
characteristic mucosal inflammatory response resulting in pronounced typhlocolitis in mice 
and swine.
14, 15
 Hypoxoside has been reported to be an anti-inflammatory drug extracted from 
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an African medicinal plant, Hypoxis hemerocallidea.
16
 In vitro studies have shown that 
hypoxoside inhibits the secretion of pro-inflammatory cytokines and the nuclear binding 
activity of NF- B.
17-20
 However, no in vivo experiments have been performed to demonstrate 
the anti-inflammatory property of hypoxoside on colitis. 
In this dissertation, our results showed that oral treatment of hypoxoside could 
ameliorate the colitis induced by B. hyodysenteriae infection, which was demonstrated by the 
reduced gross and histological lesions, reversed weight loss. The anti-inflammatory effects of 
hypoxoside were suggested to be associated with the reduction of neutrophil infiltration, 
downregulation of genes involved in NF-κB signaling pathways and decrease in mucosal 
active NF-κB subunit p65 protein levels and epithelial cell proliferation, but not anti-
microbial activity.    
 
Discussion and recommendation for future study 
 
Downregulation of detoxification-associated genes  
One of the key observations in this dissertation is that multiple detoxification-associated 
genes were identified to be downregulated following the colonization of gnotobiotic C3H 
mice with Helicobacter bilis.   
Three general phases of detoxification processes can be defined. Phase 1 reactions 
include redox reactions via cytochrome P450 (CYP) enzymes, 
21
hydration by carbonic 
anhydrases,
22
 and hydrolysis of compounds by carboxylesterases.
23
 Phase 2 reactions include 
the sulfation,
24
 glucuronidation,
25 
and glutathione
26
 conjugation of reactive intermediates, 
leading to more hydrophilic molecules, which can be more easily exported from cells. A 
specific set of ABC transporter (i.e., multi-drug resistant transporter) proteins located at the 
basolateral or apical surface of intestinal epithelial cells mediates the efflux of unconjugated 
or conjugated compounds back into the gut lumen.
27 
  
Detoxification and biotransformation of luminal agents is an important protective 
function of intestinal epithelial cells.
28
 Downregulation of detoxification genes has been 
described for several animal models of IBD (e.g., DSS-induced colitis, TCRα-/-, and transfer 
of CD45RBhi T cells) and human patients. 
29, 30
 Loss or dysregulation of detoxification and 
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biotransformation processes by the intestinal epithelium may contribute to the initiation and 
progression of IBD.
28-30
  
 Our microarray results showed that H. bilis colonization can induce significant 
downregulation of phase 1 enzymes including carboxylesterase  Ces1, Ces3, cytochrome 
P450 gene family Cyp4b1, Cyp4f1, and epoxide hydrolase Ephx2 and phase 2 enzymes 
including glucuronyl transferaseUgt8 and glutathione transferase Gstt1. Mdr1a (multiple 
drug resistant 1a, or ATP-binding cassette, sub-family B, member 1A) was also found to be 
downregulated at 15 DPI after H. bilis colonization (data not shown). In addition, the 
detoxification transcriptional factor, Car (constitutive androstane receptor, also refered to 
Nr1i3) was downregulated after H. bilis colonization. Importantly, most of these 
detoxification genes stayed downregulated at 30 and 45 DPI in comparison to control. 
Collectively, H. bilis colonization resulted in systemic downregulation of a series of genes 
associated with detoxification processes. Notably, the downregulation of detoxification –
associated genes only occured in the intestines of mice challenged with live H. bilis, but not 
dead H. bilis. Our preliminary data showed dead H. bilis challenge induced the antibody 
responses to H. bilis but did not alter the  expression of detoxification genes Cyp4b1 and 
Ugt8a, indicating that alteration of mucosal function, rather than antigen exposure alone, 
may be responsible for expression change of detoxification genes (data not shown).      
We then asked if the downregulation of detoxification genes is specific for H. bilis 
colonization. We tested the other colitis models including DSS and Brachyspira 
hyodysenteriae –induced colitis based on 2% DSS for 5 days, 7 days after 108 B. 
hyodysenteriae infection in gnotobiotic C3H mice. The similar gene change patterns were 
identified for these two colitis models, based on the significant downregulation of genes 
Cyp4b1 and Ugt8a.  
One of the critical questions for downregulation of detoxification genes is whether it is 
one of the causes/ initiators of IBD or it is simply a response secondly to the inflammation. 
Pro-inflammatory cytokines such as TNFα have been shown to downregulate the expression 
of detoxification genes.
31
 We found that hypoxoside, an anti-inflammation drug, can reverse 
the downregulation of detoxification gene Cyp4b1, which was correlated with the 
amelioration of inflammatory lesions induced by Brachyspira  hyodysenteriae and inhibition 
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of NF-κB signaling pathway (data not shown).  These results seem to support that the 
downregulation of detoxification genes is a result of inflammation or is secondary to 
inflammation. On the other hand, other evidence supports that dysregulation of the 
detoxification process may be a cause or initiator of IBD. Mice with deficiency in Mdr1a, 
one of critical genes in detoxification, spontaneously develop colitis 
32
and Mdr1a 
polymorphism has been shown to be strongly associated with ulcerative colitis.
33, 34
 
Interestingly, our results showed that the fold change of downregulation of detoxification 
genes in acute inflammation induced by DSS or B. hyodysenteriae were actually lower than 
that of mild inflammation induced by H. bilis at 15 DPI (Chapter 2 Figure 5 and 6). This 
result indicates the downregulation of detoxification might not be directly correlated with the 
degree of inflammation.  
It would be very important and interesting to directly test if dyregulation of 
detoxification genes is a cause or a result of intestinal inflammation. Specific deletion/knock-
in of some of those important genes such as Cyp4b1, Ugt8a or some transcriptional factor 
such as nuclear receptor Car would provide a definite answer. It is also worthy to try agonist 
for relevant nuclear receptors and study if the activation of detoxification process would 
prevent the intestinal inflammation. Interestingly, one recent study showed that activation of 
another detoxification-associated nuclear factor Pxr (pregnane x receptor) could ameliorate 
the DSS-induced colitis, indicating dysregulation of detoxification might be the cause of 
IBD.
35
 Given the fact that downregulation of Pxr has been identified in patients in ulcerative 
colitis
29
 and Pxr polymorphism was shown to be strongly associated with IBD,
36
 the agonist 
for detoxification transcriptional factor might be a potential therapeutic strategy to treat IBD 
patients.  
Another fundamental question about the detoxification-associated genes is whether those 
genes are derived only from epithelial cell. Is it possible that other cells in lamina propria 
also express these genes, given the fact that the whole tissue mucosa was used in our 
microarray studies? Notably, one microarray study which used intestinal epithelial cells also 
identified downregulation of a series of detoxification-associated genes, indicating 
detoxification genes might be from epithelial cells.
30 
The
 
Mdr1a gene has been identified to 
be expressed in epithelial cells and lymphocytes, hematopoietic cells. However, defect of 
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Mdr1a in the intestinal epithelial cells is the principle cause of colitis.
37, 38
 Ongoing studies in 
our laboratory are trying to use an intestinal epithelial cell line, Mode-K cells, to study the 
change of detoxification genes induced by H. bilis stimulation.  However, it is unknown 
whether the TLR4 defect in Mode-K cells from C3H/Hej mice will have an influence on 
expression of detoxification genes. One limitation of the study on detoxification genes is that 
there are no monoclonal antibodies available for many of these genes. If available, 
immunohistochemistry for those detoxification-associated proteins would provide a good 
tool to locate detoxification molecules.    
In addition, the temporal gene expression changes of detoxification genes in different 
models of intestinal inflammation would be useful. These might include the determination of 
the expression levels of detoxification genes at early (e.g., 5 days after H .bilis colonization) 
or later (12 weeks after H. bilis colonization) and determination of the expression levels of 
genes in acute versus restitution period of DSS colitis or different time points after B. 
hyodysenteriae infection. These temporal studies would identify what time points and 
intestinal inflammation models affect most or are most affected by the detoxification 
processes.  
What toxins do the detoxification genes work on? Since the gut harbor huge amount of 
bacteria and antigens, it would be difficult to determine which specific toxin or deleterious 
antigen might be a major player in the detoxification process. However, one interesting point 
for H. bilis is that this bacterium has a specific toxin, cytolethal distending toxin (CDT). CDT 
has the potential to induce distention in cells and to arrest cell division in the G2/M phase of 
cell cycle.
39
 CDT has also been shown to play a key immunomodulatory role that facilitates 
persistent colonization of H. hepaticus and that, in IL-10
-/-
mice, this alteration of the host 
immune response results in the development of colitis.
40
 The possible association between 
CDT and detoxification genes will be of interest. The study on the CDT mutant H. bilis will 
provide insights on this question.  
 In conclusion, dysregulation of detoxification genes was observed in multiple models of 
intestinal inflammation including Helicobacter bilis colonization and potentially contribute 
to the initation or perpetuation of IBD.  
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Activation of adaptive immunity 
Two microarray studies on Helicobacter bilis were described in this dissertation. The 
first study on mucosal gene expression profiles at 15, 30 and 45 DPI after H. bilis 
colonization identified the downregulation of detoxification genes, with the highest fold 
change at 15 DPI. In the second study, the comparison of mucosal gene expression profiles 
between mice colonized with H. bilis 6 weeks prior to DSS treatment and mice treated with 
DSS alone were performed.  This comparison should address the effects of H. bilis. In 
contrast to the first study, we identified a series of genes associated with activation and 
recruitment of immune cells. 
 The discrepancy between two microarray studies might be associated with the 
microarray techniques and statistic analysis. The much higher fold change of mucosal gene 
expression at 15 DPI vs. 30 and 45 DPI might skew the differentially expressed genes 
identified by microarray (false discovery rate ≤0.05 and fold change ≥ 2) into the mainly 
genes associated with 15 DPI. Actually, the relative loose statistic criteria (e.g., false 
discovery rate <0.1) will identify many more genes associated with immune responses such 
as cytokine and chemokine (data not shown).  In addition, the downregulation of 
detoxification genes was confirmed by qRT-PCR in mice colonized with H. bilis plus treated 
with DSS in comparison to mice treated with DSS alone. Another possible contributor for 
this discrepancy is that ceca tissues were used in the first microarray study while colon 
tissues were used in second microarray study.    
  Our microarray study and cell infiltration analysis demonstrated that H. bilis 
colonization could induce the activation and recruitment of T cells, B cells and macrophages. 
However, the roles of these cell types in this special intestinal inflammation (i.e., H. bilis 
colonization plus low dose DSS treatment in C3H gnotobiotic mice) are still unknown.  
Th17 T cells have been shown to play essential role in several IBD models and 
autoimmune diseases.
41
 The upregulation of IL17 gene expression in lamina propria 
lymphocytes and also mucosa levels indicate the potential importance of Th17 T cells in the 
development of colitis in this model. Adoptive transfer of T cells into SCID or Rag
-/- 
mice 
would be able to determine the importance of pathogenic T cells in the development of colitis.  
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However, we should be cautious that other T or non-T cells might also express or secret IL17. 
Intracellular staining for IL17 might be needed to test it. As for B cells, the increased 
antibody responses to commensal bacteria after H. bilis colonization were observed. The 
current paradigm suggests that immune responses to commensal bacteria play an essential 
role in the IBD development.
4
 It will be of interest to study how these antibody responses to 
commensal bacteria contribute to colitis development. The macrophages are essential cells 
for DSS colitis, which was shown by the induction of DSS colitis in SCID mice with rare 
lymphocytes.  Interestingly, H. bilis also has been shown to induce colitis in SCID mice.   
One of critical questions in our intestinal inflammation model (H. bilis + DSS) is the 
association between downregulation of detoxification genes and activation/recruitment of 
immune cells. It will be of interest to study whether the one factor leads to the other. In 
SAMP1/Yit mice -A Crohn’s disease model, bone marrow chimera experiments showed that 
increased permeability of epithelial cells, rather than activation of hematopoietic cells, was 
primary defect and would lead to the activation of T cells and development of the ileitis.
42 
 
Low dose DSS provides an additional stimulus to host colonized with H. bilis, leading to 
the development of colitis. DSS is widely considered to have direct toxic effects on intestinal 
epithelial cells.
43
 Our preliminary data suggest the DSS treatment downregulated the 
expression of genes associated with cell cycle, indicating that epithelial cells might be less 
proliferative, thus affecting intestinal barrier functions (data not shown). BrdU staining for 
epithelial cells might provide more evidences on how DSS affect the epithelial cell 
proliferation. In addition, DSS treatment has been shown to downregulate the detoxification-
associated genes.  
 
Hypothesis for intestinal inflammation models (H. bilis colonization + low dose DSS)  
From the above discussions, we hypothesize that H. bilis and DSS play synergetic and 
yet distinct roles in the development of colitis.  
Both Helicobacter bilis and low dose of DSS might affect the detoxification ability of 
intestinal epithelial cells. However, DSS might also exert direct apoptotic effects on 
epithelial cells while H. bilis itself seems to be a potent stimulator to T cells, B cells or 
macrophages in lamina propria.  
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 Single treatment with either H. bilis or low dose DSS is not be potent enough to initiate 
colitis development. However, co-treatment of H. bilis and low dose DSS may damage the 
integrity or barrier functions of intestinal epithelial cells.  The alteration of epithelial integrity 
or barrier functions allows H. bilis and commensal bacteria to access to lamina propria, to 
activate various immune cells, eventually leading to intestinal inflammation. The requirement 
of both H. bilis and DSS for the development of colitis is consistent with “Multiple-hit 
hypothesis”. 44 
 
Hypoxoside, Brachyspira hyodysenteriae, DSS and NF-kB signaling pathway 
In this dissertation, hypoxoside, an anti-inflammatory drug, has been shown to 
ameliorate the acute colitis induced by Brachyspira hyodysenteriae. More importantly, we 
showed that hypoxoside could downreglate the expression levels of genes associated with 
NF-κB signaling pathway and reduced the mucosal protein levels of p65 subunit. 
 Given the fact that many pro-inflammatory cytokines and chemokines are regulated by 
transcriptional factor NF-κB, it is expected that hypoxoside can reduce the intestinal 
inflammation through the downregulation of NF-κB signaling pathways.  
To further test the therapeutic effects of hypoxoside, we tested if oral treatment of 
hypoxoside could ameliorate or prevent DSS-induced colitis at the dose of 1.25% for five 
days. Surprisingly, it was found that hypxoside treatment did not prevent or ameliorate the 
DSS-induced colitis, as shown by no significant change in histological lesions. In addition, 
mice treated with DSS and hypoxoside groups had more intestinal bleeding in comparison to 
mice treated with DSS alone, indicating hypoxoside might have deleterious effect on tissue 
repair (data not shown).  
The mechanisms of deleterious effects of hypoxoside on DSS colitis are still unknown. 
However, accumulating evidence also suggestes NF-κB might have protective effects against 
colonic insult, especially on intestinal epithelial cells.
45-48 
We observed that hypoxoside 
treatment could reduce the proliferation of epithelial cells. Since DSS might exert direct toxic 
effect and/or induce epithelial apoptosis, the co-treatment of hypoxoside and DSS is likely to 
greatly affect the epithelial cell turnover, thus damaging the tissue repair. In addition, 
hypoxoside has been shown in vitro to inhibit cyclooxygenase-2 (Cox-2) and 
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cyclooxygenase-1 (Cox-1), 
20 
which are essential for synthesis of cytoprotective 
prostaglandins in intestine. However, controversial evidence on the effects of hypoxoside on 
Cox-1 and Cox2 also exist.
49 
 
Similarly and interestingly, another plant extract and anti-inflammatory drug, luteolin, 
was shown to ameliorate the colitis in IL10
-/- 
mice, yet aggravated DSS-induced experimental 
colitis.
50 
More importantly, luteolin treatment significantly enhanced intestinal epithelial cell 
pro-apoptotic caspase-3 activation and prevented the induction of NF-κB-Dependent 
cytoprotective molecules such as COX-2 following DSS-exposure.
50
  
It was proposed that, in the context of a primarily intact epithelial layer, antigen- (e.g. 
bacteria-) induced NF-κB activation in lamina propria mononuclear cells leads to NF-κB 
dependent pro-inflammatory cytokine secretion, thus its inhibition by luteolin likely 
ameliorates intestinal inflammation.
50, 51
 NF-κB activation in intestinal epithelial cells is 
likely protective (wound-healing response, anti-apoptotis), and its inhibition by luteolin 
consequently aggravates intestinal damage by DSS.
50, 51
 The NF-κB  function in intestine was 
illustrated in supplemental figure 1.
51 
Further investigations are needed to test if hypoxoside 
have the similar mechanisms on intestinal inflammation.  
 
Conclusion  
The results in this dissertation have suggested some possible mechanisms how different 
agents as demonstrated by a mild pathogen Helicobacter bilis and an anti-inflammatory drug 
hypoxoside modulate the gene expression profiles and alter the mucosal functions (e.g., 
epithelial barrier functions and/or immune system in lamina propria), which might contribute 
to the initiation, perpetuation or amelioration of IBD development. For instance, 
Helicobacter bilis might affect epithelial detoxification and activate the T cells, B cells or 
macrophages in lamina propria, thus increase the host susceptibility to colitis. On the other 
hand, hypoxoside could downregulate the NF-κB pathway and ameliorated Brachyspira 
hyodysenteriae-induced colitis. These studies in this dissertation identified some promising 
gene and signaling targets for IBD such as genes associated with detoxification, 
activation/recruitment of immune cells and activation of NF-κB pathways and might 
potentially contribute to the therapeutic intervention of IBD patients.  Further studies are 
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needed to dissect the individual functions of intestinal epithelial cells and lamina propria 
immune cells.  
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Supplemental Figure 1. Proposed functions of NF-κB in the intestine. 51Intestinal 
epithelial cells provide a physical barrier isolating luminal microbiota from a rich mucosal 
immune system in the lamina propria. Sustained and prolonged epithelial damage 
compromises host integrity by allowing uncontrolled bacterial translocation, followed by the 
activation of lamina propria mononuclear cells (LPMNC) such as macrophages, dendritic 
cells, and T and B lymphocytes. TLR/ NF-κB signaling in intestinal epithelial cells has a 
protective function by inducing the transcription of genes involved in wound-healing, tissue 
repair, and intestinal epithelial cell survival, thereby contributing to barrier reestablishment. 
Blocking NF-κB activity in this biological setting consequently jeopardizes intestinal 
homeostasis (left). TLR/ NF-κB signaling in LPMNC participates in antigen sampling, the 
recruitment and activation of immune cells, which in the normal host results in bacterial 
clearance and reestablishment of host homeostasis. In a colitogenic susceptible host, TLR/ 
NF-κB signaling derived from LPMNC contributes to the chronic inflammatory process and 
tissue damage through the sustained production of proinflammatory and chemoattractive 
mediators (e.g., cytokines, chemokines, nitric oxide, growth factors, etc.). Blocking NF-κB 
activity in this biological setting can attenuate intestinal inflammation (right). 
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